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Abstract 
 
Myasthenia gravis (MG) is a very well-known autoimmune disorder where 
there is an antibody mediated attack to the neuromuscular junction, 
impairing its transmission. It has a constellation of symptoms well 
characterized. The antibodies that cause the disease are known in more 
than 95% of the patients with a generalised form of the disease. Yet, there 
are still a lot to understand regarding some specific issues, namely the 
changes in the epidemiology trends, its genetic risk factors, effect of the 
disease on pregnancy and on the newborn of MG mothers, patient 
susceptibility to polyautoimmunity, refractory disease and also some 
questions related to thymomatous MG patients and their propensity to 
immunodeficiency and/or autoimmunity.  
The main aim of this research is to increase the knowledge of the 
epidemiology of Myasthenia gravis in the North of Portugal, and describe 
more accurately the clinical, serological and thymic immunopathological 
aspects of the cases identified. The above data will allow  (i) to analyse 
our findings with those of other regions in europe and the rest of the 
world;  (ii) to identify factors that may influence the course of the disease 
and response to treatments; (iii) to study the effect of the disease on 
pregnancy; (iv) to register other autoimmune disorders and correlate it 
with thymus pathology; (v) to study the thymus of the patients with 
histologically confirmed thymoma, by immunohistochemistry and to 
correlate the histology of the thymus with the clinical data (MG 
characteristics, infections, other cancers, other autoimmune disorders). 
The epidemiological study involved all the hospitals in the North of 
Portugal where patients with MG are treated. We used their databases to 
identify patients. To improve the quality of the source of patients, the 
method was complemented with identification of the prescriptions of 
pyridostigmine by the general practitioners in the north of Portugal.  
Combining these two sources of information, at 31/12/2013, we 
estimated a point prevalence for MG of 111.7 patients/106 in the north 
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of Portugal. Prevalence rose with age reaching its maximum in the 
group over 65 years old, especially in males (288.1/106).  
During the year of 2013 we estimated an incidence rate of 6.3 per 
million person/year. Among females, incidence rate was higher in the 
age group 15-49 (9.1/106), while in males, incidence increased with 
age till the maximum (22.1/106) among those aged over 65 years. 
This is the first epidemiological study on MG in Portugal. These values 
are similar to those reported either in studies in southern European 
countries, or in northern Europe, in studies with similar methods and 
size of the population studied.  
These results are consistent with most of the recent reports that 
describe higher incidence rates of MG in LOMG group, especially in 
elderly males. This information has crucial importance for the 
awareness of clinicians when dealing with this age group, and 
subsequent improvement in diagnosis and management of MG. 
Almost one third of patients (29.4%) had one type of the following 
comorbidities: other autoimmune diseases (OAID) (organ specific or 
systemic), tumours or recurrent/serious infections; 2.8% of the patients 
had ≥2 of those associated problems. The proportion of patients with 
OAID and infections was identical in EOMG and LOMG groups. Only 
tumours were more common in LOMG. 
Over the years, association of MG with Human Leucocyte Antigens (HLA) 
has been described in different populations. In European descendent 
populations HLA-DRB1*03 allele strongly influences MG susceptibility. 
In our population, there was also a strong association of HLA-DRB1*03 
and HLA-B*08 with MG, confirming that these alleles are important 
susceptibility factors for this disease, especially in the early onset MG 
subgroup (EOMG). HLA-DRB1*01 was associated with late-onset 
subgroup. To the best of our knowledge these results were not reported 
before and need replication in other populations and in larger cohorts. 
MG is not associated with infertility, but it may expose pregnant women 
to an increased risk of maternal and fetal complications. In our study, 43% 
of patients experienced an exacerbation of symptoms, especially during 
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the third trimester and postpartum. This rate of clinical worsening is 
similar to that found by others. Our study adds to the body literature 
showing that a more aggressive MG background may increase the risk of 
clinical exacerbation during pregnancy.  
We have also conducted a multicentre study, which included all MuSK-MG 
in the North of Portugal that underwent through a pregnancy. This is a 
subgroup of MG patients where the effect of the disease on the 
pregnancy, the delivery, the foetus and the changes on the MG during this 
period are much less known as this form of disease is rare. In this series, 
pregnancy did not seem to precipitate MuSK-MG or influence the MuSK-
MG course. Furthermore, there was no apparent negative impact of MG 
on pregnancy outcomes in those where pregnancy followed the MG onset. 
One case of neo-natal MG was recorded. All newborns seemed to have 
normal psychomotor development.  
The course of MG is often complicated by concomitant autoimmune 
disorders. It is important to consider coexistent MG in patients with 
autoimmune disorders that develop new or aggravated muscular 
weakness, fatigue or respiratory failure.  
On the other hand, while rare, the possibility of neurological autoimmune 
comorbidity should also be considered in myasthenic patients, especially 
if there is an unexpected deterioration of muscle weakness or poor 
response to pyridostigmine (e.g. muscle disease), or if unexpected 
neurological signs or symptoms arise in MG (e.g. peripheral nervous 
system involvement in keeping with chronic inflammatory demyelinating 
polyneuropathy (CIDP); or central nervous system illness such as 
neuromyelitis optica spectrum disorder (NMOSD); or even rarer 
manifestations such as autonomic dysfunction). The rapid diagnosis of 
the second illness will improve management and disease outcomes of 
both MG and the other autoimmune condition. 
A subset of myasthenia gravis patients is refractory to conventional 
treatments. Identifying their characteristics is important to promptly try 
to find different therapies effective in this disease subgroup.  
In this study, we investigated the clinical features of refractory MG 
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patients and to investigate a possible association between HLA-DRB1 
alleles and refractory MG. 22% of patients were classified as refractory. 
Compared to the non-refractory patients, the refractory ones were more 
likely to have a more severe MGFA classification at onset, to have 
thymomatous MG and to be seropositive, either to anti-AChR or anti-MuSK 
antibodies. HLA-DRB1*13 allele was less frequent in the non-refractory 
MG when compared to the refractory group and the control population.  
The clinical and demographic characteristics of our refractory patients are 
similar to those described in other studies. It is important to consider 
those characteristics from the onset of the disease. HLA-DRB1*13 allele 
may be a protective allele for the non-refractory group. As far as we were 
concerned there are no other immunogenetic studies in refractory MG and 
these results need to be replicated in other populations. 
It is extremely rare for early onset myasthenia gravis patients to have 
thymoma following extended removal of hyperplastic thymus. We 
described two AChR-MG patients who developed thymoma years after 
extended transternal thymectomy and highlight the clinical 
manifestations that heralded the thymoma, consequently of a severe 
immunodeficiency which resembled APECED (autoimmune 
polyendocrinopathy, chronic mucocutaneous candidiasis and ectodermal 
dystrophy) syndrome, with auto-immune regulatory (AIRE) gene defect. 
These two cases illustrated the need of searching for a thymoma in MG 
patients whose disease becomes difficult to treat after removal of a 
thymus, even if it shows only thymic follicular hyperplasia. In addition, 
thymoma needs to be considered even more in cases of severe and/or 
recurrent infections, which could reflect complex paraneoplastic immune-
deficiency associated with auto-antibodies to interleukins. 
 
We will continue the study of the thymoma associated MG with 
immunohistochemistry studies of their thymomas namely with AIRE gene 
and correlate it with the presence of severe and/or recurrent infections, 
OAID and tumours. 
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Resumo 
 
A Miastenia gravis (MG) é uma doença autoimune bem conhecida onde há 
um ataque à junção neuromuscular prejudicando o seu funcionamento. 
Caracteriza-se por uma constelação de sintomas bem definidos e os 
anticorpos que causam a doença são conhecidos em mais de 95% dos 
doentes com a forma generalizada da doença. No entanto, ainda há muito 
por entender em relação a algumas questões específicas, nomeadamente 
as mudanças nas tendências epidemiológicas, os fatores de risco 
genéticos, o efeito da doença na gravidez e nos recém-nascidos das mães 
com MG, a suscetibilidade à poliautoimunidade, os doentes refratários e 
também algumas questões relacionadas com doentes com MG associada 
ao timoma e a propensão à imunodeficiência e/ou auto-imunidade. 
A finalidade deste projeto é aumentar o conhecimento da epidemiologia 
de Miastenia gravis no Norte de Portugal, com a identificação e descrição 
dos aspetos clínicos, serológicos e imunopatológicos dos timos. Foram 
objetivos específicos: comparar a nossa população de doentes com MG 
com os de outras regiões da Europa e do resto do mundo; identificar 
fatores que possam influenciar o curso da doença e a resposta aos 
tratamentos; estudar o efeito da doença na gravidez; registar outras 
doenças auto-imunes e correlacioná-las com patologia do timo; estudar o 
timo dos doentes submetidos à timectomia, com timoma, com imuno-
histoquímica e correlacionar os estudos de imuno-histoquímica do timo 
com os dados clínicos (infeções, outras neoplasias e outras doenças auto-
imunes). 
O estudo epidemiológico envolveu todos os hospitais do Norte de 
Portugal que tratam doentes com MG. Usámos as bases de dados desses 
hospitais para identificar os doentes. Para melhorar a qualidade da fonte 
de doentes, o método foi complementado com a identificação das 
prescrições de piridostigmina pelos médicos de família no Norte de 
Portugal. A piridostigimina é um fármaco usado praticamente em todos 
os doentes com MG e é usada quase exclusivamente na MG. 
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Combinando estas duas fontes de informação, em 31/12/2013, 
estimámos uma prevalência pontual para MG de 111,7 doentes/106 no 
Norte de Portugal. A prevalência aumenta com a idade atingindo o seu 
máximo no grupo com mais de 65 anos, especialmente nos homens 
(288,1/106). 
Durante o ano de 2013, estimámos uma taxa de incidência de 6,3 por 
milhão de pessoas/ano. Entre as mulheres, a taxa de incidência foi maior 
no grupo etário 15-49 (9,1/106), enquanto nos homens a incidência 
aumentou com a idade até o máximo (22,1/106) entre os maiores de 65 
anos. 
Este é o primeiro estudo epidemiológico em MG em Portugal. E esses 
números são semelhantes aos reportados em estudos em países do sul 
da Europa ou no norte da Europa, com métodos e tamanho de amostra 
populacional similares. 
Estes resultados estão de acordo com a maioria das descrições mais 
recentes que descrevem maiores taxas de incidência de MG no grupo 
LOMG, especialmente em homens. Esta informação tem importância 
crucial para a continuação da consciencialização dos clínicos sobre a 
doença nesta faixa etária, e subsequente melhoria no diagnóstico e 
tratamento de MG. 
Quase um terço dos doentes (29,4%) apresentaram um dos 3 tipos de 
comorbilidades: outras doenças autoimunes (OAID) (órgão específico ou 
sistémica), tumores ou infeções recorrentes/graves; 2,8% dos doentes 
apresentaram ≥ 2 desses problemas associados. A proporção de doentes 
com OAID e infeções foi idêntica nos grupos EOMG e LOMG. Apenas os 
tumores foram mais comuns na LOMG. 
Ao longo dos anos foi descrita a associação de MG com o HLA em 
diferentes populações. Nas populações descendentes de europeus, o 
alelo HLA-DRB1*03 influencia fortemente a suscetibilidade à MG. 
Na nossa população, também houve uma forte associação de HLA-
DRB1*03 e HLA-B*08 com MG, confirmando que esses alelos são 
importantes fatores de suscetibilidade para esta doença, especialmente 
no subgrupo de início precoce. HLA-DRB1*01 foi associado ao subgrupo 
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de início tardio. Do nosso conhecimento, estes últimos resultados 
relativos ao subgrupo de início tardio nunca foram publicados 
anteriormente e precisam ser replicados em outras populações e em 
coortes maiores. 
A MG não está associada à infertilidade, mas expõe as mulheres grávidas 
a um risco aumentado de complicações maternas e fetais. No nosso 
estudo, 43% das doentes apresentaram exacerbação de sintomas, 
especialmente durante o terceiro trimestre e pós-parto. Esta é uma taxa 
semelhante de agravamento clínico, quando comparamos com outras 
séries publicadas. O nosso estudo associa-se à literatura mostrando que, 
na presença de uma MG de base mais agressiva a frequência de 
exacerbação clínica durante a gravidez pode ser alta. 
Realizámos um outro estudo na gravidez, multicêntrico que incluiu todas 
as doentes com MuSK-MG no Norte de Portugal que tiveram pelo menos 
uma gravidez. Este é um subgrupo de doentes onde o efeito da doença 
sobre a gravidez, o parto, o feto e as alterações na MG durante esse 
período são menos conhecidos. Nesta série, a gravidez não pareceu 
precipitar MuSK-MG ou influenciar o curso da MuSK-MG, e não houve 
impacto negativo aparente nos resultados da gravidez naqueles em que 
a gravidez foi posterior ao início da MG. Registámos um caso de MG 
neonatal e o peso destes recém-nascidos foi mais baixo, apesar de 
nenhum cumprir critérios de baixo peso ao nascimento. Todos os recém-
nascidos tiveram um desenvolvimento psicomotor normal. 
O curso da MG é muitas vezes complicado por outras doenças auto-
imunes concomitantes. É importante considerar a MG em doentes com 
doenças auto-imunes que desenvolvem nova fraqueza muscular, ou 
agravada, fadiga ou insuficiência respiratória. 
Por outro lado, embora seja raro, a possibilidade de comorbilidade auto-
imune neurológica também deve ser considerada em doentes com MG, 
especialmente se houver uma deterioração inesperada da fraqueza 
muscular ou má resposta à piridostigmina (por exemplo, doença 
muscular), ou se sinais ou sintomas neurológicos inesperados surgem na 
MG (por exemplo, envolvimento do sistema nervoso periférico compatível 
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com uma CIDP, ou doença do sistema nervoso central, como a NMOSD, 
ou mesmo manifestações mais raras, como a disfunção autonômica). O 
diagnóstico rápido de uma segunda doença melhorará a resposta ao 
tratamento da outra doença bem como da MG. 
Uma fração de doentes com miastenia gravis é refratária aos tratamentos 
convencionais. Identificar as suas características é importante para 
contribuir para tentar encontrar novas formas de tratamento eficaz neste 
subgrupo. Neste estudo, investigámos os aspetos clínicos dos doentes 
com MG refratária e uma possível associação entre alelos HLA-DRB1. 22% 
dos doentes foram classificados como refratários. Em comparação com 
os pacientes não refratários, os refratários eram mais propensos a ter 
uma classificação de MGFA mais grave no início da doença, ter MG 
associada a timoma e ser seropositivo, seja para anticorpos anti-AChR ou 
anti-MuSK. O alelo HLA-DRB1*13 foi menos frequente na MG não 
refratária quando comparado ao grupo refratário e à população controlo. 
As características clínicas e demográficas dos nossos doentes refratários 
são semelhantes às descritas noutros estudos. É importante considerar 
essas características desde o início da doença. O alelo HLA-DRB1*13 
parece ser um alelo protetor para o grupo das MG não refratárias, à 
semelhança do que descrito em outras OAID. Do que sabemos, não 
existem outros estudos imunogenéticos na MG refratária, assim estes 
resultados precisam ser replicados noutras populações. 
É extremamente raro que doentes com miastenia gravis com início 
precoce tenham timoma anos após a remoção de um timo hiperplásico. 
Descrevemos dois doentes com AChR-MG que desenvolveram timoma 
anos após a timectomia transternal extendida e descrevemos as 
manifestações clínicas que anunciaram o timoma, consequentes a uma 
imunodeficiência grave que se assemelhava à síndroma APECED 
(autoimmune polyendocrinopathy, chronic mucocutaneous candidiasis 
and ectodermal dystrophy) com defeito do gene regulador da 
autoimunidade (AIRE). 
Estes dois casos ilustram a necessidade de procurar um timoma em 
doentes MG cuja doença se torna difícil de tratar após a remoção de um 
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timo com hiperplasia folicular tímica. E que o timoma precisa de ser 
considerado em caso de infeções graves e/ou recorrentes, refletindo uma 
complexa deficiência imune paraneoplásica, que nos doentes aqui 
descritos se associou a auto-anticorpos contra interleucinas. 
 
Continuaremos o estudo dos timomas com análise imunohistoquímica, 
nomeadamente do gene AIRE, e a sua correlação com outras doenças 
autoimunes, presenças de infeções graves/recorrentes e tumores. 
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Chapter 1. Introduction 
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Chapter 1. Introduction 
 
 
1.1. Clinical features of MG 
 
1.1.1. Clinical presentations 
 
Myasthenia gravis (MG) was described for the first time by Thomas Willis 
in 1672.[1] It was the first neurological or neuromuscular disease to be 
identified as being autoantibody mediated.[2–5] 
In around 80% of patients with generalised MG, the disease is caused by 
autoantibodies to the skeletal muscle nicotinic acetylcholine receptor 
(AChR) on the postsynaptic membrane of the neuromuscular junction 
(NMJ); this is called AChR antibody positive MG (AChR-MG).  
The AChR antibodies impair neurotransmission by reducing AChR 
numbers, which is the main consequence of the antibodies and 
complement mediated damage to the neuromuscular endplate[6,7]; the 
second consequence is reduction of AChR half–life.[8] 
Since the structural and functional integrity of the NMJ is essential for 
muscle contraction and strength[9–11], and reserves of AChR are limited 
in humans, AChR loss causes muscle weakness and fatigue, the hallmark 
of clinical MG. The muscle weakness with fatigue is variable but it involves 
predominantly certain skeletal muscle groups. The weakness can be focal 
or generalized, and usually affects ocular, bulbar, neck and proximal 
extremity muscles. Respiratory muscle weakness develops only rarely, but 
can be life-threatening. Weakness is typically symmetrical, except in 
affected external eye muscles, in which the weakness is usually 
asymmetrical. [12–14] 
The evolution of MG is unpredictable, but it is generally characterized by 
the occurrence of relapses, sometimes subsequent to remissions and a 
worsening trend in the first months and years. For 85% of MG patients, 
the maximum severity is reached within less than 3 years.[13,15] 
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1.1.2. Antibodies in Myasthenia gravis 
 
AChR antibodies  
AChR antibodies can be detected by routine assays in 70% of all patients 
with MG.[16,17] AChR antibodies mostly belong to the IgG1 and IgG3 
subclasses, which activate the complement cascade, leading to damage 
of the postsynaptic membrane.[13,16] 
Routine screening for AChR antibodies uses radioimmunoprecipitation 
assay (RIA). It is based on a mixture of solubilized embryonic and adult 
AChR’s, is the most rigorously validated test for AChR antibodies, and is 
the most reliable among the validated AChR antibody tests. Positive test 
results have a near 100% specificity for MG in symptomatic individuals. 
[16,17] 
In another 5–10% of patients, AChR antibodies can only be detected with 
more-sensitive, cell-based assays [18,19], in which AChR molecules are 
clustered on the membranes of cultured test cells. This technique offers 
better sensitivity, and enables detection of low-affinity antibodies: they 
can detect antibodies in 4–66% of patients with ocular or generalized MG 
in whom antibodies cannot be detected with radioimmunoassay. [18]  
The radioimmunoassay is recommended as the first-line test because it 
has been used successfully in clinical practice; moreover, it not only 
detects the presence of AChR antibodies but can also quantify their levels. 
Supplementary cell-based testing should be performed when MG is 
suspected but the patient is negative for anti-AChR and anti-MuSK 
antibodies by RIA. [12,20] 
Total AChR antibody concentration does not correlate with symptom 
severity when patients are compared. Although, fluctuations in AChR 
antibody concentration in an individual patient have been reported to 
correlate with the severity of muscle weakness and to predict 
exacerbations. [16,20,21] 
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MuSK antibodies 
In 2001 it was described that up to 40% of them have autoantibodies to 
the muscle specific tyrosine kinase (MuSK).[22] Subsequent studies 
confirmed the existence of a subgroup of autoimmune generalised MG 
patients who lack detectable antibodies to AChR (AChR Ab– MG), but have, 
instead, MuSK antibodies.  
MuSK is another muscle specific protein expressed at the neuromuscular 
junction and has a role in neuromuscular junction development and in 
AChR clustering during development.[23,24]  
Although both MuSK-MG and AChR Ab– MG clearly improve with plasma 
exchange or intravenous immunoglobulin (IVIG), patients with MuSK-MG 
have some particular clinical and laboratory characteristics which differ 
from the most typical MG.[25] 
 
LRP4 antibodies 
More recently, antibodies to receptor related low density lipoprotein-4 
(LRP-4) were also found to be associated with some cases of seronegative 
MG. LRP-4 is a receptor for agrin and for MuSK, which are important in 
the aggregation of AChR in the neuromuscular junction plate.[26] This 
subgroup of patients seems to have a milder form of the disease.[12,27] 
 
Other antibodies in MG 
Antibodies to agrin, which activates MuSK through Lrp4 binding, and to 
ColQ (Collagen Q), the collagen tail that anchors acetylcholinesterase to 
the end-plate basal lamina, were reported in myasthenia gravis patients 
often in association with other disease-specific antibodies, mostly AChR 
antibodies. Their pathogenic role has not been proved in animal 
models.[28]  
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Other antibodies in thymoma MG and Late Onset MG 
Some MG patients have antibodies that bind in a cross-striational pattern 
to skeletal and heart muscle tissue sections. They are known as 
“striational antibodies”. These autoantibodies recognize epitopes on 
skeletal muscle proteins, including myosin, actin, actinin, and filamin. 
[21] Two types of striational antibodies directed against titin, ryanodine 
receptor (RyR) and cortactin are found in up to 95% of MG patients with 
thymoma and in 50% of late-onset MG patients.[21,28] 
 
1.1.3. Thymus and Myasthenia gravis 
 
The involvement of the thymus in the immunopathogenic mechanisms of 
MG is well established. Leopold Laquer, in 1901, was the first to establish 
a link between the thymus and myasthenia gravis.[1] 
In AChR–MG patients with early onset (before 50 years–old at onset, 
EOMG), the presence of thymic epithelial hyperplasia and multiple 
lymphoid follicles in lymphocytic infiltrations is very common (>80%).[29–
34]  
	  
Figure 1.1.3.1. Hyperplastic thymus in a patient with myasthenia gravis. Intermediate 
view of thymic follicular hyperplasia. The lymphoid follicles are composed of B cells and 
are of secondary type with formation of germinal centers. Higher power view of a 
lymphoid follicle. 
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Moreover, these thymic changes seem to be centred on rare muscle–like 
cells, thymic myoid cells that express skeletal muscle antigens and are 
located in the medulla. Their potential roles as a source of AChR for the 
autoimmunisation and as an early target of the antibody–mediated attack 
on native AChR, have been suggested through different lines of 
research.[29,34–37] 
The thymic involvement in EOMG may also explain the benefits of 
thymectomy in these cases, as observed clinically over the years and also 
in the only clinical trial in this field that was completed and published 
recently.[38] 
By contrast, AChR Ab– thymuses, including those of MuSK–MG cases, are 
usually reported as histologically normal for age or atrophic, and the 
clinical response to thymectomy is unclear.[14,39–42] 
 
 
Figure 1.1.3.2. Normal adult thymus is seen at low magnification. Beyond puberty, the 
thymus continues to atrophy, with decreasing numbers of lymphocytes, so that 
the adipose tissue becomes more prominent. Occasional Hassall's corpuscles appear in 
the lymphoid areas. 
 
 
1.1.4. Diagnosis 
 
The diagnosis of Myasthenia gravis is based on a group on typical 
symptoms, electrophysiological tests and serological studies. The answer 
to the therapeutics also help to support the diagnosis. 
Normal adult thymus is seen at low magnification. Beyond puberty,
the thymus continues to atrophy, with decreasing numbers of
lymphocytes, so that the adipose tissue becomes more prominent.
Occasional Hassall's corpuscles appear in the lymphoid areas.
Return
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Typical symptoms 
1) The presence of suggestive symptoms, isolated or, more frequently, in 
variable combination: diplopia, ptosis, without pupillary abnormalities, 
bulbar manifestations such as dysphonia, dysarthria, dysphagia, difficulty 
chewing, weakness and fatigue of the limbs, neck muscles and respiratory 
muscles; 
2) A typical variability in the symptoms with exacerbation by exercise; 
a) short duration variation during the daytime with worsened symptoms 
in the evening, during menstruation or during the occurrence of fatigue, 
b) relapses corresponding to worsening of the disease over a period of 
several weeks to several months. Ptosis is particularly helpful in the 
diagnosis, because it may vary or alternate in a few minutes and worsens 
after sustained upward gaze. If there is a significant ptosis, the ice test 
(ice cubes applied on the side of ptosis for 1 min) improves the droopy 
lid for a few seconds[13,17], 
c) the occurrence in a few days of respiratory congestion, shortness of 
breath, ineffective cough, choking, and rapid motor deterioration predicts 
a myasthenic crisis that could be life-threatening, requiring immediate 
hospitalization in intensive care unit. [13,17] 
 
Electrophysiological tests – electromyography 
The presence of an EMG decrement is essential and must be investigated 
in several proximal and distal nerve-muscle pairs and if possible after 12h 
interruption of acetylcholinesterase (AChE) inhibitors.  
The single fiber analysis that reveals an elongated jitter (the time between 
the potentials of two muscle fibers of the same motor unit) is more 
sensitive but less specific than the classical EMG and is difficult to 
perform. It must be limited to difficult cases (a negative EMG, in particular 
in ocular myasthenia).[13] 
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Serological tests 
Most MG patients have antibodies directed at proteins of the 
neuromuscular junction. The number of patients with unknown 
antibodies is less than 5%.  
The anti-AChR antibodies are highly specific for MG. If they are negative, 
it is important to search for the anti-MuSK, LRP4 or clustered AChR. If still 
negative, reconsider diagnosis. 
 
Response to the treatment 
The injection of 0.5 mg neostigmine subcutaneously or intra-muscularly 
has a significant effect on the deficit signs (ptosis, hypernasal voice, limb 
weakness) from 15 min and persisting for 2 h. The test of oral 
cholinesterase over a few weeks is quite justifiable to assess the 
functional status in daily life and over time.[13] 
 
Thorax CT scan 
All patients should perform a thorax CT scan to explore the potential 
presence of a thymoma. Scan should be reported by experienced 
radiologist. 
 
Important differential diagnosis 
Lambert-Eaton myasthenic syndrome 
There is another autoimmune neuromuscular disorder, much rarer than 
MG, in which the pre-synaptic part of the NMJ is affected, named the 
Lambert-Eaton myasthenic syndrome (LEMS).[43] It was described for the 
first time in 1960[44] and are associated to voltage gated calcium channel 
antibodies.[45]  
Up to 50-60% of cases occur as a paraneoplastic disorder (SCLC-LEMS), 
most commonly in association with small cell lung cancer but can also 
occur with other types of cancer (prostate, breast, lymphoma).[46–49] The 
other 40-50% are idiopathic, autoimmune without an identified 
	
	
29	
tumour.[50] Despite their rarity they are an important differential 
diagnosis of MG. 
 
Congenital myasthenic syndromes 
Another important group that is also a differential diagnosis with MG are 
the congenital myasthenic syndromes, especially in the cases of double 
seronegative MG. They are a heterogeneous group caused by genetic 
mutations of the proteins that interfere with the NMJ transmission.[51] It 
is very important to differentiate them from autoimmune MG, because the 
treatment is not based on thymectomy or immunosuppression. Although 
in very  rare cases they can be associated to autoimmune MG.[52] 
 
 
1.1.5. Treatments 
 
Treatments for Myasthenia gravis can be divided in three major groups: 
- symptomatic treatment; 
- disease modifying treatment or immunosuppressive treatments; 
- and thymectomy. 
 
Symptomatic treatment 
The acetylcholinesterase inhibitor pyridostigmine represents the first-
choice treatment in all types of autoimmune MG.[17] 
All MG subgroups, besides MuSK-MG, usually respond well to this 
treatment, but individual variation is considerable. In MuSK-MG, is 
reported a good response in only 50% of patients, and 10% did not 
respond at all.[19] Some MuSK-MG patients may not tolerate this 
treatment. 
In such patients, 3,4-diaminopyridine, a drug that is more used in 
Lambert-Eaton myasthenic syndrome, which increases presynaptic 
release of acetylcholine, may be tried. [53] 
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Disease modifying treatment or immunosuppressive treatments 
 
Long term immunosuppression  
 
First-line treatments 
First-line immunosuppressive drug therapy for MG includes either 
prednisone, or the combination of prednisone with azathioprine or other 
immunosuppressive agent. [54–56] According to current 
recommendations, prednisone alone should be given only as short-term 
treatment (<1 year). [55]  
Long-term prednisolone monotherapy could be considered for the 
treatment of ocular MG or if is possible to keep a low dose, but for the 
majority of other patients with MG, combination immunosuppressive 
treatment is recommended to obtain maximum effect with minimal 
adverse effects of steroids. [54–56] 
Azathioprine (2–3 mg/kg daily) is usually the first line 
immunosuppressive treatment in MG, but it takes 6–15 months to yield 
an optimal effect. So, it is used in association to prednisone, which exerts 
its full effect during the first few weeks and months of treatment. [54–56] 
When pharmacological remission or a marked improvement is reached, 
the immunosuppressive drug should be maintained in the long-term, 
whereas the steroid dose should be reduced if possible, to avoid adverse 
effects. Full drug withdrawal may lead to new exacerbations, particularly 
in MuSK-MG, thymoma MG and late-onset MG. [54–56] 
 
Second-line treatments  
There are no controlled studies that compared different drugs in MG.  
Mycophenolate mofetil is an option after the failure of first-line therapy. 
Evidence supports that the use of this drug is strongest in AChR-MG, 
although more long term studies are required.  [57,58] 
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Rituximab has been increasingly used in MG. It is a monoclonal antibody 
that binds specifically to the B-lymphocyte surface antigen CD20. For 
severe MG, and for MuSK-MG in particular, rituximab may  be given as 
first-line immunosuppressive therapy.[59,60] More than 80% of patients 
with severe or refractory MG responded to rituximab.[60] Most studies to 
date have used the same induction regimen as for rheumatoid arthritis 
and then repeated the treatment only if symptoms recurred after many 
months.[12] 
 
Alternative second-line treatments and third-line treatments 
Alternative second-line and third-line treatment options for MG include 
methotrexate, cyclosporine, tacrolimus and cyclophosphamide. 
Cyclosporine has a proven effect in well-controlled studies, but its use 
has been limited by a high risk of adverse effects. Several uncontrolled 
trials suggested that improvement was seen in 65 to 85% of MG patients 
after 12 to 30 months of treatment.[61–64] 
Methotrexate has been used as a second or third line with a steroid 
sparing effect with reasonable response. Recently there was a study 
claiming that there is no benefit in the use of methotrexate in MG[65], 
experience that has not been shared by others. Indeed, despite several 
limitations, methotrexate has been shown to provide an effective 
alternative to azathioprine in generalised MG.[61,66–68] 
Tacrolimus: there is limited yet promising information to suggest a 
beneficial role in reducing QMGS and corticosteroid burden in patients 
with refractory symptoms or new-onset MG.[69] It is similar to 
cyclosporine, tacrolimus inhibits calcineurin but has the advantage of 
being less nephrotoxic. Case series have demonstrated its efficacy in MG 
as a monotherapy or as a corticosteroid sparing agent.[61] 
Cyclophosphamide is an alkylating agent that interferes with DNA 
replication and decreases the production of lymphocytes, monocytes, and 
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macrophages. According to the literature and expert’s opinion, the use of 
cyclophosphamide has been limited to cases of refractory MG. Remission 
may be achieved after 12 months, [70] or much earlier as reported in one 
study (average treatment duration of 3.6 months in half of the patients 
treated). [71] 
 
Other treatments  
Other biologic agents have been used in an even more refractory 
subpopulation of patients: tocilizumab[72], eculizumab[73,74], 
belimumab[75] and rescue treatments (autologous hemopoietic stem cell 
transplantation)[76]. 
 
Short term and rapid action immunosuppression 
Intravenous immunoglobulins and plasma exchange 
Intravenous immunoglobulin (IVIG) is predominantly used as short-term 
immunoactive therapy in acute situations. IVIG and plasma exchange have 
similar effects on MG exacerbations. [54,55] Such treatments should 
always be given for an ongoing or imminent MG crisis, and may be also 
recommended shortly before situations in which muscle weakness is 
expected to deteriorate or lead to complications, such as surgery. IVIG or 
plasma exchange are usually combined with intensified 
immunosuppressive treatment in patients with severe disease or severe 
exacerbation. Overall, all MG subgroups — even seronegative MG — 
respond to IVIG and plasma exchange, although they may respond better 
to one than to the other treatment. Regarding seronegative patients, the 
response to those treatment imply that they also have circulating 
antibodies that are very likely pathogenic.[12,13,16,54,55] 
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Thymectomy 
In thymoma MG, the thymoma of the thymus gland should always be 
removed to treat the cancer. The response of MG to thymectomy is 
variable, and improvement of MG symptoms is usually more limited than 
in early-onset MG.[12] 
In early-onset MG, there are a number of controlled studies which showed 
that thymectomized patients have a more favourable outcome than those 
who are not.[77,78] Evidence recommends early and complete 
thymectomy in all patients with early-onset generalized MG with AChR 
antibodies, particularly those who are not symptom-free on symptomatic 
drugs alone. The fact that thymic hyperplasia is common in this subgroup 
supports a therapeutic effect of thymectomy performed early after MG 
onset. Early thymectomy will prevent export of AChR-specific T cells from 
the thymus to lymph nodes and peripheral lymphoid tissue. [20,38,77,78] 
For a good outcome, removal of all thymus tissue is 
essential.[20,38,77,78] 
Late-onset MG is traditionally regarded as less responsive or 
nonresponsive to thymectomy; however, the evidence regarding 
thymectomy in patients with late-onset MG is sparse. The fact that the 
thymus of patients in this subgroup is usually atrophic (an age-normal 
finding) does not provide any support to the use of thymectomy.[77,78] 
In MuSK-MG and LRP4-MG thymectomy is not  recommended.[20] 
Thymectomy has not shown yet to prevent generalization in ocular MG, 
or to induce remission. Thymectomy, is therefore, not yet  recommended 
for ocular MG. [55,59], although some experts have been doing 
thymectomy in selected cases of ocular MG, especially if they have some 
hint of other muscle involvement in electrophysiology tests.  
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1.1.6. MG classification and subgroups 
 
Patients with MG are usually  classified into subgroups according to 
clinical presentation and biomarkers.[20] The criteria for these subtypes 
include clinical symptoms, age of onset, thymic pathology and the 
autoantibodies.  
 
MG with anti-AChR antibodies 
MG with anti-AChR antibodies is divided into early-onset MG (symptom 
onset before 50 years) and late-onset MG (onset after 50 years).[79] In 
some studies there is an additional subgroup: the very old late onset MG 
(onset after 65 years).[80,81] 
In AChR-MG, the early-onset and late-onset disease types differ with 
respect to thymic pathology (Table 1.1.6.1.), HLA genotype and other 
genetic variables, autoimmune comorbidities, and response to therapy. 
For example, thymectomy has clear clinical benefits in early-onset MG, 
but its benefits in late-onset MG are more questionable and possibly non-
existent.[20] 
 
MuSK-MG 
The presence of anti-MuSK antibodies is usually associated with more-
severe and generalized muscle weakness, where bulbar and facial 
muscles are usually more predominantly involved early in the disease. 
Sometimes, they also  develop muscle atrophy later in the disease 
course.[53] In MuSK-MG, there seems to be less muscle fluctuation than 
in other MG subtypes, probably because the severity of the muscle 
weakness.[42,53,82] Limb weakness is less commonly affected than in 
AChR-MG, and ocular muscles can be affected in a more symmetric 
way.[53,82,83] Importantly, respiratory weakness is more likely to affect 
patients with MuSK-MG than other MG subgroups.[53,82] Therefore, 
myasthenia crisis is more commonly seen in these patients. MuSK MG is 
not associated with thymus pathology. 
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LRP4-MG 
MG with LRP4 antibodies is a subgroup more recently described and less 
well characterized.[27,84,85] It seems that in this subgroup the 
symptoms are milder, both at initial presentation and over the course of 
the disease.[86] Myasthenic crisis is very rare. A few patients have been 
reported to have a combination of anti-AChR and/or anti-MuSK and anti-
LRP4 antibodies.[19] Association to thymoma has already been reported, 
but this is very rarely found.[87]  
 
Seronegative MG 
By definition, seronegative MG patients have no anti-AChR, anti-MuSK or 
anti-LRP4 antibodies.  Patients need to have, however, MG symptoms, 
abnormal neurophysiological tests and favorable response to treatments 
usually used in typical of MG. They constitute about 10% of generalized 
MG patients.  Is an heterogeneous group, as it includes patients that may 
have typical antibodies  of low affinity or of very low concentration to be 
detected; it may include also patients with antibodies against relevant 
antigens that have not yet been identified.[18] Usually the symptoms are 
milder and the potential benefit of thymectomy has not been 
confirmed.[20] 
 
Thymoma associated MG 
MG associated to thymoma constitutes about 10-15% of all MG cases, and 
virtually all of the thymoma MG patients have AChR antibodies. 
Approximately 30% of patients with thymoma may develop MG, especially 
if they have AChR antibodies.[12,16] MG associated with thymoma usually 
responds to immunosuppressive treatments, although, when compared 
to those without thymoma, they may  require more and more prolonged 
immune treatment.[88] 
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Ocular MG 
Approximately 60-80% of patients with MG have ptosis and/or diplopia at 
onset. At 2 years after onset, 15–20% of patients with initial ocular MG 
still have purely ocular MG.[16,55] 40%–70% of ocular myasthenia patients 
have anti-AChR antibodies on the conventional assay.[55,89] Only very 
few ocular myasthenia cases have antibodies to MuSK.[55,90,91] 
 
 
Table 1.1.6.1. Myasthenia gravis: classification in subgroups 
 
Subgroup Auto-
antibodies 
Age of Onset Frequency in 
MG 
Thymus 
AChR-
MG 
Early-
Onset MG  
Anti-AChR + <50y 15-25% Thymic hyperplasia 
Late-Onset 
MG 
Anti-AChR + <=50y 35-45% Atrophic 
MuSK-MG Anti-MuSK + Any 
++Young 
females 
1-10% Normal 
LRP4-MG Anti-LRP4 + Any 
++Young 
females 
1-5% Normal 
Seronegative None Any 10-15% Normal or thymic 
hyperplasia 
Thymoma MG Anti-AChR + Any 10-15% Thymoma 
Ocular Any 
Negative in 
50% 
Any 15% Variable 
 
 
1.2. Etiopathogeny 
 
Antibodies targeting the neuromuscular junction cause myasthenia 
gravis. These antibodies bind to the postsynaptic muscle endplate and 
attack and destroy postsynaptic molecules. This process leads to 
impaired signal transduction and, consequently, muscle weakness and 
fatigability — the hallmark symptoms of MG.[12,16,20] 
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The aetiology of MG is believed to result from the interaction between 
genetic and environmental factors.[39] 
 
1.2.1. Immunology – thymus 
 
A key pathogenic finding in EOMG is the occurrence of intrathymic 
lymphoid follicles and germinal centers described as early as 1901. Once 
established, germinal centers drive the hypermutation of B cell receptor 
genes and intrathymic production of high affinity myasthenogenic anti-
AChR antibodies.[78] 
Initially the thymic myoid cells were assumed to be the initial (triggering) 
source of AChR for autoimmunization.[29] More recently, new evidence 
suggests that medullary epithelial cells express unfolded AChR subunits 
and are under attack by autoantibodies and complement just like adjacent 
myoid cells. [92–95] In light of this, it has been proposed (REF) that helper 
T cells are primed by unfolded AChR subunits expressed by MHC class I 
and II positive hyperplastic medullary epithelial cells.  Early antibodies 
elicited by primed T cells then attack nearby myoid cells (that express 
whole, native AChRs) and activate complement with subsequent release 
of AChR/immune complexes. These, in turn, activate professional antigen 
presenting cells, germinal center formation and autoantibody 
diversification. [96] 
 
 
1.2.2. Environment 
 
Environmental factors, such as drugs (i.e., D-penicillamine and IFN-I) and 
pollutants are also proposed to increase the risk of developing an 
autoimmune disease. [97] 
In EOMG there is strong evidence that a comprehensive autoimmunization 
against the AChR begins and persists in the thymus. However, the 
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immunization trigger is unknown. [98] Some suggest that a viral infection 
may trigger the initiation of this process.[79] Recent candidates are EBV 
[99,100] and Human Polyomavirus 7 (HPyV7) that were detected in 40% 
of hyperplastic thymuses (and in thymomas). [101] 
Several reports indicate that other viruses, such as cytomegalovirus, 
human foamy virus, and Nile virus, are associated with MG.[102,103] 
 
1.2.3. Genetics 
 
The association of human leukocyte antigen (HLA) class I and class II 
genes with MG is clearly established.[39,104,105] The association 
between HLA-B8 (MHC class I) and -DR3 (MHC class II) and EOMG (and 
thymic follicular hyperplasia), was confirmed in several studies. 
[39,104,106] LOMG is associated with HLA-DR2-B7.[39] 
Other susceptibility genes have also been studied.[104,107,108] Most of 
these genes are also susceptibility genes for other autoimmune diseases 
and include PTPN22, CTLA-4, IL-1b, IL-10, TNF-a, and IFN-g. [104] 
More recently, a genome-wide association study (GWAS) performed in 
northern European EOMG patients showed an association with the 
transcription factor TCF19.[109] TCF19 is involved in cell proliferation 
and differentiation and is up-regulated in human pro-B and pre-B cells. 
This gene is also highly expressed in GC cells.[110]  
Most of the genes associated with MG are involved in regulating the 
immune system. It is possible that subjects with specific alleles associated 
with lower immunoregulatory capacity may be more susceptible to 
autoimmune diseases, particularly to MG.[79] 
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1.3. Epidemiology of Myasthenia gravis 
 
Myasthenia gravis is a relatively rare neurological disease. Its prevalence 
is variable, but is around 10–20 per 100.000.[111–115] Some recent 
reports show a steady increase in MG prevalence, which seems to be due 
to an increasing incidence of MG in elderly people, particularly in Western 
countries.[116–120] 
Since the fifties, a large number of epidemiology studies on MG have been 
performed. They have been conducted worldwide describing quite 
distinct prevalence and incidence rates, according to different methods, 
classifications of the disease and the inclusion criteria 
used.[121,122,80,120,123–128]   
Two seminal reviews were published on the methodological issues and 
findings of population-based epidemiological studies of MG.[129,130] 
Carr et al review covered 55 studies performed between 1950 to 2007 
and showed prevalence rates that ranged from 15 to 179 per million 
persons and incidence rates that ranged from 1.7 to 21.3 per million 
persons per year.[129] It remains unclear whether this reflects primarily 
methodological differences or true differences in disease frequencies 
based on ethnical or other demographic factors.[130]  
Some previous studies showed a trend of increasing prevalence with 
relatively stable incidence, which was interpreted as reflecting the impact 
of effective treatment and improved diagnostic methods.[112] More 
recently, prevalence seems quite stable, but in the last two decades 
several studies report changes on MG incidence, which is mostly due to 
the group of patients with LOMG.[81,116,117,131]  
Differences in MuSK-MG and AChR-MG prevalence and incidence 
throughout the globe have also been reported. There is clear evidence 
that MuSK-MG is more common in the southern European countries than 
in the North of Europe.[82,132,133]  
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1.4. Other relevant subjects 
 
1.4.1. Polyautoimmunity and Myasthenia gravis 
 
Patients affected by one autoimmune disorder have a higher risk of 
developing another autoimmune disease. MG patients have an increased 
risk of other autoimmune disorders compared to the non-MG population. 
[134–136] The frequency of a second autoimmune disorder is 11–25.7% 
in MG patients, with most studies showing that this is highest for females 
and early onset MG (EOMG). [106,112,127,134–136] 
In a systematic review, autoimmune thyroid disease (ATD) was the most 
frequent of 23 associated autoimmune disorders, occurring in 10% of MG 
patients. [134,137] Other common autoimmune associates with MG are 
systemic lupus erythematosus (SLE) (1-8%), rheumatoid arthritis (RA) (4%), 
dermato/polymyositis and neuromyelitis optica. [134,137–140] 
Genetic studies on the development of autoimmune disorders reveal 
common susceptibility genes, most strongly at the human leukocyte 
antigen (HLA) locus. Genome-wide association studies (GWAS) on EOMG 
shed light on specific additional genetic hot spots for MG. EOMG is 
strongly associated with the haplotype HLA-B8-DR3[39], which is also 
associated with autoimmune thyroid disease, type 1 diabetes mellitus, 
Sjogren’s syndrome, inclusion body myositis, dermato/polymyositis, 
SLE.[141] 
 
1.4.2. Refractory Myasthenia gravis 
 
Therapeutic options in myasthenia gravis patients include cholinesterase 
inhibitors, thymectomy, immunosuppressive agents and short-term 
immunomodulation with plasma-exchange and intravenous 
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immunoglobulin. [28] Conventional immunosuppressive agents used in 
MG treatment include azathioprine, mycophenolate mofetil, 
methotrexate, cyclosporine, tacrolimus and cyclophosphamide.[142] A 
small proportion of myasthenia gravis patients (10-15%) are classified as 
refractory due to non-responsiveness to conventional treatments.[142] 
Refractory patients were defined as those who could not lower the 
immunotherapy for MG without clinical relapse, with MG not clinically 
controlled on their immunotherapy regimen, or who had developed 
severe adverse effects from immunosuppressive therapy for at least a 
period of 12 months.[88,142] 
Some studies show that these patients are mostly females, have young 
onset and generalized disease, and are seropositive, predominantly to 
anti-MuSK antibodies or those with thymoma.[88,142] 
This refractory MG population has been the focus of recent publications 
evaluating the response to biologic agents (rituximab[142,143], 
tocilizumab[72], eculizumab[73,74], belimumab[75]) and rescue 
treatments (autologous hemopoietic stem cell transplantation).[76] 
 
1.4.3. Myasthenia gravis in children 
 
Myasthenia that affects children can be classified into the following forms: 
transient neonatal myasthenia and juvenile myasthenia gravis (JMG). [144] 
Juvenile myasthenia gravis is a rare autoimmune neuromuscular disorder. 
It can be divided in two periods: the very early onset MG patients, younger 
than 8 years old and with a higher proportion of ocular MG (66%), and a 
puberty onset MG (8-18 years old), that is more similar to the EOMG.[145] 
JMG is more frequent in Asia than Europe or America. [146][147] 
In a French study of 40 patients with JMG, 70% had generalized MG, 52% 
had positive acetylcholine receptor antibodies, 8% had muscle-specific-
kinase antibodies, and 40% were seronegative. [148] 
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A Chinese study, which included 114 JMG patients, showed that AChR 
antibodies were present in the majority of JMG patients and were 
associated with more severe disease, while other antibodies were rare. 
[145] Genetic analysis revealed that the very early onset JMG had a more 
prominent genetic predisposition in both an autoantigen gene (CHRNA1) 
and an immunomodulating gene (CTLA4). Thymus hyperplasia was 
diagnosed more frequently in those with onset before 8 years. The 
puberty onset patients (8–18 years) appeared with intermediate 
characteristics between the very early onset JMG and the young adult 
patients. [145]. Thymomas were present in 5% of JMG patients.[145] 
The pathophysiology of juvenile myasthenia gravis is similar to that of 
adult myasthenia gravis, though important differences remain regarding 
presentation and therapeutic options. [149] 
One limitation in the treatment of these children is that randomized 
clinical studies of myasthenia gravis have been carried out primarily in 
adult populations.[149] Treatment with acetylcholinesterase inhibitors 
was effective and sufficient in 47% of patients. The 6 patients with 
generalized JMG treated with rituximab and/or immunoadsorption 
showed improvement. Thirty percent of the patients required 
hospitalization in an intensive care unit during follow-up (mean 4.7years). 
Remission without treatment occurred in 18% of patients.[148] 
Thoracoscopic thymectomy is a safe and acceptable treatment for juvenile 
MG with good disease control. The low morbidity and shorter hospital 
duration make it an excellent option for consideration.[150] 
 
1.4.4. Late Onset Myasthenia gravis 
 
In myasthenia gravis (MG), clinical manifestations can vary depending on 
the age of onset. There is no clear consensus on the definition of late-
onset myasthenia gravis (LOMG); the cut-off age was originally set at 40 
years; then, 50 years of age; this has been more generally used in clinical 
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practice and in studies.[39,131] However, a cut-off of at 60 years is 
sometimes used because the current biological status is better, and life 
expectancy of general population is higher.[151,152] 
Studies have shown that the incidence of MG has increased dramatically 
over the past 20 years, but only among those >65 years of age. [81,153] 
 Late-onset MG is traditionally regarded as less responsive or 
nonresponsive to thymectomy however, the evidence regarding 
thymectomy in patients with late-onset MG is sparse. The fact that the 
thymus of patients in this subgroup is usually atrophic (an age-normal 
finding) does not provide any support to the use of thymectomy.  
In a study comparing young onset and late onset MG patients, the elderly 
group, nine (45%) patients had accumulations of lymphocytes, indicating 
an atrophied thymus with loss of the basic structure. The elderly MG 
patients with atrophied thymic tissues had higher titres of anti-AChR 
antibody (59.6+/-81.0 nmol/L) than those with adipose infiltration of 
the thymus alone (20.1+/-20.9 nmol/L). In immunohistochemical studies, 
using image analysis, both young patients and elderly patients with 
atrophied thymic tissues were found to have significantly higher levels of 
CD20 than age-matched controls (p < 0.005).[152] 
Thymus remains functional until the sixth decade of life. Atrophy of the 
thymus and decreased output of T lymphocytes are prominent features in 
older adults, but they are not the sole changes that occur with age. 
Increase in marginal zone and B-1 B-cell numbers, a source of 
autoantibodies, could explain the increased frequency of self-reactive 
immunoglobulins in older adults. 
In patients with MG onset at 50–65 years who have thymic hyperplasia, 
the response to thymectomy might be expected to be similar to that in 
early-onset MG, and thymectomy should be considered in selected 
patients. Biomarkers are needed to establish indications for thymectomy 
in late-onset MG.  
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Antibodies against titin and RyR are most common in late-onset MG. Fifty 
percent of LOMG subgroup patients and almost all MG patients with 
thymoma have striational antibodies, but it is unknown why these 2 
groups have the same antibody profiles.[20,154] It has been suggested 
that the presence of antibodies to non-AChR muscle antigens, rather than 
the presence of thymoma or the late age of onset, is responsible for more 
severe disease in older patients.[155]  
Diagnosing MG in older adults can be challenging, weakness can be 
mistaken for motor neuron disease or a brainstem stroke, and MG is 
probably underdiagnosed in this age group.[81] Studies from Japan have 
shown that the ocular form is more common in LOMG.[147] 
The diagnosis of patients with LOMG is fundamentally not different from 
diagnosis in other age groups, although a high index of suspicion should 
be maintained due to the frequent occurrence of comorbidities in older 
people that might be confused with MG symptoms.[81] 
Treatment is also similar to EOMG, but specific consideration should be 
given to side effects. One cohort study showed adverse effects of 
cholinesterase inhibitors in 22 MG patients (age range 30–84 years, 11 of 
whom were >65 years of age) and found that age correlated with the 
cholinergic adverse effects.[156] 
Unfortunately, they have major side effects to steroids too. They include 
cataracts, hyperglycemia, diabetes, hypertension, osteoporosis, 
infections, and weight gain, which have been reported to occur in up to 
66.7% of patients; these effects are especially worrisome in older 
adults.[81] 
Some found that LOMG (defined as age 50 years) showed a statistically 
non-significant trend toward more clinically severe disease than early 
onset, but patients had a similar treatment response and outcome. [157] 
However, it was also described  a higher pharmacological remission in 
subjects with an older age at onset.[158] 
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Considering all described above, MG occurring in older adults seems to 
be more difficult to manage mainly because of the multiple comorbidities 
and side effects of medications.[81] 
 
1.4.5. Pregnancy and Myasthenia gravis 
 
MG is not associated with infertility, but it exposes pregnant women to 
an increased risk of maternal and fetal complications. The clinical course 
of pregnancy in these patients is unpredictable. Symptoms at the date of 
conception, the requirement to treat active MG symptoms, as well as the 
course of previous pregnancies do not seem to correlate with the course 
of a specific pregnancy in mothers who suffer from MG.[159]  
It has been described that about 30% of pregnant women experienced 
improvement of symptoms while a third face clinical worsening, especially 
in the first trimester and during postpartum.[159,160]  
An increase in the exacerbation rate during pregnancy in the first two - 
three year after diagnosis was also described.[161] So it is advised to 
postpone pregnancy one to two - three years after diagnosis.[159,161]  
As smooth muscle is not affected in MG, indication for cesarean delivery 
is usually reserved for obstetric indications. However, it should  be 
emphasise that 3rd stage of labour involves the contraction of voluntary 
striated muscle and this is where assistence in vaginal delivery is required 
to reduce the expulsive efforts and then minimize mother’s fatigue[159]. 
Regardless, the incidence of cesarean delivery seems to be increased in 
these patients.[162,163]   
The risk of preterm birth, low neonate birthweight or hypertensive 
disorders apparently are not increased in MG pregnant women.[163,164] 
Neonatal MG (NMG) affects 12-20 % of newborns of such pregnancies. 
Typical forms characterized by weak cry, swallowing and sucking 
difficulties usually appear during the first hours of life and disappear in 
90% of cases in 2 months. Atypical forms of arthrogryposis multiplex 
congenita are also described and represent 29% of NMG[165]. Neonatal 
MG happens in both AChR-MG and MuSK-MG.[166–171] 
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Chapter 2. Aim and Objectives 
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Chapter 2. Aim and Objectives 
 
 
The aim of this research is to increase the knowledge of the epidemiology 
of Myasthenia gravis in the North of Portugal, and describe the clinical, 
serological and immunopathological (thymus) aspects of MG cases 
identified. It is expected that that knowledge will improve the clinical 
management of the cases of MG in this setting. 
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The objectives of this study are: 
(1) to identify the patients with Myasthenia gravis in the North of Portugal;  
 (2) to study the clinical and demographic characteristics of this 
population;  
(3) to classify the patients according to Myasthenia gravis subgroups;  
(4) to calculate the incidence and prevalence of the disease as a whole 
and its subgroups;  
(5) to analise and compare our population of portuguese myasthenic 
patients with patients from other regions in Europe and the rest of the 
world;   
(6) to identify factors that may influence the course of the disease and 
response to treatments;  
(7) to study the effect of the disease on pregnancy; 
 (8) to register other autoimmune disorders and correlate it with thymus 
pathology; 
 (9) to study the thymus of the patients submitted to thymectomy, with 
thymoma, with immunohistochemistry; 
(10) and to correlate the immunohistochemistry studies of the thymus 
with the clinical data (infections, other cancers, other autoimmune 
disorders). 
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Chapter 3. Results 
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Chapter 3. Results 
 
3.1. Epidemiological study 
 
Within this research project, an epidemiological study was conducted, in 
order to estimate the prevalence and incidence of MG in the North of 
Portugal.  
We restricted this study to the North of Portugal and used two different 
sources: the clinical records from the hospitals and the pyridostigmine 
prescription register in the study area. 
This study included patients from the following hospitals: Hospital São 
João, Porto, Centro Hospitalar de Vila Nova de Gaia e Espinho, Hospital 
Pedro Hispano, Matosinhos, Centro Hospitalar do Trás-os-Montes e Alto 
Douro, Vila Real, Centro Hospitalar do Alto Minho, Viana do Castelo, 
Centro Hospitalar Entre Douro e Vouga, Feira, Hospital de Braga, Braga, 
Centro Hospitalar do Nordeste,  Mirandela, Hospital de São Teotónio, 
Viseu, Centro Hospitalar Universitário de Coimbra, Coimbra, Centro 
Hospitalar do Vale do Sousa, Penafiel and  Neuropediatric Departments 
from Centro Materno Infantil Norte, Centro Hospitalar Porto and Hospital 
de São João, Porto, Portugal. 
The pyridostigmine prescription register in the study area was obtained 
from Administração Regional de Saúde do Norte. 
The serological studies were performed in the clinical Neuroimmunology 
laboratory at the Nuffield Department of Clinical Neurosciences, Oxford 
University Hospitals, University of Oxford, United Kingdom, by Dr. Ester 
Coutinho, under supervision of Prof. Dr. Maria Isabel Leite. 
It was published in Muscle and Nerve 2016;54(3):413-21 and the full 
text follows. 
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Abstract 
We are not aware of previous studies attempting to estimate incidence 
and/or prevalence of myasthenia gravis (MG), or characterizing the 
clinical epidemiological patterns of MG in Portugal.  
We restricted this study to the North of Portugal and used two different 
sources: clinical records from the hospitals and pyridostigmine 
prescription register in the study area.  
The objectives were: to estimate the prevalence, incidence and mortality 
of MG, assessing the availability of data to do those estimates, and to 
characterise demographic, clinical and laboratory features of the MG 
cases identified.  
At 31/12/2013 we estimated a point prevalence of 111.7 patients/106.  
These figures are similar to those reported either in studies in southern 
European countries, or in the north of Europe, in studies with similar 
methods and size of the population studied.  
Prevalence rose with age reaching its maximum in the group over 65 
years old, especially in males (288.1/106).  
During the year of 2013 we estimated an incidence rate of 6.3 per 
million person/year. Our incidence rate was closer to studies from 
distinct latitudes with similar methods and to others from south of 
Europe.  
Among females, incidence rate is higher in the age group 15-49, while 
in male’s incidence increases with age till the maximum (22.1/106) in 
those aged over 65 years.  
The mortality rate attributed to MG was 0.5 per million, which is in the 
range of what others studies reported. MG features of the patients 
identified have mostly confirmed common demographic distribution 
and disease characteristics as published by others.  
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Introduction 
The disease is characterized by fatigable weakness of voluntary muscles 
and the severity varies from mild ocular symptoms to generalized 
weakness with bulbar symptoms and respiratory insufficiency. Those 
phenotype differences led to the classification of the MG in two main 
subgroups according to the muscle groups involved - ocular and 
generalised - and also according to their severity.  
MG affects people of any age, and this demographic characteristic has 
allowed additional disease classification in early onset and late onset MG 
(EOMG and LOMG respectively) with a cut off age that has changed over 
time from 40 to 50 or even 60 or 65 years at disease onset, depending 
on the studies and opinions.[39,131] 
Clinical, demographic, serological, histological and genetic features of the 
MG were first analysed together in 1980, where distinct sub-forms of the 
MG were identified.[39] This study constituted the foundation for a large 
number of epidemiological, clinical and laboratory research studies ever 
since performed worldwide. 
Epidemiological studies may be one of the ways to investigate 
predisposing factors for MG such as genetics, climate or eating 
habits.[126] They are also very important in the understanding 
autoimmunity at different ages and gender, and to study the impact of 
the disease in general health care of MG populations.  
Since the fifties, a large number of epidemiology studies on MG have been 
performed. They have been conducted worldwide describing quite 
distinct prevalence and incidence rates, according to different methods, 
classifications of the disease and the inclusion criteria 
used.[121,122,80,120,123–128]   
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Table 3.1.1. Prevalence and incidence studies on myasthenia gravis 
Author, year  Region Period Population 
(n) 
Methods of cases identification Incidence 
(per 
million) 
Prevalence 
(per 
million) 
Present 
study 
North of 
Portugal 
2013 3 644 195 Hospital registries and pyridostigmine 
databases from GP’s 
6.3 111.7 
Aragones, 
2014  
Osona, 
Barcelona 
2013 155 069 Regional hospitals registries NA 328.9 
Aragones, 
2014  
Osona, 
Barcelona 
2001-
2010 
142 337 Regional hospitals registries 28.0 NA 
Pedersen, 
2013  
Denmark 1996-
2009 
5 511 000 National registry for MG and 
pyridostigmine databases 
9.2 NA 
Pallaver, 
2011  
Trento, Italy 2005-
2009 
524 826 Hospital and GP registries, AChR serology 
registries and pyridostigmine databases 
14.8 129.6 
Montomoli, 
2012  
Pavia, Italy 1985-
2008 
493 753 Hospitals registries NA 240 
Anderson, 
2014  
Norway 1995-
2008 
4 737 171 Nationwide MG databases and 
prescription database 
8.8-16 131-145 
Heldal, 2009  Norway 1985-
2008 
4 737 131 National registry for AchR test 7.2 115.5 
Somnier, 
2005  
Eastern 
Denmark 
1970-
1999 
2 300 000 Regional hospital registries 3.5 NA 
Poulas, 2001  Greece 1992-
1997 
10 180 
913 
Anti-AchR serology registries 7.4 70.6 
 
Guidetti, 
1998  
Regio-Emilia, 
Italy 
1980-
1994 
427 493 Multiple sources: registries from different 
specialities and GP ‘s 
7.8 117.5 
MG – myasthenia gravis, GP – general practitioner, AChR – acetylcholine receptor, NA - not 
applicable 
 
Two seminal reviews were published on the methodological issues and 
findings of population-based epidemiological studies of MG.[129,130] 
Carr et al review covered 55 studies performed between 1950 to 2007 
and showed prevalence rates that ranged from 15 to 179 per million 
persons and incidence rates that ranged from 1.7 to 21.3 per million 
persons per year.[129] It remains unclear whether this reflects primarily 
methodological differences or true differences in disease frequencies 
based on ethnical or other demographic factors.[130]  
Some previous studies showed a trend of increasing prevalence with 
relatively stable incidence, which was interpreted as reflecting the impact 
of effective treatment and improved diagnostic methods.[112]  
More recently prevalence seems quite stable, but in the last two decades 
there have been several reports of a trend on changing the MG incidence, 
mostly in the group of those with LOMG.[81,116,117,131] 
It has been also reported differences in MuSK MG and AChR MG 
prevalence and incidence throughout the globe. There is clear evidence 
	
	
55	
that MuSK MG is more common in the southern European countries than 
in the North of Europe.[82,132,133] It has been also described that AChR 
MG varies with different latitudes or regions even inside the same 
country.[172–174] 
Recently some authors have addressed promising possibilities of 
combining different sources of information to identify MG cases in 
epidemiological studies, using pyridostigmine prescription register 
combined with databases with clinical records [121,125,175] or based 
uniquely on pyridostigmine prescription register.[176] 
We are not aware of previous studies attempting to estimate incidence 
and/or prevalence of MG, or characterizing the clinical, demographic and 
epidemiological patterns of this disease in Portugal. We restricted this 
study to the North of Portugal and used two different sources: clinical 
records from the hospitals in the study area and pyridostigmine 
prescription register, as in the studies we mentioned above.[125,175] 
The objectives were: to estimate the prevalence, incidence and mortality 
of MG, assessing the availability of data to do those estimates and to 
characterise the identified cases of MG. 
 
Materials and Methods 
The study focused on a geographically well-defined area of Portugal – 
the North region of Portugal, which is officially defined by NUTS II 
(Nomenclature of territorial units for statistics) and covers an area of 21 
278km².[177]  
According to the 2011 census 3 689 682 inhabitants lived in the North 
of Portugal.[177] The estimated population for the same region for 
31/12/2013 was 3 644 195 inhabitants.[178]  
To calculate de incidence rate for the year of 2013 we could not get the 
estimated population at the 30th June 2013; instead, we used the 
estimated population for the 31/12/2013, assuming that for this six 
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month period there was not a significant change in the size of the 
population. 
In Portugal, the great majority of MG patients are treated in public 
hospitals. Even when they are diagnosed in a private clinic they are 
referred to public hospitals for further workup and management. On 
rare occasions, such as in mild MG or later in the course of the disease, 
patients may be handed over to private practising neurologists or 
general practitioners (GP) as per patient choice. In both cases, 
pyridostigmine prescriptions may be continued by their GP.  
MG patients are followed up in one of the eleven public hospitals in this 
region, where there is at least one neurologist working in a Neurology 
or Neuropediatrics unit. Three hospitals located in the Centre Region of 
Portugal have also participated in this study because MG patients living 
in border areas that are under de RHA of the the North region are often 
seen there. The names of all hospitals and health units involved in the 
study are listed under the “affiliations” of the authors working in 
Portugal. 
Data was collected prospectively between 01/01/2013 and 31/12/2013. 
All patients who had the disease onset and MG diagnosis until the end of 
this period were included. 
 
Identification of MG patients 
Two complementary approaches were used to identify patients: 1) 
hospital clinical databases and/or clinical records of neurologists of the 
hospitals participating in the study (HCDB); 2) computorized data base 
of pyridostigmine prescriptions (PPDB) by the general practitioners (GP) 
working in the North region. 
1) HCBD: neurologists responsible for MG patients in each of the 
hospitals of catchment area were invited to participate. They were asked 
to identify, all MG cases currently being treated there. The diagnosis was 
verified by review of medical records. Information collected included 
sociodemographic and clinical data; patients that had not been tested 
yet for AChR or MuSk antibodies or were negative by standard assays 
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performed locally, were invited to provide a blood sample  for antibody 
tests. 
All neurologists were contacted regularly to remind them to register new 
patients, complete any clinical data still missing and also to collect a 
blood sample as appropriate. 
2) PPDB: The Regional Health Administration (RHA) services have an 
informatic prescription register that permits access to all the 
prescriptions made by the GP’s. Pyridostigmine bromide (Mestinon®) is 
used practically in all MG patients with clinically active disease and as first 
line treatment. At the same time it is used almost exclusively in MG and 
congenital myasthenic syndromes. Although the initial prescription is 
usually made by a neurologist it can be continued by a neurologist, a GP 
or both. 
By contacting the RHA services in the North region, all prescriptions for 
pyridostigmine, made by the general practitioners (GPs) in this region 
throughout the year 2013 were identified. The name of the doctor who 
made the prescription, the name of the patient and their national health 
number were available. We matched the list of patients identified in the 
HCDB with those identified in the PPDB. For those that were not included 
in the HCDB we contacted the GP doctor who made the prescription. 
Depending on their response or not to each form of contact, they were 
first sent a posted letter, a secure e-mail, and finally called by telephone, 
requesting the information required (first whether patient had MG or 
another neurological disease; second, in case of MG, clinical data was 
collected).  
Patients treated with pyridostigmine to other conditions (e.g. congenital 
myasthenic syndrome, myopathies and other neurological disorders) 
were excluded from this study.  
Combining these two sources of identification of patients was a method 
considered validated in previous studies in Denmark.[175] 
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Case definition 
Definite MG was considered if the following criteria were fulfilled:  
(a) history and examination compatible with myasthenia (fatigable 
weakness), plus  
(b) at least one positive paraclinical test (antibody test, repetitive nerve 
stimulation, single-fibre electromyogram), and/or 
(c) unequivocal improvement with pyridostigmine or immunossupression. 
[116,179] 
If a diagnosis of MG was stated in the medical records, but could not be 
definitely confirmed or ruled out due to insufficient information on one 
or more of the aforementioned criteria, cases were classified as possible 
MG. Cases with no identifiable medical records with pertinent information 
were classified as non-evaluable. 
 
Classification of MG subtype 
All definite cases were classified in MG subtypes according to antibodies 
serostatus: 
1. AChR MG: Consistent clinical picture, positive AChR antibodies (AChR-
Ab);  
2. MuSK MG: Consistent clinical picture, positive MuSK antibodies (MuSK-
Ab);  
3. Seronegative MG: Consistent clinical picture, positive 
electrophysiological tests and or response to pyridostigmine or 
immunossupression; seronegative for AChR-Ab and MuSK-Ab.  
Definite cases were classified according to the presence/absence of 
thymoma and age of onset of the disease: before 50 years of age – EOMG 
and 50 years old or older – LOMG.[117,131,132] 
 
Clinical Data 
Clinical and demographic data were collected from the patient’s medical 
records: date of birth, current age, gender, age at MG onset, age at MG 
diagnosis, neurophysiological test results, antibodies to AChR and 
MuSK, thymectomy and thymic histology, worst MGFA clinical 
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score[180], need of artificial ventilation, treatments used during the 
course of disease and MGFA status after intervention; other autoimmune 
co-morbidities, tumours and severe/recurrent infections were also 
recorded. 
 
Serological antibody tests 
All patients who had been tested positive for AChR or MuSK antibodies 
locally were not tested again. Patients whose serological status was 
negative or unknown provided a blood sample to be tested for AChR and 
MuSK antibodies (radioimmunoassay and cell-based assays if the first was 
negative).[18,181] These assays were performed in the 
Neuroimmunology Laboratory, John Radcliffe Hospital, in Oxford. 
 
Statistical Analysis 
The incidence rate (IR) refers to all incident cases in the study area 
throughout the year 2013. Prevalence date was set as 31/12/2013 for all 
patients alive and resident in the study area. Prevalence and incidence 
rate were calculated per million for all MG patients and its subgroups 
according to sex and age group.  SPSS statistics, version 22 was used. 
 
Ethical approval 
Ethical approval was obtained from the ethical committees of the 
intervenient hospitals and from the Portuguese Data Protection 
Authority (Comissão Nacional de Proteção de Dados) to collect 
demographic and clinical data from all patients and also for blood 
collection from some patients. Approval was obtained from the Ethical 
Committee of the Regional Health Administration (North of Portugal) to 
use the information related to the pyridostigmine prescriptions, to 
contact the general practitioners and to get patient’s information. 
Informed consent was obtained from each patient to access their clinical 
data, and for blood collection, if needed. 
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Results 
 
Patient identification and first disease classification 
We identified 371 patients in the HCDB and 259 patients in the PPDB.  All 
records were carefully checked as explained in the methods section, 
being included or excluded as shown in Figure 3.1. 
In the PPDB, we found 499 prescriptions made in the North region by 
the GPs, corresponding to 259 patients. From these 259 patients, 138 
were also identified in the HCDB. Letters were sent to the prescribers 
GPs of the other 121 patients, requesting information about their 
patients.  
Twenty-one answered by posted letter, 18 by email, and 71 answered 
only after a phone call to their working place. We could not get proper 
information regarding 11 patients taking pyridostigmine either 
because it was not possible to contact the GP (n=5) or because the 
clinical records did not mention the reason why pyridostigmine was 
prescribed in first place (n=6). These 11 patients were considered non-
evaluable.  
From the information collected on those 121 patients prescribed with 
pyridostigmine, 63 patients had other neurological disorders 
(congenital myasthenic syndrome, mithocondrial myopathies, other 
myopathies or other neurological conditions); these were rejected from 
the study.  
Forty-seven patients not included in the HCDB were actually MG cases. 
Overall, 418 MG patients were identified and included in the study; 
23/418 were incident cases, with onset in 2013; 11/418 died during 
2013 (Figure 3.1.1.). 
From the 407 patients alive, at the end of 2013, 398 (97.8%) were 
classified as definite MG, and 9 (2.2%) as possible MG. All the possible 
MG cases were identified in the PPDB; in their GP’s clinical files they 
were identified as having MG, but details on the disease could not be 
found. 
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Figure 3.1.1. Patient identification. Illustration of the sources of 
identification of the myasthenia gravis patients included in the study. 
Patients were identified via hospital clinical databases (HCDB) and 
pyridostigmine prescription databases (PPDB) 
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Epidemiological data 
 
At 31/12/2013 we estimated a point prevalence of 111.7 patients per 
million inhabitants (407 MG patients/3 644 195 inhabitants). During 
the year of 2013 there were 23 new MG patients. We estimated an 
incidence rate of 6.3 per million person/year.  
 
We found different prevalence and incidence rates according to the age 
group and sex (Table 3.1.2. and Figure 3.1.2.). Prevalence rose with 
age reaching its maximum in the group over 65 years old, especially 
in males (288.1/106) (Table 3.1.2. and Figure 3.1.2A.).  
 
Among females, incidence rate was higher in the age group 15-49 
(9.1/106), while in males, incidence increased with age till the 
maximum (22.1/106) among those aged over 65 years (Table 3.1.2. 
and Figure 3.1.2B). 
 
  Table 3.1.2. Variation in prevalence and incidence rate with the age  
 
 
Age 
Group 
Estimated 
Population 
of females 
n 
(PR/106) 
n 
(IR/106) 
Estimated 
Population 
of males 
n 
(PR/106) 
N 
(IR/106) 
Estimated 
Total 
Population 
N 
(PR/106) 
n 
(IR/106) 
0-14 254 838 
0 
(0) 
0 
(0) 
265 937 
1 
(3.7) 
0 
(0) 
520 775 
1 
(1.9) 
0 
(0) 
15-49 877 161 
112 
(127.6) 
8 
(9.1) 
842 519 
40 
(47.4) 
1 
(1.1) 
1 719 680 
152 
(88.3) 
9 
(5.2) 
50-64 393 757 
67 
(170.1) 
1 
(2.5) 
357 690 
52 
(145.3) 
4 
(11.1) 
751 447 
119 
(158.3) 
5 
(6.6) 
≥65 381 601 
57 
(149.3) 
3 
(7.8) 
270 692 
78 
(288.1) 
6 
(22.1) 
652 293 
135 
(206.9) 
9 
(13.7) 
  PR/106 = Prevalence per million at 31/12/2013. IR/106 = Incidence rate per million-
persons-year in 2013 
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Prevalence rates in EOMG and LOMG were similar (106.2/106 and 
113.2/106 respectively) (Table 3.1.3.). However, when the prevalence 
was analysed in relation to gender, females were predominant in EOMG 
and males in LOMG group (EOMG prevalence was 144.8/106 for 
females, and 66.7/106 for males, whereas LOMG prevalence was 
85.1/106 for females and 147.9/106 for males) (Table 3.1.3. and Figure 
3.1.2C.).  
 
 
Table 3.1.3. Variation in prevalence and incidence rate for EOMG and LOMG 
 
Age 
of MG 
onset 
Estimated 
Population 
for 
females 
n 
(PR/106) 
N 
(IR/106) 
Estimated 
Population 
for males 
n 
(PR/106) 
n 
(IR/106) 
Estimated 
Total 
Population 
n 
(PR/106) 
N 
(IR/106) 
EOMG 
 
1 131 999 
164 
(144.8) 
8 
(7.0) 
1 108 456 
74 
(66.7) 
1 
(0.9) 
2 240 455 
238 
(106.2) 
9 
(4.0) 
LOMG 
 
775 358 
66 
(85.1) 
4 
(5.1) 
628 382 
93 
(147.9) 
10 
(15.9) 
1 403 740 
159 
(113.2) 
14 
(9.9) 
 
EOMG - MG onset between 0-49 y. LOMG – MG onset ≥50 y. PR/106 = Prevalence per 
million at 31/12/2013. IR/106 = Incidence rate per million-persons-year in 2013 
 
 
Incidence rates were 4.0 per million person/year for EOMG and 9.9 for 
LOMG (Table 3.1.2). When incident rates were compared between 
genders, EOMG incident cases were predominantly females, whereas 
LOMG incident cases were predominately males (Table 3.1.2. and 
Figure 3.1.2D.). 
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Figure 3.1.2. Prevalence rate (A and C) and incidence rate (B and D) per 
million increased overall with age at disease onset, but the striking increase 
was noticed in the incidence rate in males with late onset MG. PR/106: 
Prevalence rate per million; IR/106: Incidence rate per million 
 
 
Demographical and clinical data of prevalent cases 
 
Characteristics of prevalent cases are summarised in Table 3.1.4.  
Most cases were women (58.0%). Age at 31-12-2013 ranged between 7 
and 92 years (mean 54.7 years).  The age of onset varied between 3 
and 87 years (mean 43.7 years), and majority of patient (62.4%) had 
LOMG.  
The ratio female:male in the EOMG group was 2.73:1 and in the LOMG 
0.95:1. Ocular forms accounted to 30.1% total cases, and they were 
predominant among LOMG (57.1%).  
The predominant MGFA classification at nadir was class II (57.9%). 
From 165 patients submitted to thymectomy, majority of them (69, 
Figure	2:	Prevalence		and	Incidence	rates	per	gender	in	distinct	age	groups	and	MG	onset	age
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41.8%) had thymic hyperplasia, whereas (49, 29.7%) had thymoma 
(40.8% of them occurred in the group 15-49 years and 59.2% after 50 
years of age).  
 
Majority of patient (62.8%) were treated with steroids and 33.9% with 
additional immnunossupression. A relatively high percentage of 
patients (19%) needed intravenous immunoglobulin (IVIG) or plasma 
exchange (PEX) at least once during the course of the disease. After a 
median follow-up period of 7 years (<1 to 42), 41.0% of patients were in 
remission, either complete (2.6%) or pharmacological (38.4%).  
Most of the patients (63%) in remission belonged to the group of EOMG, 
of which 22.8% had ocular MG and 77.2% had generalised MG.  
 
Almost one third of patients (29.4%) had one type of the following 
comorbidities: other autoimmune diseases (OAID) (organ specific or 
systemic), tumours or recurrent/serious infections; 2.8% of the patients 
had ≥2 of those associated problems.  
The proportion of patients with OAID (20.2% vs 16.3%) and infections 
(4.6% vs 4.4%) was identical in EOMG and LOMG groups. Only tumours 
were more common in LOMG (12.6% vs 5.9%, p= 0.026). 
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Table 3.1.4. Demographic and clinical data of the prevalent cases during 2013 
Variable Values n % 
Sex 
 
F 
M 
236 
171 
58.0 
42.0 
Age in 31 Dec 2013 
 
0-14 
15-49 
50-64 
>=65 
1 
152 
119 
135 
0.2 
37.4 
29.2 
33.2 
Age of MG onset                         
 
 
0-14 
15-49 
50-64 
>=65 
Missing 
10 
228 
82 
77 
10 
2.5 
57.4 
20.7 
19.4 
- 
Muscular Involvement  
(form of disease) 
Ocular 
Generalized 
Missing 
120 
279 
8 
30.1 
69.9 
- 
Serological status AChR antibody positive 
MuSK antibody positive 
Seronegative 
Missing 
261 
19 
85 
42 
71.5 
5.2 
23.3 
- 
Thymic histology 
(thymectomy performed in 165  
of the 407 patients (40.5%) 
Thymoma 
Thymic hyperplasia 
Normal/Atrophic 
Other (thymic cyst) 
Missing 
49 
69 
25 
1 
21 
34.0 
47.9 
17.4 
0.7 
- 
MG subtype: 
According to Ab status and  
presence of thymoma 
AChR MG + 
 
 
MuSK MG + 
 
 
Seronegative 
 
 
UKN  
 
Thymoma + 
Thymoma - 
 
Thymoma + 
Thymoma - 
 
Thymoma + 
Thymoma - 
- 
261 
46 
210 
19 
0 
19 
85 
3 
82 
42 
71.5 
12.8 
58.3 
5.3 
0 
5.3 
23.6 
0.8 
22.8 
- 
Worst MGFA Clinical Classification 
 
I 
II 
III 
IV 
V 
Missing 
120 
231 
36 
3 
9 
8 
30.0 
58.0 
9.0 
0.8 
2.2 
- 
Non-surgical Treatments Pyridostigmine 
Steroids 
Imunossupression 
Plasma Exchange 
IV IG 
399 
243 
134 
10 
75 
98.0 
61.8 
33.9 
2.5 
19.0 
Follow-up  
(years) 
≤ 2  
3-10 
11-20 
>20 
Missing  
97 
169 
76 
55 
10 
24.4 
42.6 
19.1 
13.9 
- 
MGFA 
Status  
Pos-intervention 
CR 
PR 
I 
U 
W 
Missing 
10 
150 
91 
131 
9 
16 
2.6 
38.4 
23.3 
33.4 
2.3 
- 
Comorbidities 
(OAID, tumours, or  
severe infections) 
None 
One 
Two or more 
Missing 
279 
105 
11 
12 
70.6 
26.6 
2.8 
- 
F - female, M - male, IVIG – intravenous immunoglobulins, CR - complete remission, PR - 
pharmacological remission, I - improved, U - unchanged, W - worsened, OAID - other 
autoimmune disorders. 
	
	
67	
Serological Data 
 
During the year 2013, 128 blood samples were collected from patients 
whose serological status had not been completely studied. 
Median time between MG onset and the blood collection in that group 
of patients was 7 years (0 – 42 years, standard deviation 10.7 years).  
Of the total 407 patients, we could not have a definite serological 
status in 42 (10.3%). 
Of the 365 patients with complete serological status, 261 had AChR 
antibodies (71.5%), among which 46 (17.6%) had thymoma. 19 patients 
had MuSK antibodies (5.2% of the 365 patients tested and 18.2% of the 
104 seronegative for AChR); the remaining 85 patients were double 
seronegative (23.6%) (Table 3.1.4.). 
 
Demographical and clinical data of incident cases 
 
The incident data are summarised in the Table 3.1.5. In the incident 
cases ratio female:male was similar to the prevalent data; in 60.9%, the 
age of onset was ≥50 years old, which is also very similar to the ratio 
registered in the prevalent data (62.4%). 57.1% were AChR positive and 
14.3% Musk positive. 56.5% had generalised disease; 17.4% of the 
patients there was at least one comorbidity. 
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Table 3.1.5. Demographic and clinical data of the incident cases during 2013  
 
Variables Values N (=23) % 
Sex 
 
F 
M 
12 
11 
52.2 
48.8 
Age in 31 Dec 
2013 (= age of 
onset) 
 
<15 
15-49 
50-64 
>=65 
0 
9 
5 
9 
0 
39.1 
21.8 
39.1 
MG subtype 
 
AChR MG + 
 
 
MuSK MG + 
 
 
Seronegative 
 
 
 
Missing 
 
Thymoma + 
Thymoma - 
 
Thymoma + 
Thymoma - 
 
Thymoma + 
Thymoma - 
 
- 
12 
4 
8 
3 
0 
3 
6 
0 
6 
 
2 
57.1 
19.0 
38.1 
14.2 
0 
14.2 
28.6 
0 
28.6 
 
- 
Thymic 
Hystology 
Thymoma 
Without thymectomy 
4 
19 
17.4 
82.6 
Muscular 
Involvement 
Ocular 
Generalised 
10 
13 
43.5 
56.5 
Worst MGFA 
Clinical 
Classification 
 
I 
II 
III 
IV 
V 
10 
10 
3 
0 
0 
43.5 
43.5 
13.0 
0 
0 
Comorbidities 
(OAID, 
tumours, or 
infections) 
None 
One 
Two or more 
19 
3 
1 
82.6 
13.0 
4.4 
MGFA - Myasthenia Gravis Foundation of America, OAID - other autoimmune disorders 
 
 
Description of cause of deaths occurred during the year of 2013 
 
The percentage of patients who died during 2013 was 2.6% (11/418) 
(details in Supplementary Table 3.1.6.). Deaths directly related with 
MG were 2/418 (0.48%), which represents a mortality rate directly 
attributed to MG of 0.5 per million (2/3 644 195). These deaths were 
consequence of severe dysphagia and respiratory failure/infections. 
They occurred in patients with a recent diagnosis and not yet 
controlled MG, at, respectively, 85 and 73 years of age. Three patients 
died with aggressive thymoma related complications; they were 25, 56 
and 72 years old (ages of onset had been respectively 25, 41 and 67). 
In 4 patients (aged between 84 and 89 years at the date of death), the 
cause of death was not apparently related to MG. 
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Table 3.1.6. Description of cause of death (n=11) during the year 2013 
Number of patients 
(n) 
Cause of Death Age at disease 
onset 
Age at 
death 
3 Aggressive thymoma 41, 67, 25 56, 72, 25 
2 MG related 70, 84 73, 85 
3 Acute respiratory tract 
infection 
68, 72, 62 84, 87, 88 
1 Malignant haematological 
disease 
88 89 
2 UKN UKN, 50 85, 87 
UNK - unknown 
 
 
Discussion 
 
Epidemiological figures 
We found a prevalence of 111.7 MG patients per million, which is 
similar to those reported in some European studies, e.g. Italy,[122] 
using similar methods to our study, and in Norway, in studies with 
similar methods and size of the population studied.[125,126] It is also 
very close to another previous Italian study in the Regio-Emilia region, 
with multiple sources of identifying patients but a much smaller size 
of population studied.[128] 
We estimated an incidence rate of 6.3 per million person/year. Our 
incidence rate is similar to recent studies from different latitudes 
(Norway and Denmark) with similar methods, where it varied from 7.2 
to 9.2 per million persons year,[121,125,126] and also identical to 
other studies from south of Europe - Greece and Italy,[127,128] where 
it varied from 7.4 to 7.8 per million person/year. It was, however, much 
lower than some recently published studies from Spain (Osona, 
Barcelona) [80] and Australia[176] where they found incidence rates 
above 20 per million persons year.  
Estimated incidence and prevalence rates of MG still vary 
widely.[129,80,176] A meta-analysis of epidemiological studies 
reports prevalence rates 15 times greater than incidence rates.[182] 
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Recent studies report lower prevalence to incidence ratios ranging 
from 6 to 8.[122,183] In our study this ratio is 17.  
When comparing our study with the study in the province of Osona 
which corresponds geographically to the region closest to the north of 
Portugal, they presented a much higher prevalence (328.9) and 
incidence rate (28.0) than ours, but also higher than all other studies. 
It may be related with the awareness campaign about the disease, 
mostly in the elderly, that started with the same group in that region 
in 2003 and also with the small size of the population studied (around 
150 000).[80,116,123]  
Using two methods of identifying patients (HCDB and PPDB) improves 
the quality of the data; it was previously described that using a single 
register source to identify MG cases has a higher sensitivity but a lower 
positive predictive value than the combined register method applied in 
this study.[121,175] 
In our study, 11 out of the 499 (2.2%) patients of the pyridostigmine 
prescriptions could not be confirmed to have MG, which is a small 
proportion of the number of patients studied when compared with 
other studies where MG diagnosis could not be verified by medical 
record review in about 27% of the cases.[183] 
In some studies that used pyridostigmine prescriptions as the only 
method to identify patients, the prevalence and especially incidence 
rate may be overestimated.[176] Reasons may be that pyridostigmine 
may be also used for other neurological disorders, like congenital 
myasthenic syndromes, myopathies and neurogenic bladder, and also 
that one prescription does not correspond necessarily to a new MG 
patient. In the daily practice sometimes pyridostigmine is used as a 
trial of treatment in circumstances of diagnostic uncertainty.[176]  
To our knowledge, our study was the first to verify with the GP which 
disease was being treated with pyridostigmine. We found that around 
one quarter of the prescriptions were for other conditions than MG. 
It is possible that, in our study, some patients in complete remission 
discharged from the hospitals clinics and not taking pyridostigmine 
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were not captured with our methodology. However, it is common in 
Portugal for patients in complete remission to continue being followed 
up yearly by a neurologist.  
In this study prevalence rises with age, as reported in many other 
studies,[121,183] especially in males. The highest value was in males 
above 65 years, 288.1 per million.  
Incidence rates were highest in the female EOMG group and male LOMG 
group, reaching its peak in males after 65 years (22.1 per million 
person/year). We do not have information about the evolution of these 
rates in our population, because there are no previous studies in 
Portugal. But this result is according to most of the recent reports that 
describe higher incidence rates of MG in LOMG group, especially in 
elderly males.[121,122,129,153] This information has crucial 
importance for the continued awareness of the disease in this age 
group, and subsequent improvement in diagnosis and management of 
MG. 
 
Clinical, demographic and serological features 
Our prevalent and incident data confirmed that the majority of patients 
belong to the group of LOMG, confirming others’ findings that MG is a 
disease that affects younger and also elderly people. Overall our 
clinical, histology and serological data were similar to those reported 
by other authors. There were, however some discrepancies, which 
deserve some comments.  
Overall a surprisingly high percentage of patients (19%) were treated 
with IVIG or PEX at least once during the course of the disease, 
particularly knowing that majority of patients had MGFA I or II at nadir. 
Majority of patients treated with IVIG or PEX represented a third of the 
MuSK MG patients and nearly a quarter of the AChR MG patients, which 
is in keeping with our practice preferring more intense treatment in Ab 
positive patients with acute bulbar symptoms with or without 
respiratory manifestations.  
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The percentage of AChR positive patients in generalised forms of the 
disease was lower than expected, 76.7% compared with the 85-95% 
usually reported.[117,181] This might be related with the fact that in 
35% (128/365) of the patients completely studied for their serological 
status, even considering that we used RIA and CBA methods, the blood 
had been collected at a variable time after the diagnosis (median 7 
years). Therefore, it is possible that some of the patients had already 
become negative as a consequence of treatments.[181] When possible, 
blood sample collection should be done at the time of the diagnosis and 
before immune treatments. 
Murai et al., in a nationwide survey of MG patients in Japan, reported a 
prevalence rate of 118 per million, similar to our study and also reported 
other clinical data similar to ours, including percentage of patients who 
were AChR-Ab positive at diagnosis. Other similar features included: 
MGFA I and II accounted for 80% of all MG patients; thymoma was present 
in 32.0%; and hyperplasia was observed in 38.4%.[147] 
Interestingly, in their study, there was 1 important difference compared 
with ours: They reported a prominent peak in infantile-onset MG (age 0–
4 years, 7%), but in our study, there were few infantile MG patients. Our 
lower number of infantile-onset MG patients (2.5%) is similar to findings 
from most European and American series where it varied from 1% to 
3%.[184]  
We found a percentage of 5.3% of MuSk MG in the group of prevalent 
patients, which is similar to what has been described by other authors 
in the southern European countries.[185] Interestingly, the percentage 
in the incident cases is higher, 14.3%. On the other hand, the 
proportion of AChR-MG in the group of incident cases was lower than 
expected, possibly because the proportion of ocular MG was relatively 
high, 43.5%. This may represent variations in incidence of distinct 
disease subtypes or improvement in diagnosis of rarer and limited 
forms of MG.  
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The mortality rate attributed to MG was 0.5 per million, which is in the 
range of what others studies reported.[122,129] Of note, 3 deaths 
occurred in relation with aggressive thymomas. Regarding age at 
death, six occurred between 84 and 89 years, an age that is above the 
Portuguese life span (82.8 for females and 76.9 for males).[178] 
 
Final Comments 
The methods used in this study were robust and allowed us to find a 
similar prevalence to those described in most of the studies in Europe. 
The incidence rate was lower to some of recent European studies but 
we have to consider that our study was, to our knowledge, the first to 
confront the number of pyridostigmine prescriptions with the 
pyridostigmine prescriptions for MG and not to other disorders. 
The highest prevalence and incidence rates were found in males above 
65 years of age, which are very relevant findings for neurologists and 
GPs daily practice when considering differential diagnosis and disease 
management in that age group. 
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3.2. Immunogenetic study 
 
Within this research project, we performed an immunogenetic study to 
explore the association between HLA-DRB1 susceptibility alleles and age-
of-onset in MG, in the cohort of patients followed in the 
Neuroimmunology Outpatients clinics of Centro Hospitalar do 
Porto/Hospital Santo António. 
 
The immunogenetic study was performed in Laboratório de 
Imunogenética, Instituto de Ciências Biomédicas Abel Salazar, 
Universidade do Porto, Portugal, under supervision of Prof. Dr. Berta 
Martins da Silva. 
 
It was published in Neuromuscular Disorders 2017; 27(7):650-654 and 
the full text follows. 
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Abstract 
Introduction: Myasthenia gravis (MG) is a classic autoimmune 
neurological disorder with a range of well-known symptoms and signs. 
The aetiology of MG is unknown, but both genetic and environmental 
factors are believed to have important roles. Over the years, association 
of MG with Human Leucocyte Antigens (HLA) has been described in 
different populations. In European descendent populations HLA-DRB1*03 
allele strongly influences MG susceptibility. 
 
Objective: To investigate the possible association between HLA-DRB1 
alleles and age-of-onset in MG. 
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Patients and Methods: One hundred and fourteen MG patients (82 female 
and 32 male) and 282 control individuals (CP) were studied.  Patients were 
classified according to the age of onset (early-onset ≤40, n=74 and late-
onset ≥ 50, n=20).  
Patients with thymoma (n=20) were analysed separately. HLA-DRB1 and 
HLA-A*08 genotyping was performed using PCR-SSP methodology. A 
stepwise logistic regression at an allelic level, using forward selection, 
was applied to identify the HLA-DRB1 genes contributing to MG. 
 
Results: HLA-DRB1*03 allele was overrepresented in the global MG 
population when compared to the control population (34.5%MG vs. 
15.6%CP, p<0.0001, OR=2.85, 95%CI=1.72-4.72). When the early-onset 
subgroup was considered, this association became even stronger 
(43.0%MG vs. 15.6%CP, p=1x10-6, OR=4.16, 95%CI=2.35-7.22). Regarding 
the late-onset subgroup, the frequency of HLA-DRB1*01 allele was higher 
than in the control population (50.0%MG vs. 23.4%CP, p=0.011, OR=3.27, 
95%CI=1.31-8.20). For the thymoma subgroup, the HLA-DRB1*10 allele 
frequency was significantly higher (15.8% MG vs. 3.9% Controls, p=0.029, 
OR=4.62, 95% CI=1.17-18.23) when compared to the control population. 
Regarding the HLA-B*08 allele, its frequency was significantly higher in 
the global MG population (30.6%MG vs. 13.9%PC, p=0.0004, OR=2.72, 
95%CI=1.75-4.78).   
 
Conclusions: These results demonstrate a strong association of HLA-
DRB1*03 and HLA-B*08 with MG, confirming that these alleles are 
important susceptibility factors for this disease also in our population. 
Considering the age of onset, HLA-DRB1*01 was associated with late-
onset subgroup. Thymoma MG patients have probably a different genetic 
(HLA- DRB1*10) background. To the best of our knowledge these results 
were not reported before and need replication in other populations and 
in larger cohorts. 
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Introduction 
 
Myasthenia Gravis is not considered a single entity but a heterogeneous 
disease with several subgroups. Although these subgroups share a 
common phenotype they have distinct features based on age of onset, 
severity of the disease, pathogenic auto-antibodies, thymic abnormalities, 
response to therapy and different HLA susceptibility alleles.[20,39] So far 
seven subgroups have been considered: early onset MG (EOMG), late 
onset MG (LOMG), paraneoplastic MG or thymoma MG, anti-MuSK MG, 
anti-LRP4 MG, ocular MG and seronegative MG.[20] 
The first two subgroups are characterized by anti-acetylcholine receptor 
antibodies and mainly differ in the age of onset and response to 
thymectomy. Most authors consider that the age of onset of 50 years 
separate these two subgroups.[121,122,125,126,183] Another striking 
feature that divides them is the presence of thymic hyperplasia, which is 
much more common in the early onset group[186], and the associated 
HLA susceptibility alleles. Compston was one of the first to describe this 
difference. In his work the early onset subgroup (up to 40 years of age) 
had a higher frequency of the HLA B8 DR3 haplotype and the late onset 
group of the HLA B7 DR2 haplotype.[39] Since then several HLA 
associations have been described supporting the distinctiveness of these 
two subgroups.[134,187,188] More recently an association   of HLA-
DRB1*15:01 and HLA-DQB1*05:02 and DRB1*16 in the late onset group, 
has been reported.[189,190]  Other HLA associations in thymoma MG, 
MuSK MG and ocular MG have been reported but not so 
consistently.[187,191] 
The main purpose of this study was to evaluate the association of HLA 
DRB1 alleles and HLA-B*08 with MG and its subgroups in a Portuguese 
cohort. We want also to highlight the importance of appropriate MG 
subgrouping according to clinical characteristics and its comparison with 
similar studies previously made for other ethnic groups.  
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Patients and Methods 
 
Case Definition 
MG was diagnosed if a patient had a typical clinical feature and positive 
antibodies for anti-acetylcholine receptor and/or positive repetitive nerve 
stimulation on electromyography. Patients with onset before 50 years of 
age were considered Early Onset Myasthenia Gravis (EOMG). Late onset 
Myasthenia Gravis (LOMG) patients were those with onset after 50 years 
of age. Thymoma MG subgroup were those with histopathological 
confirmation of the disease. Patients with anti-MuSK antibodies were 
excluded. 
Refractory patients were defined as those that could not scale back their 
immunotherapy without clinical relapse, were not clinically controlled on 
an immunotherapy regimen, or developed severe side effects from 
immunosuppressive therapy.[88] 
Polyautoimmunity was defined as the presence of more than one 
autoimmune disease in a single patient.[192] 
HLA Genotyping 
Peripheral blood samples were collected in EDTA. Genomic DNA was 
obtained from proteinase-K–treated peripheral blood leukocytes by using 
a salting-out procedure.[193] Low-resolution genotyping for HLA–DRB1 
locus (i.e., 2-digit HLA nomenclature) was performed using polymerase 
chain reaction with sequence-specific primers (PCR-SSP), based on 
methods previously described.[194] 
 
Control population 
Patients were compared with a control group consisting of 282 unrelated 
individuals, from the same geographic origin (north of Portugal).  
 
Statistical Analysis 
To identify the HLA-DRB1 alleles contributing to MG, a stepwise logistic 
regression, using forward selection was applied, which involves starting 
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with no variables in the model, testing the addition of each variable using 
a chosen model comparison criterion, adding the variable (if any) that 
improves the model the most, and repeating this process until none 
improves the model. It should be noted that odds ratios (ORs) obtained 
in a multivariable logistic regression analysis are adjusted for all the other 
genes included in the model and therefore differ from those obtained 
when a given gene is compared with all other genes. For the HLA-B*08 
allele analysis a Chi-square or Fisher’s exact test was used, as 
appropriate. The data were analysed using the IBM SPSS 20 statistical 
software suite. 
 
Results 
 
Clinical analysis 
One hundred and fourteen patients were included in the study. The 
clinical characteristics of these patients are described on the table 3.2.1.  
 
Table 3.2.1. Clinical characteristics of the myasthenia gravis patients (n=114) 
 n=114 Female 
(%) 
Anti-RAch  
Ab’s (%) 
Thymectomy/ 
Thymus histology (%) 
G (%) 
 
PolyAI 
(%) 
EOMG 74 63 (84) 61 (82.4) 48 (64.9) 
30 Hyperplasia (62.5) 
18 Normal (37.5) 
69 (93.2) 19 (25.7) 
LOMG 20 8 (40) 15 (75) 0/NA 13 (65) 2 (10) 
Thymoma MG 20 11 (55) 20 (100) 20 Thymoma 20 (100) 6 (30) 
G - Generalized, PolyAI – polyautoimmunity, NA-not applicable. 
  
In the 48 EOMG group, 30 (62.5%) had thymic hyperplasia and performed 
thymectomy. In the LOMG subgroup all patients had normal thorax CT 
scan and were not submitted to thymectomy.  
Twenty two patients presented criteria for refractory disease [88], 1 in the 
LOMG (5%), 6 in the thymoma group (30%) and the remaining 15 in the 
EOMG subgroup (20,3%). 
Polyautoimmunity was present in 27/114 (23.7%), and was more common 
in the EOMG and thymoma subgroups than in the LOMG subgroup (25.7 
and 30% vs. 10%).   
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Immunogenetic analysis 
 
HLA-DRB1*03 allele was overrepresented in the global MG population 
when compared to the control population (34.5%MG vs. 15.6%CP, 
p<0.0001, OR=2.85, 95%CI=1.72-4.72), as expected. When the early-
onset subgroup was considered, this association became even stronger 
(43.0%MG vs. 15.6%CP, p=1x10-6, OR=4.16, 95%CI=2.35-7.22).   
In the late-onset subgroup, but not in the EOMG subgroup, the frequency 
of HLA-DRB1*01 allele was higher than in the control population 
(50.0%MG vs. 23.4%CP, p=0.011, OR=3.27, 95%CI=1.31-8.20).  
For the thymoma subgroup, the HLA-DRB1*10 allele frequency was 
significantly higher (15.8% MG vs. 3.9% Controls, p=0.029, OR=4.62, 95% 
CI=1.17-18.23) when compared to the control population. 
The age of onset was also analysed, disregarding thymic histology, which 
means thymoma patients were included.  In the EOMG group (before 50 
years of age) the HLA-DRB1*03 allele frequency was significantly higher 
compared to controls (39.0% MG vs. 15.6% PC, p<0.0001, OR=3.43, 
95%CI=1.99-5.90). The frequency of HLA-DRB1*01 allele remained 
overrepresented in the MG patients with onset after 50 years vs. CP (42.9% 
MG vs. 23.4% PC, p=0.024, OR=2.45, 95%CI=1.11-5.45). 
Regarding the HLA-B*08 allele, its frequency was significantly higher in 
the global MG population (30.6% MG vs. 13.9% PC, p=0.0004, OR=2.72, 
95%CI=1.75-4.78).  This association was only significant in the EOMG 
subgroup (37.0%MG vs. 13.9% CP, p=2x10-5, OR=3.62, 95%CI=1.96-6.71). 
There was no association of this allele with the LOMG subgroup (20.0% 
MG vs. 13.9 %CP, p=0.462, OR=1.54, 95%CI=0.48-4.94), nor with the 
thymoma subgroup (16.7% MG vs. 13.9% CP, p=0.750, OR=1.23, 
95%CI=0.34-4.53) were observed. 
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Table 3.2.2. HLA DRB1 frequencies in myasthenia gravis and control population 
 
Controls 
(n=282) 
Global MG 
(n=114) 
EOMG 
(n=74) 
LOMG 
(n=20) 
Thymoma MG 
(n=20) 
HLA-DRB1*01 66 (23.4%) 29 (25.7%) 16 (21.6%) 10 (50.0%) 3 (15.8%) 
HLA-DRB1*03 44 (15.6%) 39 (34.5%) 32 (43.2%) 3 (15.0%) 4 (21.1%) 
HLA-DRB1*04 69 (24.5%) 30 (26.5%) 18 (24.3%) 7 (35.0%) 5 (26.3%) 
HLA-DRB1*07 72 (25.5%) 24 (21.2%) 12 (16.2%) 7 (35.0%) 5 (26.3%) 
HLA-DRB1*08 24 (8.5%) 8 (7.1%) 5 (6.8%) 1 (5.0%) 2 (10.5%) 
HLA-DRB1*09 14 (5.0%) 3 (2.7%) 3 (4.1%) 0 (0.0%) 0 (0.0%) 
HLA-DRB1*10 11 (3.9%) 5 (4.4%) 2 (2.7%) 0 (0.0%) 3 (15.8%) 
HLA-DRB1*11 55 (19.5%) 19 (16.8%) 15 (20.3%) 2 (10.0%) 2 (10.5%) 
HLA-DRB1*12 9 (3.2%) 1 (0.9%) 1 (1.4%) 0 (0.0%) 0 (0.0%) 
HLA-DRB1*13 84 (29.8%) 21 (18.6%) 11 (14.9%) 4 (20.0%) 6 (31.6%) 
HLA-DRB1*14 17 (6.0%) 7 (6.2%) 4 (5.4%) 3 (15.0%) 0 (0.0%) 
HLA-DRB1*15 56 (19.9%) 19 (16.8%) 12 (16.2%) 2 (10.0%) 5 (26.3%) 
HLA-DRB1*16 13 (4.6%) 10 (8.8%) 8 (10.8%) 1 (5.0%) 1 (5.3%) 
 
The association between HLA genotypes with other MG subgroups 
(refractory MG patients and the group with polyautoimmunity) was also 
analysed, but no statistically significant differences were found. 
 
Discussion 
 
Clinical data 
Our clinical data shows a predominance of females (84%) in the EOMG 
subgroup and a   predominance of the male gender (60%) in the LOMG 
subgroup. The frequencies of generalized disease (93.2% vs. 65%) and 
positivity to antibodies to AChR (82.4 vs. 75%) were higher in the EOMG 
subgroup than in the LOMG. These findings are similar to other published 
series.[112,116,124–127,189] 
The frequency of polyautoimmunity was high (23.7%) in our cohort. 
Robertson found a frequency of 27% in a Cambridgeshire (UK) MG 
population.[112] In the Greek population Poulas described 
polyautoimmunity in 11.6% of patients.[127] An Italian study registered 
polyautoimmunity in 14.3% of the cases.[128] In the present study 
polyautoimmunity was more common in the EOMG (25.7%) and thymoma 
(30%) subgroups than in the LOMG subgroup (10%). Polyautoimmunity 
was also more common in the women of the EOMG subgroup in the 
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Cambridgeshire study (49%).[112] Other series such as Aragones in 
Barcelona described higher frequency of other autoimmune disorders in 
the LOMG subgroup than we described in the present study (21.5%).[123] 
Similar frequencies in the EO and LOMG subgroups[189] in other 
populations have been reported. 
 
Immunogenetic Data 
We registered a positive association with the HLA-DRB1*03 allele in the 
global MG population, when compared to the control population. This 
association was even stronger in the EOMG subgroup. This is consistent 
with other important studies.[39,105] 
As reported in other fundamental studies[39,189,195,196] the classical 
HLA-B*08 allele was associated in this study in the global MG population 
and in the EOMG subgroup.  
Regarding the LOMG subgroup a positive association with the HLA-
DRB1*01 allele was found. This association has not been described 
before. A Tunisian study described an association with HLA DRB1*04 
allele[197], a Norwegian study  an association with HLADRB1*15[189] and 
an Italian study with HLA-DQB1*05:02 and DRB1*16 alleles.[190] 
Our findings regarding the EOMG and LOMG were still value even when 
dividing the patients in subgroups just considering the age and not 
thymic pathology. 
For the thymoma MG subgroup we found an association with the HLA-
DRB1*10 allele when compared to the control population. The study with 
Mexican MG mestizo patients showed an association to HLA DRB1*11 in 
thymomatous patients.[198] In a Chinese study it was found an 
association of thymomatous MG with HLA-DQA1*0401 and HLA-
DQB1*0604 but not with the alleles of HLA DRB1 locus.[199] 
Regarding HLA-DRB1*13 allele it was described to be a protective factor 
for MG in a Norwegian study[189] and to other auto-immune 
disorders[200], but in our study we could not find the same. It was less 
frequent in the EOMG subgroup when compared to the CP, but did not 
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reach a statistically significant difference. This might be related with the 
sample size. 
We could not find any association between HLA genotypes for the group 
of refractory MG patients or the group with polyautoimmunity. These 
might be because of the reduced size of the sample. 
Taking together these results demonstrate a strong association of HLA-
DRB1*03 and HLA-B*08 alleles with MG, confirming that these alleles are 
important susceptibility factors for this disease also in our population. 
Considering the age of onset, HLA-DRB1*01 was associated with late-
onset subgroup. Thymoma MG patients have probably a different genetic 
(HLA-DRB1*10) background. To the best of our knowledge these results 
have not been reported before and warrant replication in other 
populations and in larger cohorts. 
 
 
 
 
 
 
 
 
 
 
  
	
	
84	
3.3. Pregnancy and Myasthenia gravis 
 
Under this topic, two studies were conducted: 
 
- Myasthenia gravis in Pregnancy – experience of a Portuguese 
Centre; 
 
- MuSK Myasthenia gravis and Pregnancy. 
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3.3.1. Myasthenia gravis in Pregnancy – experience of a Portuguese 
Centre 
 
 
Within this research project, we performed a retrospective study on the 
pregnant women with MG in our cohort in Centro Hospitalar do Porto: 
Hospital Santo António and Centro Materno-Infantil do Norte Dr. Albino 
Aroso. We studied both the effect of the disease on pregnancy, delivery 
and foetus, and the effect of pregnancy on the disease course.   
 
It was published in Muscle Nerve 2016; 54: 715–720 and the full text 
follows: 
 
 
 
Myasthenia gravis in Pregnancy – experience of a Portuguese Centre 
 
António Costa Braga1, Clara Pinto1, Ernestina Santos2, Jorge Sousa Braga1 
 
1 Obstetrics Department, Centro Materno-Infantil do Norte Dr. Albino 
Aroso, Centro Hospitalar do Porto, Porto, Portugal; 
 2 Neurology Department, Centro Hospitalar do Porto, Porto, Portugal 
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Abstract 
 
Objective: Evaluate the clinical course during pregnancy and neonatal 
outcomes of a cohort of Portuguese patients with myasthenia gravis (MG).  
 
Methods: Retrospective study of pregnancy in a Portuguese cohort of MG 
patients. 
 
Results: 25 patients with 30 pregnancies were included. The mean 
maternal age was 32.4±4.1 years.  A miscarriage rate of 6.7% was 
observed, with the delivery of 28 newborns.  43.3% had deterioration of 
MG symptoms during pregnancy and 46.4% at postpartum. 90% were 
medicated with pyridostigmine, 43.3% with corticosteroids and 40% 
needed intravenous immunoglobulin to achieve symptomatic control. 
There were no maternal or neonatal deaths. Mean gestational time at 
delivery was 38.2 weeks. No cases of fetal growth restriction, 
preeclampsia, preterm delivery or fetal demise were observed. Global 
cesarean rate was 64.3%. Two newborns developed transient neonatal 
myasthenia.  
 
Conclusions: A high rate clinical worsening of MG status in the mother 
was observed in this retrospective study, which highlights the importance 
of a multidisciplinary approach to avoiding maternal adverse outcomes.  
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Introduction 
 
Myasthenia Gravis (MG) is relatively rare autoimmune disorder of the 
striate muscle causing neuromuscular transmission failure, clinically 
characterized by muscle weakness and fatigue.[11]  
It is mediated by autoantibodies of the IgG isotype against the striate 
muscle acetylcholine receptors (AChR).[11] These antibodies reduce the 
number of AChR present in the end plate of the neuromuscular junction, 
reducing the efficiency of the neuromuscular synaptic transmission. AChR 
number is reduced because these antibodies induce complement-
mediated lysis of AChR and increasing the rate of AChR internalization by 
creating AChR-antibody complexes.[11]  
AChR antibodies are present in 40-60% of patients with ocular MG and 
85% of generalized form.[201] When AChR antibodies are not detected, 
other humoral factors must be involved in the inactivation of the AChR. 
Antibodies against the muscle-specific kinase (MuSK), a protein involved 
in anchoring AChR in the cellular membrane, are detected in up to 40% of 
these “seronegative” patients, but there is a significant variation in the 
incidence of MuSK-MG across the world.[202]  
More recently antibodies to receptor related low density lipoprotein-4 
(LRP-4) were also associated with to some cases of seronegative MG. LRP-
4 is a receptor for agrin and for MuSK, which are important in the 
aggregation of AChR in the neuromuscular junction plate.[26]  
Anti-AChR and anti-MuSK antibodies are of IgG isotype, so they have the 
ability to cross the placental barrier and generate myasthenic symptoms 
in the fetus in the later, half of pregnancy and transiently in the newborn 
(transitory neonatal MG).[170,203] 
It affects 2 to 3 times more women than men during the second and third 
decades of life, so association between  MG and pregnancy is not 
improbable with an estimated incidence during pregnancy of 
1:20,000.[161]  
MG is not associated with infertility, but it exposes pregnant women to 
an increased risk of maternal and fetal complications.  
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The clinical course of pregnancy in these patients is unpredictable. 
Symptoms at the date of conception, the requirement to treat active MG 
symptoms, as well as the course of previous pregnancies do not seem to 
correlate with the course of a specific pregnancy in mothers who suffer 
from MG.[159]  
It has been described that about 30% of pregnant women experienced 
improvement of symptoms while a third face clinical worsening, especially 
in the first trimester and during postpartum.[159,160] An increase in the 
exacerbation rate during pregnancy in the first two - three year after 
diagnosis was also described[161]. So it is advised to postpone pregnancy 
one to two - three years after diagnosis.[159,161]  
As smooth muscle is not affected in MG, indication for cesarean delivery 
is usually reserved for obstetric indications, however, I would also 
emphasise that 3rd stage of labour involves the contraction of voluntary 
striated muscle and this is where assistence in vaginal delivery is required 
to reduce the expulsive efforts and then minimize mother’s fatigue.[159] 
However, the incidence of cesarean delivery seems to be increased in 
these patients.[162]  
The risk of preterm birth, low neonate birthweight or hypertensive 
disorders apparently are not increased in MG pregnant women.[164] 
However, the management of preeclampsia is particularly challenging 
because the use of magnesium sulfate can exacerbate symptoms of 
myasthenia and potentially lead to myasthenia crisis and therefore should 
be used with extreme caution. When eclampsia is present, alternative 
medication like phenobarbital or anticonvulsant narcotics or sedatives 
should be used to control seizures.[204] 
Neonatal MG (NMG) affects 12-20 % of newborns of such pregnancies. 
Typical forms characterized by weak cry, swallowing and sucking 
difficulties usually appear during the first hours of life and disappear in 
90% of cases in 2 months. Atypical forms of arthrogryposis multiplex 
congenita are also described and represent 29% of NMG.[165] 
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Aim 
 
The aim of this study was to review the data related to our practice with 
pregnancies in MG patients. We evaluated the clinical course, delivery and 
neonatal outcome of the pregnancies of these patients. 
 
Methods 
 
Between 2005 and 2013, 25 patients with a total of 30 pregnancies were 
followed and delivered in the Obstetric Department of Centro Hospitalar 
do Porto, Oporto, Portugal. The course of pregnancy, delivery and 
puerperium, as well as the neonatal period of 28 newborns were analyzed 
retrospectively. Data was collected from patients’ medical records, which 
were all reviewed by the same author. The diagnosis of MG was 
established by our Neurology department based on typical clinical 
symptoms, neurophysiological tests, antibodies for the disease and a 
positive response to acetylcholinesterase inhibitor 
medication/immunosuppression. This department also followed all 
patients during pregnancy. NMG was diagnosed on the basis of clinical 
signs of generalized hypotonia, weak cry, weak reflexes, sucking or 
respiratory problems. 
Myasthenia Gravis Foundation of America post Intervention status 
classification[180,205] was used to describe the disease severity at the 
fist obstetric visit, before labor and at post-partum. Clinical improvement 
or deterioration was defined taking into account the exacerbation or 
development of new symptoms and changes in the medication dosage 
(steroids, a significant increase in the dosage of pyridostigmine or 
introduction of IVIG). Clinical status was characterized by Osserman’s 
classification of Myasthenia Gravis Foundation of America[205]. 
Improvement was represented by patients who had symptoms reduction 
during pregnancy associated with reduction in medication dosage; no 
change when there were no changes in the symptomatology and no need 
for medication adjustment; deterioration in the patients who required 
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significant changes of dosages of their ongoing treatments or addition of 
secondary treatments to control symptoms exacerbation. 
 
Patient’s follow-up 
All pregnant patients were followed according to our department protocol 
by a team of obstetricians and neurologists. In the first two trimesters, all 
patients were seen once a month, then every two weeks between 32nd and 
36th weeks, and weekly after 36th week of gestation.  All patients had at 
least one Neurology appointment for trimester, except if there is any 
clinical exacerbation, where follow-up was adjusted case by case. Foetal 
ultrasound evaluation was routinely performed in all pregnancies in all 
trimesters. 
 
Statistical analysis 
Descriptive statistics was used to compute the results. Cross tables with 
Fisher exact test and Pearson X2-test (when applicable) were used to 
compare clinical exacerbation between cesarean delivery and vaginal 
delivery group and to compare the group of patients that experienced a 
deterioration of the symptoms during pregnancy or postpartum with the 
remaining patients. Mann-Whitney U test was used to compare the interval 
from the diagnosis of MG to the pregnancy between group of patients 
that experienced gestational exacerbation and the remaining patients. 
Two-sided p values less than 0.05 were used to indicate statistical 
significance. 
 
Results 
During the study period, there were 30 pregnancies in 25 patients, with 
the delivery of 28 newborns. The maternal average age at birth was 
32.4±4.1 years (range 27-41). In the first obstetric appointment, and 
considering the 30 pregnancies individually,  2 patients were in clinical 
remission without medication, 7 patients in pregnancies were in 
pharmacological remission, 2 patients had ocular symptomatology (6.7% 
in Osserman stage I) and 19 patients had mild generalized symptoms 
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(63.3% in Osserman stage II). 30% were diagnosed in less than two years 
before pregnancy and 46.7% in the previous five years. One patient was 
diagnosed during gestation.  12% of our patients had other autoimmune 
disorders and Hashimoto's thyroiditis was the most frequent association. 
AChR antibodies were detected in 76% of our patients. Anti-Musk 
antibodies were present in 2 patients (8%) and seronegative MG was 
present in 4 patients (16%). Population demographics is given in table 
3.3.1.1.  
 
Table 3.3.1.1. Demographic information  
 
Maternal age at delivery (mean) 32.4 ± 4.1 years 
Primipara 24 patients 
Multipara 6 patients 
Time diagnosis before pregnancy (mean-range) 9.3 years (1-20 years) 
Thymectomy before pregnancy 18 patients 
Thymectomy during pregnancy 1 patient 
Thymoma 5 patients 
Time between thymectomy and pregnancy  
(mean - range) 
9 years (0 – 16 years) 
Association with other autoimmune disorders 3 patients 
Hashimoto´s thyroiditis 2 patients 
Rheumatoid arthritis 1 patient  
Miscarriage  2 pregnancies 
Gestational age at delivery (mean) 38.0 ± 1.3 weeks 
Vaginal deliveries 10 pregnancies 
Cesarean section 18 deliveries 
Operative vaginal deliveries 5 deliveries 
Elective cesarean section 10 deliveries (55.6% of all 
cesarean deliveries) 
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Twenty-four patients were primiparas (80.3%), and only one had a 
pregnancy before the diagnosis of MG. Two miscarriages occurred in this 
cohort before the 10th week of gestation (miscarriage rate of 6.7%). In the 
remaining pregnancies, a full-term delivery was achieved. No multifetal 
pregnancies were present in this group. 56.7% of pregnant patients 
experienced a clinical exacerbation during pregnancy or postpartum. 
Thirteen pregnant patients (43.3%) experienced a deterioration of the 
symptoms during pregnancy; 1 case was in CSR at beginning of 
pregnancy, 4 cases were in pharmacologic remission and 1 case had 
minimal manifestations treated with corticosteroids only. 46.7% of these 
during the first trimester and 53.3% in the third trimester. No 
exacerbation was detected in the second trimester. 46.4% of our patients 
also experienced a symptomatic worsening after delivery (13 patients in 
28 full term pregnancies), where 69.2% of these patients also had clinical 
deterioration during the third trimester of pregnancy. There were no 
deaths to report in our cohort. One patient experienced a clinical 
improvement after the first trimester of pregnancy. 
 
Table 3.3.1.2. MGFA Post-intervention status classification and evolution 
during pregnancy and post-partum 
 
MGFA Post-intervention  
Status 
Before 
pregnancy 
Before 
Delivery/miscarriage 
6 Months after 
pregnancy/miscarriage 
CSR 6.7 3.3 3.3 
PR 23.3 10.0 13.3 
MM-0 3.3 3.3 0 
MM-1 3.3 0 0 
MM-2 13.3 6.7 6.7 
MM-3  50.0 33.3 33.3 
Exacerbation 0 43.3 43.3 
 
 
Four patients had more than 1 pregnancy in our study. Three patients had 
2 pregnancies (one of them with one first trimester miscarriage) and 1 
patient had 3 pregnancies (1 first trimester miscarriage). The patient with 
the 3 pregnancies never experienced any clinical exacerbation in any of 
her pregnancies, even after the miscarriage.  One patient experienced a 
clinical exacerbation during the first trimester in the first pregnancy, but 
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the second pregnancy developed without exacerbations. One patient 
experienced clinical deterioration at the end of the 3rd trimester that was 
repeated in the subsequent pregnancy. And the patient that had a 
miscarriage before a full-term pregnancy experienced a clinical 
exacerbation with worsening of ocular symptoms after the miscarriage as 
well as during the puerperium of the second pregnancy.  
The average gestation age at delivery was 38.2 weeks. There was no need 
to terminate any pregnancy before term. In our institution, the way of 
labour is always discussed with the neurologist that follows the pregnant 
MG patient. In our sample, the global rate of cesarean delivery was 64.3%, 
with an elective cesarean performed before labor in 46.4% of cases. 
Elective cesarean for neurologic indication was performed in ten patients 
and the remaining three elective cesareans were performed for pelvic 
presentation in primiparas. In 5 cases, an urgent cesarean was made and 
in all instances secondary to stationary labour. Nine patients delivered 
vaginally, with the use of the vacuum extractor in five of these cases 
(55.5%). Assisted vaginal delivery was used to shorten the second stage 
of labour for maternal fatigue. There were no significant differences in 
maternal (clinical exacerbation during puerperium) or fetal outcomes (5-
minute Apgar index) between the group of patients that delivered 
vaginally or by cesarean section. 
During pregnancy, 90% of our patients were medicated with 
pyridostigmine and 43.3% with corticosteroids (prednisone). The 
prednisone dosage varied between 5 to 50mg/day, depending on the 
severity of the signs and symptoms. 40% of patients were treated with 
intravenous immunoglobulin (IVIG) during pregnancy (repeated cycles in 
75% of cases). Azathioprine was used in 2 pregnancies (75mg/day). It was 
necessary to control symptomatology before pregnancy and it was kept 
in association with pyridostigmine and prednisone during all gestation. 
72% of these women were submitted to thymectomy before the first 
gestation. In one case, a patient was submitted to a thymectomy at the 
20th week of gestation secondary to a clinical exacerbation refractory to 
medical treatment (pyridostygmine 420 mg/day; prednisone 20 mg/daily; 
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IVIG cycle). This patient was diagnosed with a thymoma type A. After 
surgery, this gestation followed without complications, with the birth of 
a healthy newborn by an elective cesarean at 37 weeks of gestation. This 
patient experienced a 2nd pregnancy 4 years later without complications. 
In 57.9% a follicular thymic hyperplasia was described. Thymoma was 
present in 15.8% of cases (all thymoma type A of the WHO classification), 
and a normal thymic histology was described in 26.5% of these women. 
All pregnant women kept their medication until labor. During the active 
phase of the first stage and second stage of labor, neostigmine was used. 
In all cases, locoregional anesthesia was used. 
The average newborn birth weight was 2919.6g (±365.2g). No cases of 
neonatal asphyxia were diagnosed with all newborns having an Apgar 
Index above 7 in the 5th minute. 
No cases of fetal growth restriction or preeclampsia were diagnosed in 
this cohort. Seven patients (25%) were diagnosed with gestational 
diabetes of which 85,7% were treated with corticosteroids to control 
myasthenic symptoms.   
During post-partum, thirteen pregnant patients (46.4%) experienced 
deterioration of symptomatology. We report one case of myasthenic crisis 
requiring ventilation support during the postpartum period. This patient 
was medicated with prednisolone 50mg/day, pyridostigmine 540mg/day 
and IVIG every four weeks. The clinical aggravation started in the 36th 
week of gestation. No clinical control was achieved with steroid dose 
increment and an elective cesarean was performed one week later. 
Ventilation support was needed during the puerperium. Clinical 
improvement was achieved with IVIG therapy and plasma exchange. 
After the puerperium period, but during the first-year post-partum, three 
patients worsened the symptoms and in 2 of them, no worsening was 
detected during the eight weeks of puerperium. In one of these patients 
neuromyelitis optica (Devic’s disease) was diagnosed six months after 
delivery and 7 years after thymectomy.  
Two newborns developed NMG, on the third and fourth day of life. In both 
cases, the diagnosis was established based on the development of typical 
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clinical signs of NMG. These infants were floppy and developed feeding 
difficulties with necessity with feed tube. No ventilator support was 
needed in any of these patients. They were treated with 
acetylcholinesterase inhibitors. In both cases, the mother experienced 
clinical aggravation during pregnancy and was classified as MM-3 
according to MGFA post intervention classification at delivery. No major 
congenital malformations were detected. Two fetuses had pyelectasis 
grade I and one newborn developed neonatal jaundice. There were no 
cases of arthrogryposis in our cohort. 
 
Table 3.3.1.3. Osserman classification 
 
Osserman 
classification 
At first obstetric 
visit 
Immunosuppressive 
medication used at 
beginning pregnancy 
% of patients in 
each Osserman 
classification that 
deteriorate 
during pregnancy 
Classe 0 30% 22.2% without 
treatment 
77.8% treated with: 
- prednisolone 
(average dosage  
7,5mg/day) 
 
55.5% 
Classe I 6.7% 100% under 
immunosuppressive 
treatment 
- prednisolone 
(average dosage 10 
mg/day) 
50% 
Classe II 63.3% 100% under 
immunosuppressive 
treatment 
- prednisolone 
(average 25mg/day) 
- azathioprine (in 2 
cases – average 
dosage 75mg/day) 
- IVIG (in 12 cases - 
weigh adjusted 
dosage) 
36.8% 
 
When we compare the group of patients that experienced an aggravation 
of symptomatology during pregnancy or post-partum with the remaining 
patients, no statistical differences were detected between groups 
regarding the interval between diagnosis and pregnancy, parity, 
medication used, way of delivery or symptomatic state before pregnancy. 
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Discussion 
 
Pregnancy has a significant effect on MG clinical course with symptomatic 
exacerbation being reported to be as high as 45% during pregnancy and 
post-partum. Plauché[206] reported the antenatal exacerbations of 35.4% 
in the series of 164 pregnancies. Djelmis et al.[207] analyzed their 
experience of 69 pregnancies in 65 patients with MG. 30.4% showed an 
exacerbation while 44.9% had no change and 24.6% improved. 
Schlezinger[208] also described the clinical course of pregnancy in 22 
myasthenic women and reported an aggravation in a third of his patients. 
Téllez-Zentero et al.[165] in a report of 18 pregnancies described an 
exacerbation rate of 33% and Mitchel & Bebbington[209] in a series of 11 
pregnancies reported a clinical aggravation of 45.5% during the third 
trimester. Batocchi et al.[160] in 64 pregnancies showed clinical 
exacerbation in 17% of patients without treatment and in 39% of patients 
under immunosuppressive treatment.  In our study, 43% of patients 
experienced an exacerbation of symptoms, especially during the third 
trimester and postpartum. This is a similar rate of clinical worsening, 
when we compare our series to others published. Our patients also 
needed a higher than usual use of immunosuppressive therapy in 
association with acetylcholinesterase inhibitors for symptomatic control. 
In the Djelmis et al.[207] series, 23.2% were free of medication during 
pregnancy while 33.3% were treated in association with corticosteroids. 
Téllez-Zentero et al.[165] reported that 61% used pyridostigmine during 
pregnancy, but only 11% needed corticosteroids or other 
immunosuppressive medication. In our study, during pregnancy, 90% 
were treated with acetylcholinesterase inhibitors and 43.3% also required 
prednisolone to symptomatic control. The corticosteroid dosage was 
increased or started in 43.3% of our pregnancies and IVIG were started 
during pregnancy in 6 cases.  This probably means that our patients 
experienced a more aggressive MG, which could justify our rate of clinical 
worsening and a higher use of corticosteroids during pregnancy. In spite 
of this, there were no deaths in our cohort and we only experienced one 
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myasthenic crisis during postpartum and after an aggressive clinical 
deterioration during the end of the third trimester.  
The clinical course of pregnancy in these patients is usually considered 
unpredictable. Djelmis[207] showed an inverse correlation between the 
duration of the disease and the frequency of clinical aggravation while 
Scott described an inverse association between the length of this period 
and mortality[210]. In our study we didn´t find any association between 
the clinical exacerbation during pregnancy or in the puerperium and the 
previous thymectomy, use of corticosteroids or IVIG during pregnancy or 
the way of delivery. In our cohort, the mean interval between MG 
diagnosis and pregnancy was smaller in the group of patients with clinical 
aggravation during pregnancy, but this was not significantly different. 
In our group, we describe a case of thymectomy during pregnancy. 
Usually thymectomy is reserved to patients with thymoma and in young 
patients with generalized symptoms with the objective to improve long 
term outcomes[211]. In our study a thymectomy was performed during 
pregnancy in a patient with a thymoma and with a clinical exacerbation 
refractory to medical treatment.  The objective of the treatment was to 
keep pregnancy and improve the response to the medical treatment which 
was achieved. 
 Our study showed a cesarean delivery rate of 64.3%. During the study 
period, our institutional cesarean rate was 40%, which means that the 
frequency of cesarean delivery has higher in MG pregnant women. Some 
authors[162,207] also showed a higher rate of cesarean delivery in this 
group of patients. However, this is not a consensual finding[164]. In our 
institutuion the type of delivery is always discussed with the pregnant 
women and the neurologist. In the presence of clinical exacerbation in a 
patient with little motivation to a vaginal delivery, we offer the possibility 
of a cesarean delivery under locoregional anesthesia. This justifies our 
high rate of cesarean sections. Despite this, we didn´t find any maternal 
or fetal outcome difference between these two groups. 
We described an NMG rate of 7.1%. In our study, two newborns developed 
classic signs of NMG during the first 72-96 hours of life, which is little 
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later than usually described. In the literature, the onset of symptoms 
occur during the first 24 hours in 80% of cases[212]. They were treated 
with acetylcholinesterase inhibitors with spontaneous resolution of 
symptoms during the first two months of life. 
In conclusion, the present literature in pregnant patients with MG is still 
limited. Our study adds to the body literature showing that in the 
presence of a more aggressive MG background, the frequency of clinical 
exacerbation during pregnancy could be high. A multidisciplinary 
approach with neurologists and trained obstetricians allowed a good 
clinical control, avoiding maternal adverse outcomes. In this group of 
patients, pregnancy should be planned to avoid the use of foetus toxic 
medication during pregnancy, as well as, to advise women to become 
pregnant during a stable phase of the disease[54]. 
Our study also showed that an elective caesarean to prevent labor in 
unmotivated patients is safe without an increased rate of clinical 
exacerbation during puerperium.   
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3.3.2 MuSK Myasthenia gravis and Pregnancy 
 
 
Within this research project, we performed a retrospective study on the 
pregnant women with MuSK-MG in our cohort and other hospitals that 
also participated in the epidemiological study.  
As in the previous study, we analysed the effects of the disease on the 
pregnancy, the delivery and the foetus, as well as the effects of pregnancy 
on MuSK-MG.  
 
Part of the results of this study was presented at the XXIII World 
Conference of Neurology, in Kyoto, in September 2017. The abstract was 
published in the Journal of Neurological Sciences.  
 
The complete study was submitted to Neuromuscular Disorders and is 
under review after resubmission.  
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Abstract 
Background: Muscle specific kinase (MuSK) myasthenia gravis (MG, MuSK-
MG) is a rare subgroup of MG affecting mainly women during childbearing 
years.  
Objective: To investigate the influence of pregnancy in the course of 
MuSK-MG and pregnancy outcomes in females with MuSK-MG.  
Methods: A multicentric cohort of 17 women with MuSK-MG was 
identified; 13 of them with ³1 pregnancy, were studied retrospectively.  
Results: MuSK-MG onset age was 35,4 years (15-66); 23,0% had other 
autoimmune disorder; 46,2% were treatment refractory. Thirteen women 
experienced 27 pregnancies, either after MG onset (group I) (n=4; 
maternal age at conception = 29.8 years) or before MG onset (group II) 
(n=23; maternal age at conception = 26.2 years). In group I pregnancy 
occurred in average 9.8 years after the MG onset; it occurred in average 
17.0 years before MG in group II. In group I, all were on steroids at time 
of conception, one on azathioprine and another receiving IVIG regularly. 
There were mild exacerbations that responded to treatment adjustments. 
There were no relapses in the 12 months following the delivery. There 
was no preeclampsia, birth defects or stillbirths in either group; 3 
miscarriages in group II. One case of neo-natal MG was recorded. All 
newborns seemed to have normal psychomotor development.  
Discussion: In this series, pregnancy did not seem to precipitate MuSK-
MG or to influence the MuSK-MG course, and there was no apparent 
negative impact in pregnancy outcomes in those where pregnancy 
followed the MG onset. 
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Introduction 
Muscle specific kinase (MuSK) myasthenia gravis (MG, MuSK-MG) is a 
subgroup of MG described for the first time in 2001.[213] It corresponds 
to around 5% of the total MG cases[12] and up to 40% of the AChR negative 
MG patients.[42] MuSK-MG affects mainly oculo-facial-bulbar muscles and 
may develop myopathic weakness and muscle atrophy. [83] Early 
respiratory crises are frequent, [214] and traditionally is seen as a more 
severe and treatment refractory form of the disease. [142,215] 
Frequently it affects women during childbearing years. In a study that 
included two cohorts of 110 MuSK-MG patients 85% were female, with 
disease onset typically in the fourth decade.[53] 
MG, regardless its antibody status, is not associated with infertility, but it 
may expose pregnant women to an increased risk of maternal and fetal 
complications. The clinical course of pregnancy in these patients is 
unpredictable.[159,216] It was described that about 30% of pregnant 
women experienced improvement of symptoms while a third face clinical 
worsening, especially in the first trimester and during postpartum. 
[159,160,217] 
An increase in the exacerbation rate during pregnancies taking place in 
the first two - three years of disease was also described.[160,161] So 
patients are  sometimes advised to postpone pregnancy to two - three 
years following  disease onset.[160] The risk of preterm birth, low 
neonate birthweight or hypertensive disorders apparently are not 
increased in MG pregnant women in general.[54] 
Neonatal MG (NeoMG) affects 7-20 % of newborns of such pregnancies. 
Typical forms characterized by weak cry, swallowing and sucking 
difficulties usually appear during the first hours of life and disappear in 
90% of cases in 2 months.[165,216] There have been descriptions of 
neonatal MG in MuSK-MG. [166,218,219] 
Specifically, the effect of pregnancy in MuSK-MG was not described yet. It 
is important to understand whether pregnancy influences the course of 
MuSK-MG and vice-versa.  
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Methods 
A multicentric cohort of 17 women with MuSK-MG from 7 hospitals in the 
North of Portugal was identified. Those with ³1 pregnancy (n=13) were 
studied retrospectively.  
Data was collected from patients’ medical records by their doctor. 
Informed consent was obtained.  
 
MG clinical information 
The diagnosis of MuSK-MG was based on clinical symptoms, 
neurophysiological tests, and positive anti-MuSK antibodies. Age of MG 
onset, past medical history, including miscarriage and preeclampsia, 
polyautoimmunity and treatment at the time of conception were recorded. 
Refractory MG was defined according predefined criteria.[88] Myasthenia 
Gravis Foundation of America post Intervention status classification[205]  
was used to describe the disease severity at the fist obstetric visit, before 
delivery  and post-partum. Clinical improvement or deterioration was 
defined taking into account the exacerbation, including myasthenia crisis, 
or development of new symptoms; changes in the medication dosage 
(steroids, pyridostigmine) or introduction of IVIG were also recorded and 
analysed in the clinical context. Clinical status was characterized by 
classification of Myasthenia Gravis Foundation of America.[205] 
 
Pregnancy related information 
Age at conception and interval between conception and MG onset were 
recorded. Information on intrauterine growth retardation, hydramnios, 
fetal akinesia, if was pre-term/full-term delivery, type of delivery, type of 
anesthesia, weight of the neonate at birth, Apgar index and presence of 
neo-natal MG (NeoMG) were collected. NeoMG was diagnosed on the basis 
of clinical signs of generalized hypotonia, weak cry, weak reflexes, 
sucking or respiratory problems. 
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Results 
The results are summarized in table 3.3.2.1. 
 
Patients – MG and pregnancy 
Thirteen women with MuSK-MG had at least one pregnancy. The age at 
MG onset was 35,4 years (15-66), 46,2% were refractory[88] and 23,0% 
had other autoimmune disorder (anti-phospholipid syndrome, sacroiliitis 
and thyroid autoimmune disorder). These thirteen women experienced 27 
pregnancies, either after MG onset (group I) (n=4; maternal age at delivery 
= 29.8 years) or before MG onset (group II) (n=23; maternal age at delivery 
= 26.2 years). There was no statistically difference between the age of MG 
onset in the two groups (p=0.26, Fisher exact test).  
In group I pregnancy occurred in average 9.8 (4-14) years after the MG 
onset and it occurred in average 17.0 (2-39) years before MG in group II 
(pregnancy before MG). There was no case of maternal MG (onset during 
pregnancy or in the postpartum period of 6 months).[220] 
 
In group I (pregnancy after MG onset), all four patients were on 
pyridostigmine and steroids at the time of conception, one was also 
taking azathioprine and another one was receiving IVIG monthly. 
Concerning MGFA status, one was at pharmacological remission (PR), one 
with minimal symptoms (MM), and two were at IIB in the beginning of 
pregnancy. There were mild exacerbations that responded to a small 
increase on the dose of pyridostigime, but one patient that worsened 
from IIB to IIIB and the interval for IVIG was shortened to every 3 weeks. 
There was no myasthenia crisis during pregnancy. There were no 
miscarriages. There was no record of intrauterine growth retardation, 
hydramnios or fetal akinesia. There were two pre-term deliveries (35 w 
and 36+6w, because of premature rupture of membranes). Two 
underwent cesarean sections (one obstetric reason and one per choice); 
all four patients received anesthesia (one general and three epidural).  
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In group II, there were 3 miscarriages; one of unknown cause and two 
occurred in the patient with anti-phospholipid syndrome. There was no 
evidence of intrauterine growth retardation, hydramnios or fetal akinesia.  
 
Neonatal health 
There was one record of neo-natal MG; the mother was the patient that 
had worsened to the stage IIIB and was receiving IVIG. The neonate was 
full-term, born by cesarean section and under general anesthesia. The 
Agar Index was 9/10, but had a very weak sucking reflex, weak cry and 
was difficult to wake up during the two first weeks of life. The mother had 
papillary carcinoma of the thyroid; baby was also tested for thyroid 
hormones, which were normal. Anti-MuSK antibodies were not tested in 
that period. Baby recovered completely by the end of the third week of 
life. In group I, there were no exacerbations in the 12 months postpartum. 
All newborns seemed to have normal psychomotor development. 
There was no preeclampsia, birth defects or stillbirths in either group. 
There was lower neonate birthweight in group I when compared with 
group II (2761g vs 3313g, p=0.008), but none had criteria for low neonate 
birth weight (<2500g).  
Considering the group II, there were 4 cesarean sections and 16 vaginal 
deliveries. All the cesarean sections were performed for obstetric reasons 
(ex: pelvic presentation). All newborns had normal development. Three 
women developed another autoimmune disease years after the 
pregnancy. 
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Table 3.3.2.1. MuSK-MG: Summary of clinical data of the mother, pregnancy, 
delivery and the newborn 
 
 Group I  
(pregnancy after MG 
onset) 
Group II  
(pregnancy before MG 
onset) 
MuSK-MG patients (n) 4 9 
Age at MG onset 19,8 y 44,0 y 
Polyautoimmunity at the time 
of the conception 
0 3 
  1 TAD 
  1 Sacroiliitis 
  1 APS 
MG severity at 
 Conception 
IIB (2) 
PR (1) 
MM (1) 
NA 
Treatments  
at Conception 
Pyridostigmine (4) 
Azathioprine (1) 
IV IG (1) 
NA 
Exacerbations 1 (IIB to IIIB) NA 
Myasthenia crisis 0 NA 
Changes in treatments 1 (decreased interval 
of IV IG) 
NA 
Pregnancy (n) 4 23 
Age at Conception 26,5 y 29,8 y 
Interval between MG  
onset and pregnancy (min-
max) 
9,8 y (4-14) -17,0 y (2-39) 
Miscarriages 0 3  
(1 UKN cause,  
2 mother with APS) 
Pre-eclampsia 0 0 
Hydramnios 0 0 
Birth defects 0 0 
Fetal akinesia 0 0 
Intrauterine growth 
retardation 
0 0 
Delivery 4 20 
Pre-term/full-term delivery 2/2 (35w, 36w+6d) 0/20 
Type of delivery 2 C-section (1 per 
choice,  
1 obstetric)  
2 vaginal 
4 C-section 
16 vaginal 
Type of anesthesia 1 general 
3 epidural 
4 general 
2 epidural 
Newborn – Infant 4 20 
Birth weight 2761 3313 
Neonatal MG 1 0 
PMD All normal All normal 
 
NA- not applicable, TAD – thyroid autoimmune disease, APS- anti-phospholipid 
syndrome, PMD- Psycho-motor development. 
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Discussion 
In the group that pregnancy occurred after Musk-MG onset, group I, it 
seems there was not a major effect of the pregnancy on the disease; only 
one experienced moderate worsening (from IIB to IIIB), probably because 
the pregnancy occurred many years after the MG onset when the disease 
was already on treatment, and stable, for a long period of time.  
At the same time, it did not seem that MuSK-MG or its treatment had 
impacted negatively on the pregnancy, attending that it did not occur any 
complications as miscarriages, pre-eclampsia, birth defects, intrauterine 
growth retardation, hydramnios, fetal akinesia or stillbirths. And none of 
the new-born had low birth weight, although the weight in this group was 
slightly lower than in the group II. Whether this could be related to 
treatments is difficult to know.  
Despite of the rarity reported[166], we registered a case of a newborn 
with symptoms suggestive of neonatal MG.  
Regarding the group II pregnancies occurred many years before the onset 
of the disease (average of 17.0 years, 2-39 years). Reports point to 
pregnancy and the postpartum period as a risk period for the start of the 
disease, [221–223] but, in this cohort of patients (9 women with 23 
pregnancies), pregnancy did not seem a precipitating factor for the 
development of MuSK-MG.   
Recently a case-control study using population data from Norway and the 
Netherlands, studied 246 females with onset of the disease in their 
reproductive years (15–45 years of age), including AchR-MG and Musk-MG 
patients, and found 15% of cases of maternal MG. [220] From the 246 MG 
cases, 6 were MuSK-MG and they found one case of maternal MuSK-MG. 
There are also reports of other cases of maternal MuSK MG.[167,218,219] 
In group II the average age of MuSK-MG onset was 44,0 years, it might be 
that the risk factors for the development of the disease had less influence 
of the hormonal changes of the pregnancy [224] but were more similar to 
those of the late onset MG.[153] 
Musk-MG is a rarer form of the disease, it would very important to study 
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these issues in bigger multicentric cohorts of this subgroup of the disease 
or case-control studies. Meanwhile, and taking into account our study and 
those published[166,216,218–220] there seems to be a consensual 
clinical impression and evidence that women with MuSK-MG may have 
healthy pregnancies. Furthermore, their MG may remain well-controlled 
during pregnancy, around delivery time and in the post-partum period. 
Close monitoring and appropriate management by experienced 
Obstetricians, Pediatricians and Neurologists will be, however, required.     
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3.4. Polyautoimmunity and Myasthenia gravis	
 
Within this research project, we performed a retrospective study on the 
coexistence of other autoimmune disorders and MG in our cohort in 
Centro Hospitalar do Porto/Hospital de Santo António and analysed the 
characteristics of this group of patients.  
 
It was published in Journal of the Neurological Sciences, 2017 Oct 
15;381:39-40 and the full text follows: 
 
Myasthenia gravis with systemic and neurological polyautoimmunity  
 
Sara Duarte*1, Ernestina Santos*,1,2 Joana Martins1, Ana Martins Silva1,2, 
Carlos Lopes3, Guilherme Gonçalves2, Maria Isabel Leite4.  
 
*These authors contributed equally to this work. 
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Introduction  
Autoimmune diseases share symptoms and signs, pathophysiological 
mechanisms and genetic and environmental susceptibilities, facts that 
support the existence of a common origin [225] though it may be 
influenced by multiple factors. Polyautoimmunity refers to the presence 
of more than one autoimmune disease in a single patient and this is well 
documented in great majority of the spectrum of autoimmune diseases, 
particularly those mediated by autoantibodies, including myasthenia 
gravis (MG).[226] 
Myasthenia gravis is caused by antibodies directed against the 
acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or, less 
frequently, to lipoprotein-related protein 4 (Lrp4) or agrin, all located in 
the postsynaptic membrane at the neuromuscular junction[12]. Anti-
AChR positive MG is traditionally associated with thymus pathology, 
either thymic hyperplasia or thymoma. The frequency of 
polyautoimmunity in MG has been reported between 11.6%-32% 
[112,127,189], which is superior to the general population risk (5%). [141] 
 
Material and methods 
We analysed all patients with MG (214) in follow-up between 1992 and 
2016 in a Portuguese tertiary centre for the co-occurrence of other 
autoimmune disorders, with a special focus on the neurological ones. MG 
and the other diseases were diagnosed based on well-established clinical, 
electrophysiological, imagiological and serological criteria. 
 
Results  
Associated systemic autoimmune disorders in myasthenia gravis  
We found other autoimmune disorders in 37 patients with MG (17%). Six 
patients have a combination of more than one autoimmune disease 
besides MG (multiple autoimmune syndrome). Autoimmune thyroid 
disease was the most frequent, followed by rheumatoid arthritis and anti-
phospholipid syndrome (table 3.4.1.).  
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Table 3.4.1. Systemic autoimmune comorbidities  
Autoimmune disorders (17%) n=37/214 
Autoimmune thyroiditis 14 
Rheumatoid arthritis 5 
Anti-phospholipid syndrome 5 
Psoriasis 4 
Sjogren syndrome 3 
Systemic lupus erythematosus 2 
Pernicious anemia 2 
Vitiligo 2 
Acquired immunodeficiency (C1q deficit) 1 
Alopecia areata 1 
Idiopathic thrombocytopenic purpura 1 
Lichen planus 1 
Primary biliary cirrhosis 1 
Reactive arthritis 1 
Reactive lymphadenitis 1 
Rheumatic fever 1 
Seronegative arthritis 1 
Total 46 
 
As expected, the frequency of a second autoimmune disorder is highest 
for females (68%) with early onset MG (EOMG) (mean age at onset is found 
to be 41 years). The majority of these patients have the generalized form 
of myasthenia (78%) and the anti-AChR antibodies were positive in 78%. 
Thymectomy was performed in 19 patients (51%), with thymic hyperplasia 
being the most common histological diagnosis. In most cases, MG 
preceded the onset of the other autoimmune disease (62%) and 
immunosuppression didn’t seem to affect the development of a second 
condition (68% had not been exposed to immunosuppressive agents when 
the other disorder emerged).  
 
Associated neurological autoimmune disorders in myasthenia gravis 
Of 214 patients with MG 11 (5%) have another autoimmune neurological 
disease: three of the central nervous system, seven of the peripheral 
nervous system and one of the autonomic nervous system (table 3.4.2.).  
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Table 3.4.2. Neurological autoimmune comorbidities 
 
Pt 
nr 
Gender 
Age 
at MG 
onset 
MG 
form 
Anti-
AChR 
Ab 
Thymectomy  
(Yes or No) 
Histology 
Treatment at 
the time of the 
second illness 
presentation 
Time 
between 
MG and 
other AI 
disease 
(years) 
Other AI 
neurological  
disease 
1 F 28 G Pos 
Yes 
TH 
0 14 
Neuromyelitis 
optica  
with AQP4 
antibodies 
2 F 18 G Pos 
Yes 
TH 
0 9 
Neuromyelitis 
optica  
with AQP4 
antibodies 
3 M 39 Oc Neg No 0 9 
Autoimmune 
encephalitis 
with GAD65 
antibodies 
4 F 27 G Pos No NA 0 Myositis 
5 M 32 G Pos 
Yes 
Thymolipoma 
NA 0 Myositis 
6 F 39 G Pos No 
Methotrexate; 
prednisolone 
-6 Myositis 
7 M 42 G Pos No 
IVIG; 
prednisolone 
-4 Myositis 
8 M 69 G Neg 
No 
Thymoma 
NA 0 Myositis 
9 M 38 G Pos 
Yes 
Normal 
0 21 
Parsonage-
Turner 
syndrome 
10 F 39 G Pos 
Yes 
TH 
0 2 CIDP 
11 F 30 G Neg 
Yes 
Thymoma 
NA 0 
Intestinal 
pseudo-
obstruction 
syndrome with 
anti-
CV2/CRPM5 
Pt nr: patient number; F: female; M: male; MG: myasthenia gravis; G: generalized, Oc: ocular. AChR: 
acetylcholine receptor; pos: positive; neg: negative; TH: Thymic hyperplasia; AI: autoimmune; NA: not 
applicable; IVIG: Intravenous immunoglobulin; CIDP: chronic inflammatory demyelinating 
polyradiculoneuropathy.
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The patients were examined for a second neurological condition only 
when unusual signs or symptoms arose, when there was an unexpected 
deterioration or poor response to treatment. The majority (54.5%) of these 
patients are females with EOMG (average age at MG onset is found to be 
36 years), and almost all have generalized MG. Anti-AChR antibodies were 
positive in 73% (8/11); there were other autoantibodies in relation with 
other autoimmune disease in six cases. Six patients (55%) were 
thymectomized. As previously reported [138,140], thymoma seemed to 
associate more frequently with muscle disease, whereas hyperplasia 
seemed to be linked to neuromyelitis optica spectrum disease (NMOSD). 
The MG manifestations preceded or coincided with those of other 
autoimmune neurological disorder in most cases (9/11; 82%) (average 
time between onset of symptoms of MG and the other disease was 4 
years). The average diagnostic delay of the second neurological disease 
was 1.5 years. The majority of patients (5/7; 71%) had not yet been 
exposed to immunosuppression when the second illness emerged. 
 
Discussion and conclusions  
The course of MG is often complicated by concomitant autoimmune 
disorders. Our results are in line with this observation and appear to be 
relevant in general as well as in specialised neurological clinical practice.  
It is important to consider coexistent MG in patients with autoimmune 
disorders that develop new or aggravated muscular weakness, fatigue or 
respiratory failure.  
On the other hand, while rare, the possibility of neurological autoimmune 
comorbidity should also be considered in myasthenic patients, especially 
if there is an unexpected deterioration of muscle weakness or poor 
response to pyridostigmine (e.g. muscle disease), or if unexpected 
neurological signs or symptoms arise in MG (e.g. peripheral nervous 
system involvement in keeping with CIDP; or central nervous system 
illness such as NMOSD; or even rarer manifestations such as of autonomic 
dysfunction) [2]. The rapid diagnosis of the second illness will improve 
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management and disease outcomes of both MG and the other 
autoimmune condition. 
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3.5. Refractory Myasthenia gravis 
 
Under this topic we studied the clinical, demographic and immunogenetic 
characteristics of the refractory MG patients in our cohort. 
 
Part of the results were presented in international conferences:  
 
- Refractory Myasthenia gravis: clinical and demographic data, 
presented at the XXIII World Conference of Neurology, in Kyoto, 
September 2017. The abstract was published in the Journal of 
Neurological Sciences. 
- Refractory Myasthenia gravis and HLA, presented in the European 
School of Neuroimmunology, in Venice, June 2017. The abstract 
was published in the Journal of Neuroimmunology. 
 
The manuscript is currently under submission; the full text is as follow. 
 
- Refractory Myasthenia gravis: Clinical, demographic and 
immunogenetic characteristics in a portuguese cohort. 
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3.5.1. Refractory Myasthenia gravis: Clinical, demographic and 
immunogenetic characteristics in a portuguese cohort 
 
Ernestina Santos 1,2, Andreia Bettencourt 2,3, Sara Duarte 1, Denis Gabriel 1, 
Vanessa Oliveira1, Bárbara Leal2,3, Claúdia Carvalho2,3, Ana Martins da Silva 
1,2, Paulo Pinho Costa2,3,4, Carlos Lopes 2, Guilherme Gonçalves 2, Berta 
Martins da Silva 3, Maria Isabel Leite5 
 
1. Neurology Department, Centro Hospitalar do Porto Hospital de Santo 
António (CHP-HSA), Porto; 2. Unit for Multidisciplinary Research in 
Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar-
Universidade do Porto (ICBAS-UP); 3. Immunogenetics Laboratory, 
Instituto de Ciências Biomédicas Abel Salazar-Universidade do Porto 
(ICBAS-UP); 4.Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA), Porto; 
5. Nuffield Department of Clinical Neurosciences, Oxford University 
Hospitals and University of Oxford, Oxford. 
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Abstract 
Background: A subset of myasthenia gravis patients is refractory to 
conventional treatments. Identifying their clinical and genomic 
characteristics may be important to contribute for the development of 
effective strategies in this subgroup. 
 
Objective: The aim of our study is to describe the clinical features of 
refractory MG patients and to investigate a possible association between 
HLA-DRB1 alleles and refractory MG. 
 
Methods: A retrospective study of 172 MG patients followed in the 
Neuroimmunology Outpatients clinics was performed. Patients were 
classified as refractory or non-refractory based on predefined criteria, and 
clinical features were compared. Chi-square/Fisher’s exact and Mann-
Whitney tests were used to investigate associations between clinical and 
demographics characteristics and response to treatment. 114 MG patients 
(22 refractory and 92 non-refractory) were genotyped for the HLA-DRB1 
locus using PCR-SSP methodology. A group of 282 healthy individuals was 
used as control population. 
 
Results: Thirty eight out of 172 patients were classified as refractory 
(22%). Compared to the non-refractory patients, the refractory ones were 
more likely to have a more severe MGFA classification at onset (p=0.02), 
to have thymomatous MG (p=0.03) and to be seropositive, either to anti-
AChR (p=0.05) or anti-MuSK antibodies (p=0.03). Differences regarding 
sex, age of onset, presence of other autoimmune diseases, malignancies 
(other than thymus) or severe/opportunistic infections were not observed. 
HLA-DRB1*03 was more frequent in the non-refractory vs control 
population (38.0% vs. 15.6%, p=3x10-6). HLA-DRB1*13 allele was less 
frequent in the non-refractory group when compared to the control 
population (13.0% vs. 29.8% respectively, p=0.002). And HLA-DRB1*13 
allele was more frequent in the refractory MG when compared to the non-
refractory group (40.9% vs 13.0%, p=0.003).  
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Discussion: Refractory MG patients represent a substantial subgroup in 
the disease. It is important to consider their characteristics from the onset 
of the disease for a better management of these patients. HLA-DRB1*13 
allele appears to have a protective role as it was reported before in other 
autoimmune disorders. 
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Introduction 
Myasthenia gravis, a rare autoimmune disorder of the neuromuscular 
transmission, antibody-mediated, characterized by fatigable muscle 
weakness is increasingly acknowledged as a syndrome more than as a 
single disease.[28] 
In the generalized form of the disease around 85% of patients have 
antibodies detected against the nicotinic acetylcholine receptor (AChR) at 
the neuromuscular junction. The remaining patients have antibodies 
against other components of the postsynaptic muscle endplate, such as 
muscle specific receptor tyrosine kinase (MuSK), LRP4 or are triple 
seronegative (unidentified or undetected antibody).[20] Around 10 to 15% 
of MG cases are associated to thymoma.[20] 
Therapeutic options in myasthenia gravis patients include cholinesterase 
inhibitors, thymectomy, immunosuppressive agents and short-term 
immunomodulation with plasma-exchange and intravenous 
immunoglobulin. [28] Conventional immunosuppressive agents used in 
MG treatment are azathioprine, mycophenolate mofetil, cyclosporine, 
tacrolimus and cyclophosphamide.[142] A proportion of myasthenia 
gravis patients are classified as refractory due to non-responsiveness to 
conventional treatment. It corresponds to a small but important portion 
of the MG population (10-15%). [142] 
Refractory patients were defined as those who could not lower the 
immunotherapy for MG without clinical relapse, with MG not clinically 
controlled on their immunotherapy regimen, or who had developed severe 
adverse effects from immunosuppressive therapy for at least a period of 
12 months.[88,142] 
Some studies show that these patients are mostly females, have young 
onset and generalized disease, and are seropositive, predominantly to 
anti-MuSK antibodies or associated to thymoma.[88,142] 
This refractory MG population has been the focus of recent publications 
evaluating the response to biologic agents (rituximab[142,143], 
tocilizumab[72], eculizumab[73,74], belimumab[75]) and rescue 
treatments (autologous hemopoietic stem cell transplantation)[76]. 
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Over the years, association of MG with Human Leucocyte Antigens (HLA) 
has been described in different populations.[49,105,106,189–191,196] 
Apparently, their relation with a refractory course was not studied in 
myasthenia gravis so far. It was studied in other autoimmune disorders, 
as in rheumatoid arthritis.[227] It was also related to disease severity and 
progression in rheumatoid arthritis[227–229] and in multiple 
sclerosis.[230,231] 
Identifying refractory patient’s characteristics is important to contribute 
to a better management of treatment approaches and to contribute to the 
development of therapies effective in this subgroup. 
 
Objective 
Our aim was to describe the clinical and demographic features of 
refractory MG patients and compare them to those with a non-refractory 
disease. This study also explored the existence of a correlation between 
the refractory group of patients and HLA-DRB1 locus susceptibility alleles. 
 
Methods 
We did a retrospective study of 172 MG patients followed in the 
Neuroimmunology Outpatients clinics of Centro Hospitalar do 
Porto/Hospital Santo Antonio. Patients were classified as refractory or 
non-refractory based on predefined criteria[88]: those who could not 
lower their immunotherapy without clinical relapse, were not clinically 
controlled on their immunotherapy regimen, or had severe side effects 
from immunosuppressive therapy.  
Clinical features were compared in the two groups regarding 
demographic and clinical characteristics: age of onset, sex, generalized 
versus ocular, MGFA classification, MG antibodies status, thymectomy and 
thymic pathology, presence of other autoimmune disorders, malignancies 
(other than thymus) or severe/opportunistic infections. Chi-
square/Fisher’s exact and Mann-Whitney tests were used to investigate 
associations between clinical and demographics characteristics and 
response to treatment. 
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From the total 172 MG patients mentioned above, 114 MG patients (22 
refractory and 92 non-refractory) were genotyped for the HLA-DRB1 locus 
using PCR-SSP methodology. A group of 282 healthy individuals was used 
as control population. 
 
HLA Genotyping 
Peripheral blood samples were collected in EDTA. Genomic DNA was 
obtained from proteinase-K–treated peripheral blood leukocytes by using 
a salting-out procedure.[193] Low-resolution genotyping for HLA–DRB1 
locus (i.e., 2-digit HLA nomenclature) was performed using polymerase 
chain reaction with sequence-specific primers (PCR-SSP), based on 
methods previously described.[194] 
 
Control population 
Patients HLA alleles frequencies were compared with the ones from a 
control group consisting of 282 unrelated individuals, healthy blood 
donors, from the same geographic origin (north of Portugal). 
 
Statistical Analysis 
Chi-Square/Fisher’s exact and Mann-Whitney tests were used to 
investigate associations between clinical/demographics characteristics, 
response to treatments and HLA DRB1 alleles frequencies. The data were 
analyzed using the IBM SPSS 20 statistical software suite. 
 
Results 
Clinical and demographic data 
38 out of 172 patients were classified as refractory (22%).[88] Some of the 
patients fulfilled more than one of the criteria for refractory MG. Eighteen 
patients were doing IV IG chronically, thirteen had been under two or more 
different immunossupressors agents and fourteen were under prednisone 
= or > than 20 mg per day. The average interval of follow-up was 12 years 
(2-40). 
Average age at onset was 37 years in the non-refractory group versus 33.5 
	
	
122	
years in the refractory group (p>0.05). The distribution of age of onset in 
the two groups is illustrated in the Graph 3.5.1.1. There were no 
differences regarding sex, females were 68% in the non-refractory and 
71% in the refractory group(p>0.05). Ocular form was present in 93,1% in 
the non-refractory versus 6.9% in the refractory group and the generalized 
form was 78,5% in the non-refractory group vs 21,5% in the refractory 
group (p>0.05). 
 
Graph 3.5.1.1. Distribution of the MG age of onset in the two groups refractory 
and non-refractory MG 
 
Compared to the non-refractory patients (Table 3.5.3.1.), the refractory 
ones were more likely to have a more severe MGFA classification at onset 
(p=0.02), to have thymomatous MG (p=0.03) and to be seropositive, either 
to anti-AChR (p=0.05) or anti-MuSK antibodies (p=0.03). Seronegative MG 
was more common in the non-refractory group 30% vs 7.9% in the 
refractory (p=0.006). 
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We could not find any difference regarding presence of other autoimmune 
diseases, malignancies (other than thymus) or severe/opportunistic 
infections. Polyautoimmunity was present in 26.9% in the non-refractory 
group vs. 18.4% in the refractory group (p>0.05). 
Table 3.5.1.1. Clinical and demographic characteristics of MG patients 
 Non-refractory 
(n = 134) 
Refractory 
(n = 38) 
p-value 
Female 92 (68.7%) 27 (71%) 0.78 
Age, median (IQR) 57 (44-69) 49.5 (40-63) 0.11 
Age at diagnosis 37 (25-59) 33.5 (24-53) 0.58 
Clinical manifestation   0.07 
  Ocular 27 (93.1%) 2 (6.9%)  
  Generalized 91 (78.5%) 25 (21.5%)  
MGFA classification   0.02 
  I 32 (23.9%) 12 (23.9%)  
  IIa 32 (23.9%) 13 (34.2%)  
  IIb 10 (7.5%) 3 (7.9%)  
  IIIa 0 1 (2.6%)  
  IIIb 0 1 (2.6%)  
  Iva 0 1 (2.6%)  
  IVb 0 1 (2.6%)  
Pharmacologic remission 46 (34.3%) 6 (15.8%) 0.03 
Complete remission 14 (10.5%) 1 (2.6%) 0.13 
Serologic status    
   AChR+ 87 (65.8%) 31 (81.6%) 0.05 
   MuSK 5 (8.93%) 4 (30.8%) 0.03 
   Seronegative 39 (30%) 3 (7.9%) 0.006 
Thymectomy 54 (40.3%) 21 (55.3%) 0.10 
Thymoma 12 (23%) 10 (50%) 0.03 
Other autoimmune diseases 36 (26.9%) 7 (18.4%) 0.52 
Malignancy 9 (16.4%) 2 (15.4%) 0.93 
Severe/opportunistic infections 5 (10%) 1 (9%) 0.93 
IQR – interquartile range. MGFA – Myasthenia Gravis Foundation of America Clinical 
Classification. Statistically significant if p-value < 0.05. 
	
	
124	
Immunogenetic data 
We found that HLA-DRB1*03 was more frequent in the non-refractory vs 
control population (38.0% vs. 15.6%, p=3x10-6). 
HLA-DRB1*13 allele was less frequent in the non-refractory group when 
compared to the control population (13.0% vs. 29.8% respectively, 
p=0.002). At the same time, HLA-DRB1*13 allele was more frequent in the 
refractory MG when compared to the non-refractory group (40.9% vs 
13.0%, p=0.003) (Table 3.5.1.2.). 
 
Table 3.5.1.2. HLA-DRB1 genotyping and Refractory Myasthenia gravis 
 
HLA- 
A: 
Controls 
(n=282) 
B: 
Refractory  
MG (n=22) 
C: Non- 
refractory  
(n=92) 
P 
global 
p 
A vs. 
B 
P 
A vs. 
C 
P 
B vs. 
C 
DRB1*01 66 (23.4%) 6 (27.3%) 23 (25.0%) 0.889 0.681 0.716 0.847 
DRB1*03 44 (15.6%) 4 (18.2%) 35 (38.0%) 2.5x10-5 0.749 3x10-6 0.073 
DRB1*04 69 (24.5%) 7 (31.8%) 23 (25.0%) 0.745 0.443 0.877 0.533 
DRB1*07 72 (25.5%) 4 (18.2%) 20 (21.7%) 0.604 0.443 0.494 0.696 
DRB1*08 24 (8.5%) 3 (13.6%) 5 (5.4%) 0.396 0.416 0.350 0.182 
DRB1*09 14 (5.0%) 1 (4.5%) 2 (2.2%) 0.517 0.930 0.257 0.539 
DRB1*10 11 (3.9%) 0 (0.0%) 5 (5.4%) 0.496 0.345 0.514 0.261 
DRB1*11 55 (19.5%) 3 (13.6%) 16 (17.4%) 0.743 0.500 0.685 0.657 
DRB1*12 9 (3.2%) 1 (4.5%) 0 (0.0%) 0.196 0.732 0.085 0.041 
DRB1*13 84 (29.8%) 9 (40.9%) 12 (13.0%) 0.002 0.276 0.002 0.003 
DRB1*14 17 (6.0%) 0 (0.0%) 7 (7.6%) 0.405 0.236 0.574 0.179 
DRB1*15 56 (19.9%) 3 (13.6%) 16 (17.4%) 0.704 0.477 0.632 0.657 
DRB1*16 13 (4.6%) 2 (9.1%) 8 (8.7%) 0.276 0.350 0.132 0.965 
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Discussion 
Clinical and demographics 
Refractory MG represents a significant subgroup of the disease. In our 
cohort, the frequency of the refractory MG patients was 22%. This rate is 
slightly higher than in other populations where it corresponds to 10-
15%.[142] Maybe it happens in our cohort because it is a tertiary centre, 
where more difficult patients are sent to second opinion. 
To have a worse MGFA classification at onset, being seropositive either 
for AChR or anti-MuSK antibodies were the characteristics associated with 
a refractory course in our cohort. 
MuSK-antibody positive MG patients generally respond to conventional 
immunotherapy, but require higher corticosteroid doses to manage 
symptoms and have lower remission rates than AChR- antibody positive 
patients.[82,232] In our study, refractory MuSK-antibody MG patients 
corresponded to 44,4% of the total MuSK-antibody MG patients. 
Nine out of 22 patients (40,9%) with thymoma MG were refractory 
patients. [233] Akaishi found that patients with MuSK-Ab showed worst 
severity at the same level as thymoma-associated MG patients, although 
this result was not statistically significant because of the small number of 
patients.[234] We also found that another important refractory MG 
subgroup is thymoma MG. 
This study mentioned previously that included 923 japanese MG patients 
also found that those with ocular MG and those who are seronegative have 
a better response to treatments.[234] In our study, seropositive patients 
were more likely to have a generalized disease. 
Thymectomy, regardless of the histology, was found in other studies to 
be associated with a refractory course.[88] In our study we could only find 
that in those with thymoma, and not thymic hyperplasia, normal histology 
or atrophic histology. 
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These characteristics, worse MGFA classification at onset, being 
seropositive either for AChR or anti-MuSK antibodies associated with a 
refractory course of the disease should prompt for a more aggressive 
treatment from the beginning of the disease, more careful weaning of the 
steroids and earlier start of immnussupressors agents. 
 
Immunogenetics 
The functional basis of the association between specific HLA alleles and 
development of autoimmune disorders is not completely understood. The 
molecular mimicry hypothesis proposes that certain HLA alleles are more 
efficient in presenting pathogen epitopes that share structural features 
with self-peptides to mature T cells. Once the response to the pathogen 
is initiated the self-antigen is also recognized and disease ensues. The 
central selection failure theory propose that certain HLA alleles are less 
efficient at presenting self-peptides to developing T cells in the thymus, 
so negative selection fails. [235] Another hypothesis postulate that 
different alleles can modulate the immunologic profile of an individual, 
through antigen-independent mechanisms, resulting in either promoting 
a higher autoimmune predisposition or, in opposition, a more efficient 
immune regulation. [200] 
Considering that there is an association of HLA-DRB1 alleles with different 
autoimmune diseases[200,231] and their course, and also the well-known 
susceptibility alleles for the different MG subgroups[49,106,189] we 
explored which HLA-DRB1 alleles could be influencing a refractory course 
in myasthenia gravis. 
The previous immunogenetic analysis of this cohort confirmed the well-
known association of MG with HLA-DRB1*03. [106] In this study 
compelling evidence is provided that this association is driven by non-
refractory patients and controls, as no significant difference between 
refractory patients and controls was observed. 
We also uncovered a protective role for HLA-DRB1*13 in the non-refractory 
group, that was masked in the previous study, as the subgroup division 
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was by age of onset and not considering the refractory course of the 
disease. 
HLA-DRB1*13 allele has also been pointed has protective factor for several 
other autoimmune disorders: Systemic Lupus Erythematosus, Psoriasis or 
Psoriatic Arthritis, Rheumatoid Arthritis, Systemic Sclerosis and Multiple 
Sclerosis.[200] 
This is the first time, to our knowledge that an association of 
immunogenetic biomarkers and refractory MG was reported. 
 
Final Comments 
In conclusion, our results show that refractory MG patients are a subset 
of MG patients with clinical features that are distinct from those of non-
refractory patients. These patients are more likely to be seropositive, 
either to anti-AChR or to anti-MuSK antibodies, to have a thymoma and to 
have a more severe MGFA classification at onset. 
The distinct characteristics of refractory patients suggest underlying 
biological differences between the non-refractory and refractory MG 
groups. We found that the refractory group has a different immunogenetic 
background, being more similar to the controls than the non-refractory 
subgroup.  
It is important to be aware of refractory traits characteristics from the 
onset of the disease for a better management of these patients. The 
identification of biomarkers for refractory disease will be essential for the 
development of newer therapeutic approaches. 
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3.6 Infections, neoplasms and other autoimmunity in 
thymoma associated Myasthenia gravis 
 
This chapter was based in two studies, the first was the study of two case 
reports and the analysis of their thymus at two moments of the disease: 
 
- Thymoma following thymectomy of hyperplastic thymus in 
young onset Myasthenia gravis: clinical features heralding the 
thymoma; 
 
 
And the second is still being conducted. It has the objective to study the 
occurrence of infections, neoplasms (other than thymus) and systemic 
autoimmunity in thymoma associated MG with AIRE gene and other 
immunohistochemistry studies: 
 
- Infections, neoplasms and other autoimmunity in thymoma MG 
and AIRE gene. 
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3.6.1. Thymoma following thymectomy of hyperplastic thymus in 
young onset Myasthenia gravis: clinical features heralding the 
thymoma 
 
Part of this study was presented in XI International Congress of 
Neuroimmunology, in Boston, November 2012, and the abstract was 
published in Journal of Neuroimmunology. The manuscript is currently 
under submission. 
 
 
Thymoma following thymectomy of hyperplastic thymus in young 
onset Myasthenia gravis: clinical features heralding the thymoma 
 
Ernestina Santos1,2, Ana Martins Silva1,2, Philipp Stroebel3, Antonio 
Marinho4, Nick Wilcox5, Guilherme Goncalves2, Carlos Lopes6, Alexander 
Marx7, Maria Isabel Leite4 
 
1-Department of Neurology, Hospital Santo Antonio, University of Porto, 
Porto, Portugal; 2- Instituto de Ciencias Biomedicas de Abel Salazar, 
University of Porto, Porto, Portugal;3-Institute of Pathology, University 
Medical Center Göttingen, University of Göttingen, Göttingen, Germany; 
4-Department of Clinical Immunology, Hospital Santo Antonio, Centro 
Hospitalar Porto, University of Porto, Porto, Portugal; 5-Neurosciences 
Group, Department of Clinical Neurology, Institute of Molecular Medicine, 
John Radcliffe Hospital, Oxford, United Kingdom; 6-Department of 
Pathology, Hospital Santo António, Centro Hospitalar Porto, Instituto de 
Ciencias Biomedicas de Abel Salazar, University of Porto, Porto, Portugal; 
7-Institute of Pathology, University Medical Centre Mannheim, University 
of Heidelberg, Mannheim, Germany 
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Abstract:  
Background: It is extremely rare for young onset myasthenia gravis (MG) 
patients to have thymoma following extended removal of hyperplastic 
thymus. We present two anti-acetylcholine receptor MG (AChR-MG) 
patients who developed thymoma years after extended transternal 
thymectomy and highlight the clinical manifestations that heralded the 
thymoma, consequently of a severe immunodeficiency which resembled 
APECED (autoimmune polyendocrinology, chronic mucocutaneous 
candidiasis and ectodermal dystrophy) syndrome, with auto-immune 
regulatory (AIRE) gene defect. 
 
Case 1: a 20 years-old female with generalized MG received extended 
transternal thymectomy revealing thymic follicular hyperplasia. After 15 
years of stable, mild MG on chronic steroid therapy, she got worse 
(recurrent severe respiratory infections needing ventilation and plasma 
exchange). She also developed alopecia totalis, oral candidiasis, recurrent 
genital Herpes simplex infections and recurrent severe respiratory 
infections. A WHO B2 type thymoma was removed, but MG and associated 
manifestations did not improve, and patient died at 52 years-old with a 
severe pneumonia and respiratory failure. Retrospectively, she was found 
to have high levels of anti-IL22, IL-17A and IL-17F antibodies.  
 
Case 2: a 27 years-old male with generalized MG was treated with 
immunosuppression and extended transternal thymectomy revealing 
thymic follicular hyperplasia. MG was initially difficult to treat needing 
plasma exchanges, but became stable with steroids and cyclosporine. 
Seven years after MG onset, he presented extensive skin lesions and 
worsened myasthenic symptoms with generalized severe bulbar and 
respiratory involvement. Imaging and histology revealed thymoma type 
B3 with pleural dissemination. Skin lesions were diagnosed as 
paraneoplastic exfoliative erythoderma. He had severe immunodeficiency 
(CD4 lymphocytes= 99/µL) with several nosocomial infections (P. 
aeruginosa, Klebsiella, CMV and became HBV DNA positive), chronic 
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diarrhoea and a chronic hepatitis with unknown cause (infeccious vs 
autoimmune). Thoracic radiotherapy (dose 30 Gy) was followed by 
chemotherapy, but the patient died of massive pulmonary 
thromboembolism. He was found to have high levels of anti-IL22, IL-17A 
and IL-17F antibodies. 
 
Discussion: These two cases illustrate the need of searching for a 
thymoma in MG patients whose MG becomes difficult to treat after 
removal of a thymus with thymic follicular hyperplasia. Thymoma needs 
to be considered even more in case of severe and/or recurrent infections, 
which could reflect complex paraneoplastic immune-deficiency that in the 
here described patients were associated with auto-antibodies to 
interleukins.  
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Thymoma following thymectomy of hyperplastic thymus in young 
onset Myasthenia gravis: clinical features heralding the thymoma  
 
Background:  
Thymomas are rare thymic epithelial tumors that are often associated with 
autoimmune disorders among which myasthenia gravis (MG) is the 
commonest.[227,228]. In addition, autoimmune and other mechanisms 
underlie thymoma-associated humoral and cellular immune defects (e.g. 
hypogammoglobulinemia) that commonly entail life-threatening 
infections.[227,228]  
Thymectomy is an accepted therapeutic option for myasthenia 
gravis[229,230]. Extended thymectomy aims to dissect the 
macroscopically recognizable thymus together with the anterior 
mediastinal fat, taking into account that mediastinal adipose tissue may 
harbor substantial thymic extensions on microscopic examination [229]. 
There are several reports on recurrences of MG because of incomplete 
removal or ectopy of thymic tissue, while reports on thymomas arising 
from remnant or ectopic thymic tissue following transternal thymectomy 
are sparse.[231–235] Associated diseases, particularly MG, are often the 
presenting manifestation of thymomas, but others occur after 
thymectomy and may sometimes herald thymoma recurrence. This also 
applies to thymoma-associated immunodeficiencies and subsequent 
severe and/or chronic infections such as chronic mucocutaneous 
candidiasis (CMC), cryptococcal meningitis and Kaposi sarcoma.[228] 
APECED is the eponym of a genetic syndrome that typically comprises 
autoimmune polyendocrinology, chronic mucocutaneous candidiasis and 
ectodermal dystrophy. The endocrine and infectious findings have an 
immune basis and result from mutations of AIRE (autoimmune regulator), 
which is a crucial gene in the induction of thymic self-tolerance[236]: AIRE 
protein mediates expression of thousands of tissue-specific self-antigens 
by medullary thymic epithelial cells, while this expression is missing in 
AIRE deficiency states, in which multi-organ autoimmunity develops 
because of faulty negative selection of auto-reactive T cells.[237]  
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Some of the APECED syndrome features are also found in patients with 
thymoma regardless the development of MG.[236] There is some evidence 
that the clinical features of APECED syndrome correlate with the 
absence/reduction of specific pro-inflammatory interleukins (IL17 A, IL 
17F, IL 22) and the presence of neutralizing antibodies to these 
interleukins. Neutralizing antibodies to IL17 were also found in some 
thymoma patients with CMC.[237] In those patients it was hypothesized 
that production of autoantibodies against these TH17-produced cytokines 
was related to thymocyte development with defective negative selection 
in thymomas with lack of AIRE expression.[237] 
 
 
Objective:  
To report two patients with early onset MG, submitted to extended 
transternal thymectomy, with thymic hyperplasia, that later in life 
developed clinical manifestations heralding a thymoma. 
 
Case Reports:  
Case 1: 
A 20 years old woman started to suffer from occasional unilateral eyelid 
ptosis. Few years later, after delivery, she had diplopia, unilateral eyelid 
ptosis and mild dysphagia. Electromyography confirmed decrement of 
compound muscle action potential (CMAP) amplitude on repetitive 
stimulation. MG was diagnosed. She improved with pyridostigmine, but 
mild ptosis persisted. In 1987, at 35 years, she worsened, experiencing 
also limb weakness, mild dysphagia, dysphonia. It was decided to start 
treatment with steroids. After this she rapidly worsened, needing 
admission to intensive care unit because of respiratory failure. She was 
submitted to extended transternal thymectomy and histology revealed 
thymic follicular hyperplasia.  
She improved and remained stable (MGFA IIA) for more than 10 years, 
although steroids could never be completely discontinued. 
	
	
134	
In 1997, at age 45, she had recurrent respiratory tract infections, some 
of which with admission to the intensive care unit for ventilation support 
and worsening of myasthenic symptoms requiring treatment with plasma 
exchange. Anti-AChR antibodies and CT scan was not performed at this 
time. She presented with chronic oral and genital candidiasis and severe 
onychomycosis. She also had recurrent herpes simplex genital ulcers that 
were painful, difficult to treat and became chronic. She developed 
alopecia totalis, because of that and the recurrent severe infections 
thymoma was suspected. Thorax MRI confirmed the presence of a 
mediastinal mass. She was submitted to thymoma removal. Histological 
analysis revealed a WHO B2 type thymoma. After the surgery, she was free 
of myasthenic symptoms and required no treatment but soon she 
developed neck weakness requiring treatment with pyridostigmine and a 
mild dose of steroids. Antibodies to AChR were positive, 8.0 nmol/L.  
Seven years after the surgery, myasthenic symptoms got worse that were 
largely refractory to plasma exchange and intravenous immunoglobulins, 
developed severe recurrent respiratory tract infections, requiring 
repeated admissions to the intensive care unit. Genital herpes simplex 
ulcers and onychomycosis also persisted, being refractory to treatment. 
She died of a severe pneumonia at 52 years of age. 
Retrospective study of her serum showed high levels of neutralizing 
antibodies to the proinflammatory interleukins IFN-α, IFN-ω, IL-17A, IL-17F 
and IL-22 by the time the thymoma was diagnosed. 
Immunohistochemistry of archival paraffin material revealed loss of AIRE 
expression in the thymoma but not in the hyperplastic thymus removed 
during the first surgery, although it had a weak expression.  
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Figures 
 
 
Fig. 3.6.1.1. Thymus as resected in 1987, following corticosteroid treatment. a. Non-neoplastic 
thymic tissue with moderate involution of the cortex (C) and lymphoid follicular hyperplasia as 
revealed by a germinal centre (GC) in the medulla (M) [H&E, x50]. b. Cytokeratin 19 staining 
highlights epithelial cells in the cortex (C) and medullary epithelial bands (MEB). c. High number 
of CD20-positive B cells with clear-cut follicle formation in the thymic medulla. d. Staining for AIRE 
revealed an inadequate paucity of AIRE-positive cells (arrows), likely due to corticosteroid 
treatment. Hassall’s corpuscle (HC). [Immunoperoxidase in b. – d., x50 in b. and c., x200 in d.]  
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Fig.	3.6.1.	2.	Overview	of	the	resection	specimen	of	1997.	a.	Adjacent	to	the	capsule	surrounding	the	thymoma	(left)	
there	 is	 atrophic	 non-neoplastic	 thymic	 tissue	 (right)	 with	 massive	 cortical	 involution	 and	 paucity	 of	 Hassall’s	
corpuscles	[H&E,	x50].	b.	Cytokeratin	19	staining	highlights	epithelial	cells	in	the	thymoma	and	the	remnant	thymic	
tissue.	c.	 CD20-positive	B	 cells	 (without	 follicle	 formation)	are	 conspicuous	only	 in	 the	 thymus.	d.	 Staining	of	 the	
thymus	for	AIRE	revealed	a	 lack	of	AIRE-positive	cells	 (again	after	antecedent	 immunosuppressive	treatment	with	
corticosteroids).	[Immunoperoxidase	in	b.	–	d.,	x50	in	b.	and	c.;	x200	in	d.] 
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Fig.	3.6.1.3.	a.	WHO	type	B2	thymoma	with	a	conspicuous	perivascular	space	[H&E,	x200].	b)	Cytokeratin	19	staining	
highlights	 the	 epithelial-free	 perivascular	 space	 with	 vague	 surrounding	 “palisade”	 of	 epithelial	 cells.	 c.	 	 Typical	
paucity	of	CD20-positive	B	cells	in	the	thymoma	(compare	to	Fig	1c.).	d.		Lack	of	AIRE	expression	in	B2	thymoma	as	is	
typical	 for	>95%	of	 thymomas,	 including	apparently	all	B2	 thymomas,	 irrespective	of	 the	presence	or	absence	of	
mucocutaneous	candidiasis	(Ströbel,	2007;	Kisand,	2010).	[Immunoperoxidase	in	b.	–	d.;	x50	in	c.;	x200	in	b.	and	d.] 
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Case 2:  
In June 2003, a 27 years old man started generalized weakness, 
difficulties in playing football with falls, difficulty in chewing, dysphonia, 
diplopia and unilateral ptosis. Electromyography showed decrement of 
CMAP’s in the repetitive nerve stimulation of the facial and cubital nerves 
and a high titre of AChR antibodies. Generalized MG was diagnosed and 
he started pyridostigmine, 300 mg/day with partial improvement. Thorax 
CT scan showed an enlargement of the thymic tissue. In August 2003, he 
had a thoracic trauma after a fall. He worsened his weakness of the neck 
and the limbs and started dysphagia. He was treated with prednisolone 
90 mg/day and pyridostimine 420 mg/day 20 days later. One month later 
he was readmitted for extended transternal thymectomy. Histology 
showed a thymic follicular hyperplasia. Six days after surgery he 
developed severe dysphagia and herpes zoster infection at the level of the 
T8 dermatome. He was successfully treated with IVIG and acyclovir. Five 
days later he worsened again of the dysphagia and neck muscles 
weakness he was treated with plasma exchange. But soon he developed 
respiratory weakness, requiring mechanical ventilation. At that time, S. 
aureus sepsis related to the plasma exchange catheter was diagnosed. 
Because of the bulbar symptoms IVIG was repeated and started 
cyclosporin A progressively up to 4 mg/kg/day. During the following year, 
the steroids were tapered slowly and he was stable.  
He was stable under cyclosporine 200mg/day and pyridostigmine 420 
mg/day until July 2010. At this time, he developed an erythematous rash 
spreading from the thorax to the upper limbs and simultaneously ocular 
symptoms, dysphonia and dysphagia reappeared. Steroids were 
reintroduced without significant improvement. Skin biopsies were 
performed and it was diagnosed a pityriasis rosea in the first and a liquen 
planus in the second. In November 2010, he was readmitted because of 
bulbar symptoms, proximal tetraparesis and dyspnoea. Thorax CT scan 
showed a mediastinal mass around the supra-aortic trunk with contrast 
enhancement and multiple lesions in the pleura. A mediastinal biopsy 
showed a thymoma type B3. PET scan suggested that the disease was 
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locally invasive. Skin lesions were later considered to be paraneoplastic 
erytrodherma. He was treated with plasma exchange, but soon worsened 
again needing mechanical ventilation. Plasma exchange was repeated for 
23 sessions. He continued to deteriorate, always dependent on 
mechanical ventilation and a feeding tube. The tumour was considered 
unresectable. He had several infections: Pseudomonas aeruginosa 
pneumonia and then became persistently present in the respiratory 
secretions, Klebsiella p. infection, CMV systemic infection, positive HBV 
DNA), chronic hepatitis with uncertain cause (CMV, HBV, toxic or 
autoimmune) and persistent diarrhoea, with malabsorption, causing 
severe nutritional deficits, and which cause was not found. He had a 
severe immunodeficiency (CD4+=99/µL). Since the patient’s condition 
precluded chemotherapy, radiotherapy (dose 30 Gy) to the mediastinum 
was performed. His nutritional state slowly improved and in February 
2011 he started chemotherapy with (cyclophosphamide, doxorubicin and 
cisplatin). After the first session of chemotherapy his condition 
deteriorated again needing invasive ventilation. Thoracic CT scan showed 
a massive pulmonary thromboembolism. Despite the treatment with 
intravenous heparin he died 48 hours later. 
Retrospective analysis of patient’s serum from 2010, when his thymoma 
was diagnosed, revealed showed high levels of neutralizing antibodies to 
IFN-α, IFN-ω, IL-17A, IL-17F and IL-22. 
 
Discussion: 
We report here on two patients with early onset AChR MG who showed 
exacerbated MG and unusual other paraneoplastic phenomena in 
conjunction with thymoma development many years after extended 
transternal thymectomy. To the best of our knowledge, only five 
thymomas developing after thymectomy for non-thymomatous MG have 
been described so far, [231–235] however without reporting on anti-
cytokine autoantibodies that in one of the patients was associated with 
features of APECED. 
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Our review of sections from the original thymectomy specimens 
confirmed the diagnosis of TFH and provided no evidence that a thymoma 
had been overlooked. Therefore, it is most likely that the thymomas in 
our patients arose from thymic remnants that escaped removal during the 
first surgery in spite of ‘extended transsternal thymectomy’. This 
approach aims to remove all extensions and heterotopic foci of thymic 
tissue in the mediastinal and part of the cervical fat in addition to the 
main body of the thymus. However, about 5% of thymic tissue is left 
behind as compared to the abandoned “maximal thymectomy” approach 
that requires combined transsternal and transcervical surgery without 
apparently improving the control of MG symptoms[238]. Microscopic 
extensions of thymic tissue may escape surgical removal particularly 
around and between large vessels in the vicinity of the aortic arch[239]. 
This possibility is particularly obvious in our 2nd patient, because his 
thymoma occurred in an unusual location, “around the supra-aortic trunk” 
(see above). The alternative scenario that a late metastasis of an 
overlooked thymoma was the source of the tumors appears less probable. 
However, a caveat concerns the paucity of slides that were available for 
our review of the historic thymectomy material, reflecting the lack of 
guidelines about how many paraffin blocks should be prepared from non-
neoplastic thymectomy specimens. “Microthymomas” in particular may 
escape macroscopic detection and limited sampling[240,241]. In fact, on 
extensive sampling as required in the recent MGTX study on non-
thymomatous AChR-MG one unexpected thymoma was detected among 
60 thymectomy specimens[38]. In any case, the admittedly low risk of 
malignant transformation of remnant thymic tissue may be considered in 
the debate on whether extensive or limited approaches are preferable in 
conventional or robotic thymectomy for non-thymomatous MG. 
[38,229,242,243] 
An unusual finding in our two patients concerns their immunological 
features in addition to exacerbated MG in connection with thymoma 
development: both patients showed identical profiles of anti-cytokine 
autoantibodies, including those that are typical of thymoma patients in 
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general (IFN-α, IFN-ω), but also rare neutralizing autoantibodies to TH-17 
cytokines, IL-17A, IL-17F and IL-22 that are typical of APECED syndrome 
patients, i.e. patients with germline mutations of the ‘autoimmune 
regulator gene’, AIRE. By contrast, almost all thymomas (including the 
tumor of patient 1) have shown deficient AIRE protein expression in their 
neoplastic thymic epithelial cells despite a wild-type AIRE gene [244], and 
it is unknown, why APECED features are so uncommon[244] and why 
autoantibodies to TH-17 cytokines are confined to a minority of thymoma 
patients[237]. On the other hand, since the autoantibody-mediated 
functional defect of TH17 cytokines underlies the innate 
immunodeficiency that leads to chronic candidiasis[245], only the rare 
thymoma patients with these autoantibodies show chronic 
candidiasis[237] or even a broader spectrum of APECED symptoms (ref. 
[236] and our patient 1). Therefore, it is not too surprising that patient 1 
showed APECED features, while it is a new and unexpected observation 
that patient 2 did not have such features - despite the presence of anti-
TH17 cytokine. The reason for this discrepancy between the two patients 
is currently unknown.  
Instead of APECED-like symptoms, patient 2 showed more ‘unspecific’ 
serious infections (including Pseudomona aeruginosa and other bacterial 
infections and CMV infection) in connection with acquired severe 
deficiency of CD4+ T cells that is known to occur in variable association 
with autoimmune B lymphopenia in a subset of thymoma patients. [246–
249] 
In any case, it is most remarkable that the two thymoma patients 
presented here had a coincidence of two findings: One that is rare among 
thymoma patients, namely severe immunodeficiency against a 
background of anti-TH17 autoimmunity, and another one that is even 
much rarer, namely thymoma development years after subtotal 
thymectomy for non-thymomatous AChR MG. More such cases need in 
depth immunological investigation to get a hint whether this coincidence 
is more than fortuitous. 
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Conclusion: 
These cases are extraordinarily informative, enabling us to study in each 
patient the clinical, serological and thymic features of MG as both 
autoimmune and paraneoplastic disease. Not only are the alopecia and 
severe and recurrent infections, particularly the mucocutaneous 
candidiasis, known complications of thymoma: they are also signs of a 
complex underlying immunodeficiency that apparently has an 
autoimmune basis, as in APECED patients.  
In cases of autoimmune MG submitted to extended transternal 
thymectomy that become refractory to treatments a thymoma should be 
searched. 
 
Acknowledgment: Prof. Willcox and Meager for anti-interleukin antibody 
detection. 
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3.6.2 Infections, neoplasms and other autoimmunity in thymoma MG 
and AIRE gene 
 
This study is still being performed.  
The clinical and demographic data has been collected. We analysed the 
frequency of infections (severe, recurrent or opportunistic), neoplasms 
and other autoimmunity in patients with thymoma MG of our cohort. 
Some of this data was already presented in international meetings, as 
described below. 
The histopathological studies are currently being performed.  
The objective of the study is to correlate the clinical data with the 
histopathological findings. 
 
Works presented in international meetings: 
 
- “Clinical review of thymoma in Myasthenia gravis patients. 
Viral and fungal infections may indicate poor prognosis”, in the 
International Conference of Neuromuscular Disorders, in Naples 
July 2010 and the abstract was published in Journal of 
Neuromuscular Diseases; 
 
- “Extra-thymic malignancies in myasthenia gravis patients”, in 
the 12th International Conference on Myasthenia Gravis and 
Related Disorders, in New York, May 2012, organized by 
Myasthenia Gravis Foundation of America and the New York 
Academy of Sciences; 
 
- “Polyautoimmunity, tumours and infections in myasthenia 
gravis”, in the 3rd International Congress on Controversies in 
Rheumatology & Autoimmunity, in Sorrento, March 2014.  
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Infections, neoplasms and other autoimmunity in thymoma MG and 
AIRE gene  
Introduction 
The thymus, a lymphoid organ with a lobular structure, is important for 
the development of T cells. Specifically, thymocytes (T cell precursors) are 
subjected to both negative and positive selection in the thymus. [97,98] 
Each lobule of the thymus has a cortex that contains densely packed CD4 
and CD8 double-positive thymocytes and a medulla that contains sparser 
CD4 or CD8 single-positive thymocytes.[97,98] 
Mainly in the cortex, thymocytes are subjected to positive selection, in 
which precursors with low reactivity to the MHC complex are 
deleted/eliminated. Subsequently, the thymocytes are subjected to 
negative selection in the medulla, a process that deletes/eliminates cells 
that have reactivity against self-antigens.  
Thymic epithelial cells (TECs) and thymic dendritic cells (tDCs) are 
considered to be responsible for the positive and negative selection of 
thymocytes.  
In most cases of thymoma associated MG (TAMG) the source of the 
autoreactive T cells is almost certainly the highly abnormal but 
thymopoietically active thymoma microenvironment, as also suggested by 
unusual antigen specificities of CD4+ T cells in thymoma patients.[77,98] 
The role of CD8+ T cells in the pathogenesis of AChR-MG is less clear but 
likely of high relevance at least in EOMG and LOMG considering their 
association with MHC class I risk alleles.[78] 
TAMG typically occurs after 50 years of age but children may rarely be 
affected. In contrast to EOMG, there is no major gender bias and no strong 
HLA association. Immunodeficiency states of which some have an 
autoimmune basis, are also quite frequent. [237,246] Apart from rare 
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exceptions that showed anti-MuSK antibodies[250,251] or were 
seronegative. [252,253] 
TAMG is more commonly than EOMG accompanied by additional 
autoimmune diseases: the spectrum of them is broader but partially 
overlapping with the spectrum in EOMG [254–256]. Immunodeficiency 
states are also quite frequent [237,246].  
Another pathogenic feature, although it is shared by almost all MG(+) and 
MG(-) thymomas, is defective expression of the autoimmune regulator 
AIRE. [244] 
In thymoma-associated Myasthenia gravis the focus is on the role of 
abnormal intratumorous T cell selection and activation, lack of 
intratumorous myoid cells and regulatory T cells as well as deficient 
expression of the autoimmune regulatory gene (AIRE) by neoplastic 
thymic epithelial cells. [98] 
The failure of peripheral tolerance mechanisms in such tumor patients is 
by all likelihood also a facet of the tolerance breakdown observed in 
thymomas. [254] However, the unusually high frequency (>50%) of 
thymoma-associated autoimmune phenomena compared to their low 
frequency (<5%) in other tumor types suggests that additional mechanism 
are likely operative in TAMG [246,256].  
Taking into account that autoimmune diseases are more prevalent in 
patients with thymopoietically active thymomas than in thymopoietically 
inactive thymomas, and that MG is virtually never encountered in patients 
with thymic carcinoma (that are generally devoid of thymopoietic activity) 
[254,256,257], a pathogenetic role of central self-tolerance failure in 
TAMG seems to be important.  
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The Thymus and AIRE gene 
The thymus selects T cells, thus ensuring T cell tolerance. Thymoma can 
be associated with immune dysregulation manifesting as autoimmunity 
and/or immunodeficiency. A particular challenge to physicians treating 
patients with thymoma is the possible occurrence of both autoimmunity—
requiring immunosuppression—and immunodeficiency. [78,246] 
Major laboratory findings of this syndrome are hypogammaglobulinemia, 
few or absent circulating B and T cells, and an abnormal CD4:CD8 T cell 
ratio.[98,246,249] 
Immune dysregulation in thymoma patients has only been described in 
case reports and small case series. To date, no clear link between 
histologic type of thymoma and immunologic manifestations can be 
drawn. [246] 
The pathogenesis of immunodeficiency in patients with thymoma has 
long remained a mystery, yet recently functionally relevant anticytokine 
autoantibodies have been linked to the clinical phenotype observed in 
these patients. [237,245,254,255,258,259] 
Autoantibodies neutralizing key components of the immune system can 
thus lead to an increased risk of infections.[237] 
Given the high incidence of immunodeficiency/infections in these 
patients, thymoma should probably be excluded in adults presenting with 
recurrent (severe) infections and suspicion of primary immunodeficiency. 
[227,249,260] 
Knowing the fact that autoimmune regulator mutations are associated 
with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy, 
lack of autoimmune regulator expression in a subset of thymomas may 
partially explain the loss of tolerance and the development of 
autoimmunity seen in these patients. [237,244] 
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In the absence of the AIRE protein, many tissue-specific self-antigens are 
not expressed in the thymus, and multi-organ autoimmunity develops 
because of faulty negative selection of autoreactive T cells. [236] 
Autoimmune polyendocrinopathy syndrome type 1 (APS1), also known as 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy, is 
caused by defects in a single gene. Patients with this rare disease have 
mutations in both copies of AIRE gene (for autoimmune regulator). [259] 
By definition, the patients have at least two of the “APS1 triad”— 
hypoparathyroidism (HP), Addison disease (AD), and chronic 
mucocutaneous candidiasis (CMC). However, the clinical phenotype is 
highly variable. Characteristically, patients present with CMC and/or skin 
disorders, usually early in childhood; these symptoms are followed 
(sometimes 1–3 decades later) by autoimmune endocrine disorders, 
which may also target the gonads and/or endocrine cells in the gut, 
pancreatic islets, and thyroid gland. [254,259] 
In addition, some had alopecia, keratoconjunctivitis, vitiligo, and 
vasculitis, and few were growth-hormone-deficient. [259] 
Starting in infants or young children, the typical diagnostic triad of APS-I 
comprises hypoparathyroidism (HP), autoimmune adrenal insufficiency 
(AI) and chronic mucocutaneous candidiasis (CMC). Many patients develop 
other autoimmune manifestations, e.g. premature ovarian insufficiency 
(POI), vitiligo, alopecia, autoimmune hepatitis, keratitis, enamel dysplasia, 
and/or intestinal malabsorption. Phenotypes vary widely, even within 
families; some patients are first recognized in adulthood. [254] 
Generation of the T cell repertoire in the thymus involves selection of 
those T cells that recognize only foreign substances. T cells that can react 
against self-antigens are eliminated, and the AIRE gene is thought to be 
involved in this “education process.” Like those with APS1, patients with 
thymomas make autoantibodies not only against target organs (especially 
muscle in their case), but also against interferon alpha (IFN-α) and 
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interferon omega (IFN-ω), two secreted immune regulators.  
The most obvious link between these disparate syndromes is that, in 
nearly all thymomas, the neoplastic TECs fail to express AIRE detectably, 
implying reduced expression of AChR, insulin and GAD65. [254] 
 
Material and Methods 
Clinical and Demographic Data 
Here we retrospectively analysed the frequency and clinical presentation 
of autoimmune manifestations, infections and neoplasms (other than 
thymus) in patients with MG and a histologically confirmed thymoma 
diagnosed in a multicentric study which included 5 hospitals in the north 
of Portugal: Centro Hospitalar do Porto, Centro Hospitalar de Vila Nova de 
Gaia, Hospital de São João, Instituto Português de Oncologia e Hospital 
de Pedro Hispano.  
 
Histopathological studies of the thymomas cases 
Currently, we are studying the samples of thymomas of TAMG cases from 
the mentioned above hospitals. 
 
The histopathological studies of the thymus are being performed at 
Serviço de Anatomia Patológica, Centro Hospitalar do Porto, under 
supervision of Dr. Jose Ramon Vizcaíno and Prof. Doutor Carlos Lopes. 
 
We are performing the studies necessary to classify thymomas according 
to WHO classification, and also additional immunohistochemistry studies.  
 
These includes the study of:  
-    expression of AIRE gene; 
- expression of CD8+CD45RA+ and CD103 in order to understand 
whether the cases with opportunistic infections might be associated 
with a poor CD8+CD45RA+ export capacity.  
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- expression of CD20*, CD79a, PAX5, CD23 and CD138. Since anti-
cytokine antibodies are said to be produced within the thymoma, 
we want to study whether there is a correlation between 
autoantibody-positivity in the sera and the occurrence of B cells 
(CD20*, CD79a, PAX5), lymphoid follicles (CD23) and plasma cells 
(CD138, kappa/lambda) inside the respective thymomas (not only 
in the adjacent remnant thymus). 
 
Objective 
The objective of the study is to correlate the clinical data, the frequency 
and clinical presentation of autoimmune manifestations, infections and 
neoplasms (other than thymus) in patients with TAMG with AIRE gene 
expression, poor CD8+CD45RA+ export capacity and/or the presence of 
B cells and lymphoid follicles inside the thymoma. 
 
 
Results 
This is an ongoing study. 
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Chapter 4. Summary and Discussion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
151	
Chapter 4. Summary and Discussion  
 
Epidemiological study  
We estimated a point prevalence for MG of 111.7 patients/106 in the 
North of Portugal (a 31/12/2013). Our method of estimation is valid, 
as explained in the methods section and in the published paper. This 
estimate is similar to those reported either in studies in southern 
European countries, or in the north of Europe, in studies with similar 
methods and size of the population studied. [122,125,126,128] 
Prevalence rose with age reaching its maximum in the group over 65 
years old, especially in males (288.1/106), as reported in many other 
studies.[121,183]  
During the year of 2013 we estimated an incidence rate of 6.3 per 
million person/year. Our incidence rate was similar to those reported 
in studies from distinct latitudes with similar methods and to others 
from south of Europe. [121,125–128] 
Among females, incidence rate was higher in the age group 15-49 
(9.1/106), while in males, incidence increased with age till the 
maximum (22.1/106) among those aged over 65 years. We do not have 
information on changes in incidence over time, because these is the 
first epidemiological study on MG in Portugal. But this result is in 
agreement with most of the recent reports that describe higher 
incidence rates of MG in LOMG group, especially in elderly 
males.[121,122,129,153] This information has crucial importance for 
the awareness of clinicians when dealing with this age group, and 
subsequent improvement in diagnosis and management of MG. 
 
The mortality rate attributed to MG was 0.5 per million, which is in the 
range of what others studies reported.[122,129]  
Of note, 3 deaths occurred in relation with aggressive thymomas. 
Regarding age at death, six occurred between 84 and 89 years, an age 
that is above the Portuguese life span (82.8 for females and 76.9 for 
males).  
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Clinical, demographic and serological features 
Our prevalent and incident data confirmed that the majority of patients 
belong to the group of LOMG, confirming others’ findings that MG is a 
disease that affects younger and also elderly people. Overall our 
clinical, histology and serological data were similar to those reported 
by other authors. There were, however some discrepancies, which 
deserve some comments.  
Overall a surprisingly high percentage of patients (19%) were treated 
with IVIG or PEX at least once during the course of the disease, 
particularly knowing that majority of patients had MGFA I or II at nadir. 
Majority of patients treated with IVIG or PEX represented a third of the 
MuSK MG patients and nearly a quarter of the AChR MG patients, which 
is in keeping with our practice preferring more intense treatment in Ab 
positive patients with acute bulbar symptoms with or without 
respiratory manifestations.  
Almost one third of patients (29.4%) had one type of the following 
comorbidities: other autoimmune diseases (OAID) (organ specific or 
systemic), tumours or recurrent/serious infections; 2.8% of the patients 
had ≥2 of those associated problems.  
The proportion of patients with OAID (20.2% vs 16.3%) and infections 
(4.6% vs 4.4%) was identical in EOMG and LOMG groups. Only tumours 
were more common in LOMG (12.6% vs 5.9%, p= 0.026), which is in 
keeping with what is expected in general population. 
Our lower number of infantile-onset MG patients (2.5%) is similar to 
findings from most European and American series where it varied from 
1% to 3%. [184] 
We found a percentage of 5.3% of MuSK MG in the group of prevalent 
patients, which is similar to what has been described by other authors 
in the southern European countries. [185] Interestingly, the percentage 
in the incident cases is higher, 14.3%. On the other hand, the 
proportion of AChR-MG in the group of incident cases was lower than 
expected, possibly because the proportion of ocular MG was relatively 
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high, 43.5%. This may represent variations in incidence of distinct 
disease subtypes or improvement in diagnosis of rarer and limited 
forms of MG.  
 
Immunogenetic study 
Over the years, association of MG with Human Leucocyte Antigens (HLA) 
has been described in different populations. In European descendent 
populations HLA-DRB1*03 allele strongly influences MG 
susceptibility.[39,134,187,188] 
This study investigated the possible association between HLA-DRB1 
alleles and age-of-onset in MG. 
The results of the study demonstrated a strong association of HLA-
DRB1*03 and HLA-B*08 with MG, confirming that these alleles constitute 
important susceptibility factors for this disease also in our population. 
Considering the age of onset, HLA-DRB1*01 was associated with late-
onset subgroup. Thymoma MG patients have probably a different genetic 
(HLA- DRB1*10) background.  
To the best of our knowledge these results were not reported before and 
need replication in other populations and in larger cohorts. 
 
Pregnancy and Myasthenia gravis 
It is well recognised that MG does not affect fertility, but it may expose 
pregnant women to an increased risk of maternal and fetal complications. 
The clinical course of pregnancy in these patients is not well known.  
This study evaluated the clinical course, delivery and neonatal outcome 
of the pregnancies of our MG patients. 
Regarding the influence of the pregnancy on the MG, 43% of patients 
experienced an exacerbation of symptoms, especially during the third 
trimester and postpartum. This is a similar rate of clinical worsening as in 
other studies published.[209] 90% were treated with acetylcholinesterase 
inhibitors and 43.3% also required prednisolone to symptomatic control.  
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There were no deaths in our cohort and we only experienced one 
myasthenic crisis during postpartum, following an aggressive clinical 
deterioration that occurred by the end of the third trimester.  
We described an NMG rate of 7.1%. Two newborns developed classic signs 
of NMG during the first 72-96 hours of life, which is little later than usually 
described. They were treated with acetylcholinesterase inhibitors with 
complete resolution of symptoms during the first two months of life. 
Our study adds to the body literature showing that a more aggressive MG 
background is a predictive factor for clinical exacerbation during 
pregnancy. A multidisciplinary approach with neurologists and trained 
obstetricians allowed a good clinical control, avoiding maternal adverse 
outcomes. In this group of patients, pregnancy should be planned to 
avoid the use of foetus toxic medication during pregnancy, as well as, to 
advise women to become pregnant during a stable phase of the disease. 
 
The other study on pregnancy and MG was a multicentric study that 
included all MuSK-MG in the North of Portugal that underwent through a 
pregnancy. This is a subgroup of MG patients where the effect of the 
disease on the pregnancy, the delivery, the foetus and the changes on the 
MG during that period are less known. As far we are concerned there are 
no other series on MuSK-MG and pregnancy.  
In our series, pregnancy did not seem to precipitate MuSK-MG or to 
influence the MuSK-MG course, and there was no apparent negative 
impact in pregnancy outcomes in those where pregnancy followed the MG 
onset. These results should be regarded with caution because is a small 
series. 
 
Polyautoimmunity in Myasthenia gravis 
 
Polyautoimmunity refers to the presence of more than one autoimmune 
disease in a single patient and this is well documented in great majority 
of the spectrum of autoimmune diseases, particularly those mediated by 
autoantibodies, including myasthenia gravis.  
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We found other autoimmune disorders in 37 patients with MG (17%). Six 
patients have a combination of more than one autoimmune disease 
besides MG (multiple autoimmune syndrome). 
As expected, the frequency of a second autoimmune disorder is highest 
for females (68%) with early onset MG (EOMG) (mean age at onset is found 
to be 41 years). The majority of these patients have the generalized form 
of myasthenia (78%) and the anti-AChR antibodies were positive in 78%. 
Thymectomy was performed in 19 patients (51%), with thymic hyperplasia 
being the most common histological diagnosis. In most cases, MG 
preceded the onset of the other autoimmune disease (62%) and 
immunosuppression didn’t seem to affect the development of a second 
condition (68% had not been exposed to immunosuppressive agents when 
the other disorder emerged). 
Of 214 patients with MG 11 (5%) have another autoimmune neurological 
disease: three of the central nervous system, seven of the peripheral 
nervous system and one of the autonomic nervous system. 
The course of MG is often complicated by concomitant autoimmune 
disorders. It is important to consider coexistent MG in patients with 
autoimmune disorders that develop new or aggravated muscular 
weakness, fatigue or respiratory failure.  
On the other hand, while rare, the possibility of neurological autoimmune 
comorbidity should also be considered in myasthenic patients, especially 
if there is an unexpected deterioration of muscle weakness or poor 
response to pyridostigmine (e.g. muscle disease), or if unexpected 
neurological signs or symptoms arise in MG (e.g. peripheral nervous 
system involvement in keeping with CIDP; or central nervous system 
illness such as NMOSD; or even rarer manifestations such as of autonomic 
dysfunction). The rapid diagnosis of the second illness will improve 
management and disease outcomes of both MG and the other 
autoimmune condition. 
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Refractory Myasthenia gravis 
 
A subset of myasthenia gravis patients is refractory to conventional 
treatments. Identifying their characteristics is important to contribute to 
try to find different therapies effective in this subgroup.  
38 out of 172 patients were classified as refractory (22%). This rate is 
slightly higher than in other populations where it corresponds to 10-15%. 
[142] Maybe it happens in our cohort because it belongs to a tertiary 
centre where more difficult patients are referred for treatment. 
Compared to the non-refractory patients, the refractory ones were more 
likely to have a more severe MGFA classification at onset, to have 
thymomatous MG and to be seropositive, either to anti-AChR or anti-MuSK 
antibodies. 
We could not find any difference regarding sex, age of onset, presence of 
other autoimmune diseases, malignancies (other than thymus) or 
severe/opportunistic infections.  
HLA-DRB1*13 allele was less frequent in the non-refractory MG when 
compared to the refractory group and the control population.  
The clinical and demographic characteristics of our refractory patients are 
similar to those described in other studies. It is important to consider 
those characteristics from the onset of the disease. HLA-DRB1*13 allele 
was less common in the non-refractory group. HLA-DRB1*13 allele may 
be a protective allele for the non-refractory MG patients. As far as we were 
concerned there are no other immunogenetic studies in refractory MG and 
these results need to be reproduced in other populations.  
 
Infections, neoplasms and other autoimmunity in thymoma 
associated Myasthenia gravis  
 
It is extremely rare for young onset myasthenia gravis (MG) patients to 
have thymoma following extended removal of hyperplastic thymus. We 
described two anti-acetylcholine receptor MG (AChR-MG) patients who 
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developed thymoma years after extended transternal thymectomy and 
highlight the clinical manifestations that heralded the thymoma, 
consequently of a severe immunodeficiency which resembled APECED 
(autoimmune polyendocrinology, chronic mucocutaneous candidiasis and 
ectodermal dystrophy) syndrome, with auto-immune regulatory (AIRE) 
gene defect. 
 
These two cases illustrated the need to search for a thymoma in MG 
patients where MG becomes difficult to treat years after removal of a 
thymus with thymic follicular hyperplasia. And that thymoma needs to be 
considered even more in case of severe and/or recurrent infections, which 
could reflect complex paraneoplastic immune-deficiency associated with 
auto-antibodies to interleukins, as found in genetic conditions associated 
with AIRE mutations.  
 
This knowledge led to another study that is still going on.  
We studied the frequency and clinical presentation of autoimmune 
manifestations, infections and neoplasms (other than thymus) in patients 
with MG and a histologically confirmed thymoma diagnosed in a 
multicentric study which included 5 hospitals in the north of Portugal. The 
aim is to correlate it with AIRE gene expression, poor CD8+CD45RA+ 
export capacity and/or the presence of B cells and lymphoid follicles 
inside the thymoma in the immunohistochemistry analysis of the 
thymoma samples. 
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5. Conclusions and Final Comments 
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Chapter 5. Conclusions and Final Comments 
  
This epidemiological work enabled to Know the prevalence of the disease 
in the North of Portugal, as well as to know the prevalence for the different 
MG subgroups. More importantly, it allowed us to recognize that MG 
prevalence is higher in the elderly.  
Furthermore, the study allowed us to calculate the incidence of MG in the 
same region. Like in other populations in different parts of the world, the 
MG incidence in the north or Portugal has been rising mostly in the elderly 
men. 
This is a very important message to communicate to other neurologists, 
internal medicine doctors and general practitioners once awareness for 
such a treatable, but potentially serious, condition in older age groups 
will permit earlier intervention and thus a better outcome.  
 
Being a model of antibody-mediated autoimmune disease, MG has been 
well recognised as having immunological, genetic and environmental 
influences. It was therefore, reassuring that our immunogenetic study 
confirmed the HLA susceptibility alleles as previously described in many 
different EOMG populations. On the other, we were able to find that LOMG 
has different immunogenetic characteristics, and found a different HLA 
susceptibility allele for this subgroup, which may explain some distinct 
characteristics of these patients in comparison to the EOMG, the most 
relevant of which is the gender bias (males in LOMG).  Whether the LOMG 
HLA susceptibility alleles are indeed protective against an early onset of 
disease is a question that would be interesting to look into in future.  
 
The study of the pregnant MG women identified an important proportion 
of patients that worsens during pregnancy and deserve special attention 
and care. There were no important complications in their children. We 
also focused in the MuSK-MG pregnant women analysis and it showed that 
pregnancy did not seem to precipitate MuSK-MG or to influence the MuSK-
MG course, and there was no apparent negative impact in pregnancy 
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outcomes in those where pregnancy followed the MG onset. Pregnancy in 
MG is in general welcome and any MG patient at childbearing age should 
be offered expert counselling on this matter. MG services should have a 
robust support from obstetrics to provide helpful advice, and good quality 
and safe service to pregnant MG patients at any stage of their pregnancy, 
delivery and post-partum.    
 
Polyautoimmunity in MG is a subject of great interest and relevance. We 
found that polyautoimmunity is common, either with other organ-specific, 
systemic or neurological autoimmune disorders. Is very important to 
diagnose them early and treat them promptly to improve the outcome of 
both MG and other diseases. 
 
Recognizing and, if possible, predicting, the characteristics of MG patient 
with refractory disease is crucial. It allows making clear plans for 
monitoring the disease course and treating the disease more intensively 
from as early stages as possible to prevent major complications. 
Immunogenetic studies in larger disease cohorts may help to identify 
factors of poor prognosis and poor response to conventional treatments 
in MG.    
 
Finally, we identified that some of the thymoma MG patients were more 
susceptible to severe/recurrent infections, endocrine or autoimmune 
disorders. We are performing additional studies to try to understand the 
mechanism why it happens.  
 
Future studies in MG should concentrate on understanding why MG is 
becoming more common in older populations and also define strategies 
to identify such patients promptly and treat them early. 
Given the difficulty in understanding the reason for such increase in 
prevalence and incidence of LOMG, it would be helpful to identify 
biological markers and environmental factors potentially associated with 
the risk of the disease. 
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It would be worth identifying new treatments for MG patients, in particular 
for those over the age of 50 or 60 years, where side effects of steroids 
and other chronic immunosuppressive treatments cause serious 
complications. Comorbidities are very frequent and interaction of poly-
medications can also contribute to increased morbidity in MG. 
We are confident that the studies conducted and presented in this thesis 
will have a positive impact in clinical practice in MG not only in the hospital 
where the studies were performed, but in the hospitals where the patients 
were recruited from. Patients’ diagnosis and management will continue 
improving regardless of their age or gender, their social background or 
where they live.  
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